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In horses, perioperative mortality rates are higher than in many other species. Reasons for 
this include their character, high body weight, and the frequent occurrence of severe 
ventilation-perfusion mismatching and cardiovascular depression during anaesthesia. 
Several of these factors cannot be altered substantially or are difficult to treat, but different 
approaches to treat cardiovascular depression are available. The first step is to confirm its 
presence. Clinical evaluation of the cardiovascular status and routine monitoring of heart 
rate and arterial blood pressure provide useful information, but do not allow assessment of 
cardiac output and vascular tone. An easily applicable and reliable method of measuring 
cardiac output would allow better evaluation of the cardiovascular status of each patient. 
Therefore, the first aim of this PhD thesis was to identify and evaluate possible alternative 
techniques to measure cardiac output in horses.   
   Once low cardiac output has been detected, inotropic drugs are often needed to 
normalize oxygen delivery in anaesthetized horses. The second major aim of this PhD 
thesis was to evaluate alternative drugs with inotropic properties that could be used in 
horses under clinical conditions. The human and equine literature was reviewed to identify 
an inotropic drug which had received little attention but appeared promising for use during 
equine anaesthesia. Subsequently, the effectiveness and safety of this drug were evaluated, 
both under experimental conditions and in clinical cases, alone or combined with other 
commonly used drugs.   
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Inadequate oxygen delivery in anaesthetized 
horses: consequences, aetiology, diagnosis 
and treatment 
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Cardiovascular depression as a cause of 
inadequate tissue oxygen supply during 
equine anaesthesia: diagnostic aids and 
principles of treatment 
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SUMMARY 
Anaesthesia-related mortality is higher in horses compared to other species and is often 
attributable to inadequate tissue oxygenation, resulting from the effects of anaesthetic 
drugs, recumbency and other predisposing factors. More specifically, arterial oxygen 
content, arterial blood pressure and cardiac output are often low during equine 
anaesthesia. Diagnostic techniques routinely available to the equine anaesthetist for 
detecting cardiovascular depression include subjective clinical assessment and 
measurement of arterial blood pressure. An easily applicable, continuous, reliable and 
cheap method for measuring cardiac output would allow a better estimation of oxygen 
delivery. Pulse contour analysis appears promising in this respect. Once cardiovascular 
depression has been diagnosed, an appropriate treatment should be initiated, including 
reduction of anaesthetic depth, fluid therapy and use of cardiovascular stimulant drugs. 
 
 
 
 
 
 
 
 
 
Diagnosis & treatment of cardiovascular depression 
 
8 
 
Introduction 
The mortality rate associated with general anaesthesia and/or surgery in horses was assessed 
by different groups of researchers, but results from these studies are variable and usually 
difficult to compare. Although death should be a clear-cut outcome that can be assessed 
objectively, it is more difficult to determine whether death is related to or induced by 
anaesthesia, or rather the result of underlying diseases or surgical complications. Perioperative 
mortality was reported to be 0.8 % in horses undergoing different types of surgery (Tevik 
1983), 0.63 % in horses undergoing elective surgery, with only 0.08 % directly attributable to 
anaesthesia (Mee et al. 1998a), 0.68 % in horses undergoing orthopaedic surgery, radiography 
or minor soft tissue surgery (Young & Taylor 1993) and 31.4 % in horses undergoing 
emergency procedures (Mee et al. 1998b). More recently, Bidwell et al. (2007) reported a 
comparatively low mortality rate in horses undergoing surgery in a private referral practice, 
with a prevalence of fatalities directly related to anaesthesia of 0.12 %, which rose to 0.24 % 
with the inclusion of horses killed or dying within 7 days after general anaesthesia. The 
majority of these horses were healthy and underwent procedures lasting less than 1 hour, 
which may have contributed to the low mortality rates. Other reasons may include differences 
in the criteria used to define anaesthesia related death, the reasons for surgery, familiarity of 
the anaesthetists with the relatively fixed anaesthetic protocols used in this practice, etc.  
   Undoubtedly, the largest epidemiological study investigating equine peri-anaesthetic 
mortality was the “Confidential Enquiry into Perioperative Equine Fatalities” (CEPEF). In 
this report, Johnston et al. (2002) described the risk of death during anaesthesia or within 7 
days following anaesthesia in 41,824 horses, anaesthetized in 129 different clinics over a 
period of 6 years. At the end of the 7 day period, an overall death rate of 1.9 % was found. 
These horses were classified as „dead‟ because they died unexpectedly or were euthanized 
because of perioperative complications unrelated to pre-existing disease. Another 4.8 % of the 
horses died or were euthanized because of an inoperable lesion found at surgery or as a result 
of pre-existing disease, but these horses were classified as „put to sleep‟.  
      When cause of death was further analyzed in noncolic horses in the CEPEF study, it was 
demonstrated that 33 % of deaths were due to cardiac arrest (including postoperative 
cardiovascular collapse), 32 % of horses were euthanized because of fractures or myopathies 
observed during the recovery period, while the remaining 35 % of deaths were from a range 
of causes (Johnston et al. 2002). The study therefore confirmed the well accepted concept that 
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most causes of perianaesthetic death in horses are linked with cardiovascular depression 
and/or inadequate tissue oxygen supply. Indisputably, cardiac arrest is a form of 
cardiovascular depression and is often caused by inadequate myocardial oxygen supply. Also, 
the association between hypotension during anaesthesia and postoperative myopathy has been 
well established in horses (Grandy et al. 1987, Serteyn 1988, Lindsay et al. 1989, Richey et al. 
1990). Even in the muscles of healthy anaesthetized horses, an anaerobic metabolic response 
has been demonstrated using the microdialysis technique (Edner et al. 2005). Although 
myopathies are not necessarily lethal, the prognosis if often very poor when larger muscle 
groups are involved or when a more generalized myopathy occurs. The horses are unable to 
stand, leading to excitation and prolonged recumbency, thus causing further muscle damage. 
In some cases, this vicious circle necessitates euthanasia. Additionally, myoglobin from 
affected muscles can cause nephropathy and acute renal failure. Fractures may also occur 
during unsuccessful attempts to stand due to muscle weakness (Lindsay et al. 1989). It 
therefore seems likely that at least some of the fractures in the CEPEF study were associated 
with muscle dysfunction/myopathy caused by inadequate oxygen delivery during anaesthesia. 
Young & Taylor (1993) obtained comparable results in 1,314 ASA (American Society of 
Anaesthesiologists) class I and II horses. The main cause of death in that study was myopathy 
(4 out of 9 horses), while another 2 horses re-fractured a leg after osteosynthesis, most likely 
as a result of myopathy. In conclusion, it can be stated that perioperative death in horses is 
closely linked with inadequate tissue oxygen delivery.  
   The death rate for noncolic horses was calculated to be 0.9 %, while this number increased 
to 11.7 % in colic horses (Johnston et al. 2002). In most studies investigating the prognosis of 
equine colic cases, variables which assess cardiovascular status were found to be good 
prognostic guides. Examples include heart rate (HR), packed cell volume (PCV), capillary 
refill time, mucous membrane colour and/or blood pressure (Parry et al. 1983, Pascoe et al. 
1983, Puotunen-Reinert 1986, French et al. 2002, Stephen et al. 2004, Mair & Smith 2005, 
Proudman et al. 2005, Proudman et al. 2006). Once again, this confirms the importance of 
maintaining cardiovascular function during anaesthesia, especially in high risk patients such 
as the colic horse. Appropriate monitoring of anaesthetized horses should enable the clinician 
to detect cardiovascular depression in a timely fashion. However, before appropriate measures 
can be taken to prevent or treat inadequate tissue oxygen supply, a clear understanding of the 
underlying mechanisms is necessary to allow a logical approach to treatment.
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Cardiovascular depression as a cause of inadequate tissue oxygen supply 
Oxygen delivery (DO2) is calculated as the product of arterial oxygen content (CaO2) and 
cardiac output (   ) (Lumb 2005) (Table 1). However, oxygen supply to individual tissues is 
not only determined by total oxygen delivery, but also by the degree of perfusion of 
individual tissues. The latter depends on    , smooth muscle tone in precapillary arterioles 
(which also determines systemic vascular resistance) and transmural pressure in the blood 
vessels of a certain tissue, which is important for maintaining the patency of these vessels. 
Since transmural pressure is the difference between intravascular and extravascular pressures, 
it is highly influenced by blood pressure. Inadequate tissue oxygen supply can therefore result 
from decreases in arterial oxygen content,    , systemic vascular resistance (SVR) or blood 
Table 1: Formulas to calculate some valuable cardiovascular/respiratory parameters 
Variable Formula 
 
Oxygen delivery 
(DO2) 
(L/min) 
 
     
                       
    
 
 
 
Arterial oxygen 
content (CaO2) 
(mL/L) 
 
                                        
                    
 
Mixed venous oxygen 
content 
(C O2) 
 
                                       
                    
 
End-capillary 
pulmonary oxygen 
content 
(CćO2) 
 
                                       
                    
(For practical reasons, PćO2 is usually assumed to be equal to 
PAO2) 
 
Alveolar oxygen 
partial pressure 
(PAO2)  
(kPa)
 
 
                                 
(where PaCO2 = arterial carbon dioxide tension and  
PIO2  = partial pressure of inspired oxygen  
= FIO2(PB(kPa) – 6.3 kPa)     
(with FIO2 = oxygen fraction in inspired dry air)  
 
 
Degree of venous 
admixture (       ) 
(%) 
 
 
  
   
 
         
         
 *100% 
 
 
Alveolar-to-arterial 
oxygen tension 
gradient  
(P(A-a)O2) (kPa) 
 
 
                              
 
Systemic Vascular 
Resistance (SVR) 
(dyne.sec/cm
5
) 
 
     
                           
          
 
(where MAP = mean arterial pressure and RAP = right atrial 
pressure) 
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pressure, especially in tissues with high extravascular pressures (e.g. muscles) or high oxygen 
consumption (e.g. brain). Due to a complicated interplay between all these factors (Fig. 1), a 
delicate balance must be maintained by the body and interference with the normal 
homeostatic mechanisms by administration of anaesthetic drugs can result in pronounced 
changes in oxygen supply to individual tissues. 
   Arterial oxygen content is the sum of the amount of oxygen bound to haemoglobin and the 
amount of oxygen dissolved in plasma (Table 1). The former is measured as the saturation of 
haemoglobin with oxygen in arterial blood (SaO2), the latter as the arterial partial pressure of 
oxygen (PaO2). In anaesthetized horses, respiratory function is often compromised due to 
mismatching between ventilation and perfusion of the lungs (Nyman & Hedenstierna 1989), 
leading to dead-space or „wasted‟ ventilation and right to left pulmonary shunts. These 
respiratory problems seem to occur due to the combined effects of recumbency and general 
anaesthesia, since in laterally recumbent conscious ponies, mean PaO2 and PaCO2 were 
reported to range between 85 and 97 mm Hg and between 39 and 43 mm Hg respectively. 
These values were not significantly different from those in standing ponies (Rugh et al. 1984). 
Pulmonary shunt fractions (       ) (Table 1) of 20 to 25 % were reported in healthy, 
spontaneously breathing, laterally recumbent, halothane anaesthetized horses (Hall et al. 
1968). In another study, the shunt fraction increased from a mean of 1 % in conscious horses 
to a mean of 34 % in dorsally recumbent anaesthetized horses (Nyman & Hedenstierna 1989). 
It was suggested that this was mainly due to atelectasis (Nyman et al. 1990). These shunt 
flows induce an increased alveolar-to-arterial oxygen tension gradient (P(A-a)O2) (Table 1), 
leading to a lower than expected value for PaO2. Although PaO2 is important because it 
represents unbound oxygen immediately available for diffusion into the tissues, the amount of 
oxygen bound to haemoglobin (SaO2) is quantitatively of greater importance as it forms a 
much larger part of the total CaO2. Fortunately, the sigmoid shape of the oxyhaemoglobin 
dissociation curve allows a large reduction in PaO2 before SaO2 starts to decline (Bohr et al. 
1904), thus avoiding large changes in CaO2 until respiratory function is severely 
compromised. 
   The second determinant of tissue oxygen supply is    , which is usually lower during 
anaesthesia than in conscious animals. Many anaesthetic drugs commonly used in horses, 
including acepromazine (Stepien et al. 1995), α2 agonists (Wagner et al. 1991), barbiturates 
(Patschke et al. 1975) and volatile agents (Steffey & Howland 1980), reduce    , either 
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Fig. 1: Schematic overview of the different factors which play a role in determining tissue 
oxygenation 
 For abbreviations: see general list of abbreviations 
through a direct negative inotropic and/or negative chronotropic effect, a central depressant 
effect (reduced sympathetic and/or increased vagal outflow) or any combination of these. The 
exact mechanisms through which the agents exert these effects differ from drug to drug, but 
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as volatile anaesthetics are an essential component of most clinical protocols used for 
prolonged anaesthetic procedures in horses, the mechanism of their cardiovascular depressant 
action deserves further attention.  
   Volatile anaesthetics depress myocardial contractility by influencing calcium homeostasis in 
the cardiac cell (Pagel et al. 1993, Wheeler et al. 1994), with a decrease in intracellular 
calcium transients (Bosnjak & Kampine 1986, Bosnjak et al. 1992). Most agents inhibit the 
influx of calcium through slow channels (Rusy and Komai 1987) and depress the maximal 
uptake of calcium by the sarcoplasmic reticulum (Casella et al. 1987). Halothane was also 
reported to evoke a net loss of calcium from the sarcoplasmic reticulum of rat heart cells 
(Wheeler et al. 1988). In addition, inhalants decrease the myofibrillar responsiveness to 
calcium and/or the calcium sensitivity of the contractile proteins (Housmans & Murat 1988, 
Bosnjak et al. 1992). Finally, small but significant decreases in serum ionized and total 
calcium concentrations were reported in horses anaesthetized with halothane and isoflurane 
(Gasthuys et al. 1985, Grubb et al. 1999).  
   Besides their effects on    , many anaesthetic drugs, including acepromazine (Steffey et al. 
1985), 2 agonists (McCashin & Gabel 1975), propofol (Oku et al. 2006), isoflurane (Raisis et 
al. 2000) and sevoflurane (Aida et al. 1996), also affect vascular smooth muscle tone in 
horses. The net result of constriction or dilation of vessels depends on the type and number of 
vessels involved and their localization. As an example, large veins normally contain about 60 
% of the blood volume, but their capacitance can be greatly altered by autonomic nervous 
system activity (Power & Kam 2001). Together with the effective circulating blood volume, 
venous capacitance determines the mean systemic filling pressure (Pmsf), which represents 
the theoretical pressure throughout the systemic blood vessels when blood flow would stop. 
The difference between Pmsf and RAP determines venous return to the right heart (Fig. 1). 
Venous vasodilation may reduce Pmsf and therefore venous return, although this effect is 
somewhat attenuated because of a simultaneous decrease in venous resistance (Fig. 1). The 
arteriolar smooth muscle tone determines the distribution of     towards the different organs, 
SVR (and thus arterial pressure) and intravascular pressure in the capillaries (Power & Kam 
2001). When all other factors remain constant, arteriolar vasodilation will increase the 
perfusion in a tissue, but if this occurs on a larger scale throughout the body, eg. due to the 
administration of larger doses of acepromazine (Steffey et al. 1985), systemic vascular 
resistance may decline markedly, leading to hypotension and possibly collapse of the vessels 
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perfusing tissues with high extravascular (intracompartmental) pressures, such as the muscles 
of recumbent horses (Lindsay et al. 1980).  
   Compared to other species, horses appear to be more susceptible not only to the respiratory, 
but also to the cardiovascular depressant effects of general anaesthesia (Eberly et al. 1968, 
Gillespie et al. 1969, Hall 1971). Combined with their high body weight and their propensity 
to develop ventilation-perfusion mismatch when anaesthetized and placed in a recumbent 
position, this means that tissue oxygenation is often inadequate in anaesthetized horses. 
Sufficient monitoring is therefore needed to detect signs of cardiopulmonary deterioration at 
an early stage and appropriate measures must be taken to avoid or treat any problems. 
 
Detecting cardiovascular depression during equine anaesthesia 
During equine anaesthesia, cardiovascular monitoring usually consists of clinical assessment 
(pulse rate/quality, mucous membrane colour, capillary refill time, skin turgor, etc.), 
electrocardiography, pulse oximetry and invasive measurement of arterial blood pressure. 
Since the latter requires placement of an arterial catheter, blood sampling for arterial blood 
gas analysis, which is useful to detect hypoxaemia, is also often performed. Although arterial 
pressure is important in the prevention of severe complications, measurement of     allows a 
better assessment of cardiovascular function and additional parameters such as stroke volume, 
oxygen delivery and systemic vascular resistance (provided right atrial pressure is known) can 
be calculated (Table 1). Numerous techniques have been described to measure    , including 
the Fick principle (Fick 1870), indicator dilution methods (Lagerlof et al. 1950), rebreathing 
of carbon dioxide (Klausen 1965), electromagnetic flowmetry (Brunsting et al. 1970), pulse 
contour analysis (Kouchoukos et al. 1970), Doppler echocardiography (Steingart et al. 1980) 
and thoracic electrical bioimpedance (Mattar et al. 1986). A continuous thermodilution 
method, using readings from a thermistor incorporated into the pulmonary catheter was 
developed, mainly for intensive care purposes in man (Luchette et al. 2000). However, the 
response time in sheep was reported to be rather slow (Siegel et al. 1996).  
   In horses, the indicator dilution techniques have been used most frequently (Muir et al. 
1976). When performed carefully, the dilution techniques are as accurate as an 
electromagnetic flowmeter placed around the aorta (Kouchoukos et al. 1970), but usually  
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Fig. 2:  Short description of cardiac output (   ) measurements using the lithium dilution and 
pulse contour analysis techniques 
require placement of a central venous and/or pulmonary artery catheter. In 1993, Linton et al. 
described the use of lithium chloride for a new indicator dilution technique to measure     
(Fig. 2). This technique was later commercialized under the tradename LiDCO
®
. It was 
demonstrated that the technique was reliable in horses (Linton et al. 2000) and that 
measurements using a peripheral injection of lithium chloride were comparable to those after 
central venous injection in dogs, eliminating the need for central venous catheterization 
(Mason et al. 2002). However, the technique only allows intermittent assessments of    . It has 
been reported that transoesophageal echocardiography is an effective and non-invasive 
method for measurement of     in anaesthetized horses (Young et al. 1996). With this 
technique,      is calculated as the product of the velocity-time integral of blood flow through 
the aorta, the cross-sectional area of the aorta and heart rate. However, a long, expensive 
device is needed in horses, the technique does not provide continuous measurements and 
technical experience is required. Also, the user may have difficulty to obtain a good alignment 
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of the ultrasound beam, which should be parallel to the blood flow. This is even more difficult 
when performing transthoracic echocardiography. Finally, the technique is minimally invasive 
but does not allow calculation of certain parameters derived from    , such as SVR, unless 
arterial and central venous pressures are simultaneously monitored. 
   Cardiac output is rarely measured in horses anaesthetized for clinical purposes because no 
„ideal‟ measurement technique is available, i.e. one that is accurate, continuous, easy to 
perform and minimally invasive. However, the estimation of     based on analysis of the 
arterial pressure wave seems to fulfil most of these criteria, as it allows continuous, beat-to-
beat assessment of     and only requires the insertion of an arterial catheter. Based on a 
mathematical model (Kouchoukos et al. 1970), these techniques allow calculation of changes 
in stroke volume or     from the arterial pressure wave, but require calibration in each patient 
using an absolute method, such as thermodilution or lithium dilution (Jansen et al. 1990). The 
accuracy of the original formulas was rather disappointing compared to other methods of 
measuring     in man, dogs and pigs (Alderman et al. 1972, Starmer et al. 1973, Verdouw et 
al. 1975, Wesseling et al. 1976). Later on, a more complicated, nonlinear, time-varying three-
element model was developed, the “Modelflow” method, which was found to be more 
accurate (Wesseling et al. 1993). This formula was the basis for the commercial PiCCO
®
 
system, which needs an initial calibration using the thermodilution technique (Gödje et al. 
2002).  
   The PulseCO
®
 software (Fig. 2) uses yet another formula to calculate     during every heart 
beat from the beat duration, ejection duration, mean arterial pressure and the modulus and 
phase of the first harmonic of the arterial waveform. It is usually calibrated by the lithium 
dilution technique, which offers the advantage that no pulmonary catheterisation is needed 
and that the two techniques can be conveniently combined into one monitor, the LiDCO-
Plus
®
. Another advantage is that PulseCO
®
 incorporates a model of pressure transfer from the 
aorta to the radial artery, whereby wave reflections are taken into account, which should make 
the technique more accurate (Linton & Linton 2001). Compared to thermodilution and 
LiDCO
®
 in man, PulseCO
®
 reliably tracked changes in     for at least 8 hours after cardiac 
operations (Hamilton et al. 2002). Because the PulseCO
®
 algorithm was developed for use in 
humans, the reliability in animals remains uncertain. If the technique proved to be reliable in 
horses, it would be an invaluable technique for     measurement in this species, where 
assessment of cardiovascular function is of fundamental importance to improve survival rate. 
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Principles of treatment 
To reduce the complication rate in equine anaesthesia, some preventive measures should be 
taken in all anaesthetized horses, including preoperative preparation of the horse (with 
correction of any abnormalities when possible, e.g. hypovolaemia), use of sufficient padding, 
careful positioning of the horse (to avoid myopathies), availability of equipment for artificial 
ventilation, reduction of anaesthesia duration if possible, etc. The anaesthetic protocol also 
has an important role, e.g. it has been reported that less muscular injury results from 
hypoxaemia during isoflurane compared to halothane anaesthesia (Whitehair et al. 1996). 
Although such measures are of fundamental importance to reduce the incidence and severity 
of problems resulting from anaesthesia-related cardiovascular depression, cardiovascular 
function per se must also be restored whenever it deteriorates during anaesthesia. Three 
general principles are the fundaments of the prevention and treatment of cardiovascular 
depression in any species: reduction of anaesthetic depth (if possible), high-volume fluid 
therapy and use of drugs which stimulate the cardiovascular system. In daily practice, the aim 
is usually to maintain mean arterial pressure above 70 mm Hg in anaesthetized horses to 
reduce the incidence or severity of myopathy (Young 1993, Duke et al. 2006), since 
intracompartmental pressure in the dependent muscles of adult horses, on an adequately 
padded surface, reaches values of 30-40 mm Hg (White & Suarez 1986), while vascular 
transmural pressure needs to be greater than 30 mm Hg for adequate microcirculation (Young 
1993). However, as stated above, not only maintaining blood pressure but additionally 
measuring and optimizing cardiac output would be desirable.  
   Volatile anaesthetics have only poor analgesic properties (Tomi et al. 1993, Petersen-Felix 
et al. 1995) and, depending on the circumstances, may even be anti-analgesic (Zhang et al. 
2000). Consequently, reducing anaesthetic depth in response to cardiovascular depression is 
usually not possible when only an inhalant is used for maintenance of anaesthesia during 
painful surgical procedures. However, as a preventive measure, the use of locoregional 
anaesthetic/analgesic techniques (Tobias 1996, Tobias et al. 1996, Doherty et al. 1997, 
Morley et al. 2002, Haga et al. 2006) and/or systemically administered anaesthetics/analgesics 
(Brandl & Taeger 1991, Muir & Sams 1992, Doherty & Frazier 1998, Muir et al. 2003) can 
reduce the need for volatile anaesthetics by providing additional analgesia, hypnosis and/or 
muscle relaxation, the 3 cornerstones of anaesthesia. Similarly, intratesticular, intrafunicular 
and subcutaneous administration of lidocaine reduced the need for additional doses of 
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ketamine and romifidine during total intravenous anaesthesia for field castration in horses 
(Portier et al. 2009). Combining anaesthetic drugs may result in less pronounced side effects, 
not only when dose requirements are reduced, but also when the anaesthetic agents have 
opposing effects on the cardiovascular system. As an example, the cardiovascular depressant 
effects of inhalants (Steffey & Howland 1980) might be partially offset by the administration 
of a constant rate infusion of ketamine (Muir & Sams 1992), which usually increases heart 
rate and arterial blood pressure by increasing sympathetic efferent activity (Wong & Jenkins 
1974). It is therefore clear that, with respect to cardiovascular function, balanced anaesthetic 
techniques have many advantages over the use of a single agent for maintenance of 
anaesthesia. 
   In humans and small animals, high-volume fluid therapy can be an effective means of 
increasing circulating volume and cardiovascular performance. In horses and other large 
animals, this is less readily achieved because very large volumes need to be infused, 
especially when isotonic crystalloids are used. Indeed, 75 to 85 % of the administered volume 
moves to the interstitial space within the first hour after intravenous administration (Griffel & 
Kaufman 1992). In shock cases, the recommended administration rates of isotonic crystalloids 
in dogs and cats are respectively situated around 90 and 55 mL/kg within 10 to 15 min (Day 
2000). In equine practice, even when using multiple, large-gauge, short catheters and 
pressurized infusion systems, such infusion rates are rarely, if ever, reached. Due to their 
larger molecular size, colloid solutions are better retained within the vasculature and are 
therefore more effective at quickly restoring plasma volume, because smaller volumes result 
in greater plasma volume expansion compared with crystalloids (Shoemaker et al. 1981). A 
cheaper alternative is the use of hypertonic saline (Danowski et al. 1946), which first causes a 
shift of water into the plasma from red blood cells and endothelium and then from the 
interstitium and tissue cells (Mazzoni et al. 1988). Although the increase in blood volume is 
transitory, it occurs in only a fraction of the time needed with iso-osmotic fluids at the same 
infusion rate. Furthermore, capillary hydraulic resistance may be reduced and tissue perfusion 
improved since hypertonic saline causes haemodilution and endothelial cell shrinkage, 
(Mazzoni et al. 1988). Use of hypertonic saline in horses or ponies has been reported by 
several authors (Bertone et al. 1990, Dyson & Pascoe 1990, Schmall et al. 1990, Gasthuys et 
al. 1992). 
   Despite the use of balanced anaesthetic protocols and fluid administration, cardiovascular 
stimulant drugs are often needed in anaesthetized horses. Among the drugs most often used in
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 anaesthetized horses are the sympathomimetic agents dobutamine, dopamine, ephedrine and 
noradrenaline, but many other drugs exist which exert a stimulating effect on the 
cardiovascular system. The following part of this chapter presents a general overview of the 
different classes of available drugs, with specific attention to the effects that have been 
reported in horses.  
Conclusions 
Horses are prone to develop inadequate tissue oxygen supply during anaesthesia, a factor 
which contributes to the high mortality related with anaesthesia in this species. To optimize 
oxygen delivery, cardiovascular depression needs to be diagnosed and treated. No ideal 
method to measure cardiac output in anaesthetized horses under clinical circumstances is 
available, but the pulse contour analysis (PulseCO
®
) technique appears promising. When 
cardiac output is found to be low, reduction of anaesthetic depth and high volume fluid 
therapy are useful measures, but pharmacological support of the cardiovascular system is still 
often needed in horses.     
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SUMMARY 
Cardiovascular stimulant drugs include antimuscarinics, inotropic drugs and 
vasopressors. Antimuscarinic drugs increase heart rate and, for many reasons, are not 
suitable to augment cardiac output (   ) unless it is decreased by bradycardia which is 
not related to hypertension. Inotropic drugs include digitalis glycosides, β-
sympathomimetics, calcium salts, calcium sensitizers and phosphodiesterase III 
inhibitors. Although the mechanism of action differs between these agents, most 
inotropes increase the availability of calcium to the contractile apparatus of the cardiac 
muscle. For routine cardiovascular support during equine anaesthesia, digitalis 
glycosides seem to be of limited usefulness, because of their unfavourable 
pharmacokinetic properties and toxicity. Extensive research has been performed on the 
β-sympathomimetics, of which dobutamine appears to remain the most useful agent for 
use in anaesthetized horses. Calcium salts are not always effective, the effects depend on 
the cardiovascular situation of the individual horse. The use of calcium sensitizers has 
not been described in horses, but these drugs are quite expensive and long acting and 
are most likely best reserved for patients with specific cardiac diseases. Available data 
on the use of phosphodiesterase III inhibitors, i.e. inodilators, in horses is very limited. 
Vasopressors, such as vasopressin analogues, calcium salts and α-sympathomimetics are 
useful only when hypotension is caused by vasodilation, e.g. induced by drugs or 
endotoxins, while myocardial contractility and     are normal or even increased and 
vascular transmural pressure needs to be restored to maintain a normal tissue 
perfusion. 
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Introduction 
Cardiovascular depression frequently occurs and can induce detrimental effects in 
anaesthetized horses, especially because this species is also prone to hypoxaemia during 
anaesthesia. Despite the use of balanced anaesthetic techniques and intensive fluid therapy, 
additional pharmacological support is often needed to optimize cardiac output (   ) and blood 
pressure. This can be achieved by the use of chronotropic, inotropic or vasoactive drugs. The 
classification of these drugs into a single class is often not possible, e.g. noradrenaline exerts 
both positive inotropic (Garb 1950) and vasoconstrictive (Sutton et al. 1950) effects. 
Theoretically, vasodilators may also increase     by reducing afterload, but this approach will 
often induce hypotension with a reduction in tissue perfusion pressure.  
   The drugs most typically used to increase heart rate (HR) in equine clinical practice are the 
anticholinergics which competitively antagonize the muscarinic effects of acetylcholine 
without affecting the nicotinic receptors at the neuromuscular junction. These drugs are 
therefore more precisely referred to as antimuscarinic drugs (Calvey & Williams 2001b). 
Available inotropic drugs include digitalis glycosides, β-adrenergic agonists, calcium salts, 
calcium sensitizers and phosphodiesterase (PDE) inhibitors (Notterman 1991, Choudhury & 
Saxena 2003, Via et al. 2003). Except for vasopressin analogues and perhaps calcium salts, 
most vasopressors that are routinely used clinically are α-adrenergic agonists (Kee et al. 
2003). 
 
Antimuscarinics 
Both naturally occurring and synthetic antimuscarinic drugs affect organs innervated by 
postganglionic parasympathetic fibres, such as the heart, non-vascular smooth muscle, the 
eyes and glandular tissues (Calvey & Williams 2001b). The anticholinergic drugs most often 
used in equine practice are atropine, glycopyrrolate and hyoscine. Atropine (or hyoscyamine), 
probably the best known anticholinergic drug, is an alkaloid that can be extracted from the 
plant Atropa belladonna (deadly nightshade). It has been suggested that the juice of the 
belladonna berry, which contains atropine, was already used by Cleopatra for cosmetic 
purposes, i.e. to induce mydriasis (Emsley 2008). Atropine has been used mostly for 
premedication and to antagonize the muscarinic effects of anticholinesterase drugs, but also 
for other specific indications, e.g. to produce mydriasis in humans with glaucoma (Derby 
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1868) or as an antisialagogue (Kentala et al. 1990). Heart rate was reported to increase two- to 
threefold after administration of atropine (0.04 mg/kg intravenously) in awake horses (Hamlin 
et al. 1972). The drug has been widely used in horses to antagonize the bradycardic effects of 
α2 agonists (Alitalo et al. 1986, Gasthuys et al. 1990).  
   Glycopyrronium is another antimuscarinic drug often used by human and veterinary 
anaesthetists. Unlike atropine, it does not readily cross the blood brain barrier or the placenta 
because it is an ionized quaternary amine (Calvey & Williams 2001a). In humans, it is an 
effective antisialagogue with a long duration of action (approximately 6 hours) which does 
not tend to cause other antimuscarinic effects when used at moderate doses (e.g. 0.2 mg total 
dose). Indeed, clear effects on HR and pupillary size are only observed at higher doses 
(Calvey & Williams 2001a). In dogs (Richards et al. 1989) and horses (Singh et al. 1997, 
Dyson et al. 1999), the cardiac effects appear to be more comparable to those of atropine.  
   In humans, hyoscine (scopolamine) has a shorter duration of action, produces less 
tachycardia, is a more powerful antisialagogue and has less bronchodilator activity compared 
to atropine (Calvey & Williams 2001a). It is a useful drug in the prevention and treatment of 
motion sickness (Spinks et al. 2007) and has also been used in combination with opioids to 
produce „twilight sleep‟ (Gauss 1906). In equids, hyoscine butylbromide, a quaternary 
ammonium derivative of scopolamine, is often used for its spasmolytic properties (Roelvink 
et al. 1991, Boatwright et al. 1996), although the drug can increase HR in horses (Geimer et 
al. 1995, Marques et al. 1998, Borer & Clarke 2006). 
   As mentioned earlier, the main cardiovascular effect of antimuscarinics is positive 
chronotropism. Although HR is one of the determinants of    , attempting to increase     using 
chronotropic drugs is usually not recommended unless a clear bradycardia is present. When 
high heart rates are pharmacologically induced, myocardial oxygen consumption increases 
(Van Citters et al. 1957), while the proportion of time spent in diastole diminishes. Since 80 
% of the total coronary blood flow actually occurs during the diastolic phase (Power & Kam 
2001a), tachycardia may compromise myocardial oxygen delivery. This effect will be 
attenuated by a reflex metabolic coronary arteriolar dilatation (Power & Kam 2001a), but 
hypoperfusion and hypoxia of the myocardium can still occur, e.g. when tachycardia is 
severe, cardiac disease is present or drugs affecting coronary vascular resistance have been 
administered. In those cases, cardiac oxygen supply can become insufficient, resulting in 
decreased myocardial contractility (Jose & Stitt 1969, Nayler et al. 1971) or arrhythmias 
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(Senges et al. 1979, Hjalmarson 1980). Atropine has also been shown to increase the 
arrhythmogenicity of dobutamine in halothane anaesthetized horses (Light & Hellyer 1993). 
Finally, most antimuscarinic drugs have a negative effect on intestinal motility (Ducharme & 
Fubini 1983, Singh et al. 1996) and can induce signs of abdominal discomfort or colic in 
horses (Ducharme & Fubini 1983). These side effects might be avoided by using selective 
muscarinic type-2 antagonists such as methoctramine (Teixeira Neto et al. 2004). In equine 
anaesthesia, atropine has been widely used to counteract bradycardia and atrioventricular 
(AV) blocks after administration of α2 agonists (Brouwer et al. 1980, Gasthuys et al. 1990). 
Atropine was also shown to reduce the dose of dobutamine needed in order to maintain mean 
arterial pressure (MAP) above 70 mm Hg (Weil et al. 1997), but this strategy is somewhat 
controversial. An important part of the bradycardia induced by α2 agonists is attributable to a 
baroreceptor reflex in response to the initial hypertension associated with the administration 
of these drugs. Administering a positive chronotropic agent under such circumstances may be 
associated with even more pronounced increases in blood pressure. Cardiac work will also be 
higher since     increases in the presence of a high afterload, associated with α2 agonist – 
induced vasoconstriction. Finally, any chronotropic effects of other drugs, e.g. dobutamine, 
will be accentuated and may lead to pronounced tachycardia. For all these reasons, the use of 
antimuscarinic drugs for cardiovascular support is preferrably limited to horses with severe 
bradycardia unrelated to hypertension and which are not predisposed to develop 
gastrointestinal problems. 
 
Inotropes 
All positive inotropic drugs, such as digitalis glycosides, β-sympathomimetics, calcium salts, 
calcium sensitizers and phosphodiesterase inhibitors, increase myocardial contractility. 
Although there are differences in the exact mode of action of these drugs, the end result is 
virtually always (except for calcium sensitizers) an increased availability of calcium (Ca
2+
) to 
the contractile myocardial apparatus (Choudhury & Saxena 2003). Because of differences in 
additional positive or negative effects, preferred route of administration, efficacy and/or 
pharmacokinetic properties, the suitability of these products for use during anaesthesia differs 
from drug to drug. Also, their effects in horses are not always the same as in other species. 
From a pharmacokinetic and pharmacodynamic point of view, an ideal inotropic drug for use 
during anaesthesia needs a rapid onset and short duration of action with a reliable dose-effect 
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relationship and no tendency to accumulate, irrespective of the duration of administration and 
the health status of the patient. Indeed, these properties allow administration as a constant rate 
infusion (CRI) with the ability to rapidly alter plasma concentrations and associated 
cardiovascular effects. Ideally, the drug should also not induce side effects or overly increase 
myocardial oxygen consumption. 
   
Digitalis glycosides 
The digitalis glycosides form a group of more than 300 steroid-containing compounds that 
exert clear electrophysiologic effects on the heart. The most popular drugs are digoxin and 
digitoxin, which are used clinically, as well as ouabain, which is mostly used under laboratory 
conditions (Jortani & Valdes 1997). Cardiac glycosides increase the intracellular sodium 
concentration in the myocardial cells by inhibiting the Na
+
, K
+
-ATPase pump. This leads to a 
reduced extrusion of Ca
2+
 in exchange for Na
+
 and therefore an increased intracellular 
concentration of Ca
2+
, resulting in an increased force of contraction
 
(Calvey & Williams 
2001b). A second effect of the inhibition of Na
+
, K
+
-ATPase is a reduced inward K
+
 transport 
and therefore a less negative resting membrane potential. This leads to increased automaticity 
and possibly impaired conduction and excitability, explaining the toxic arrhythmogenic 
activities of digitalis (Adams 2001). At therapeutic concentrations, digoxin also increases the 
initial rate and the amount of Ca
2+
-induced Ca
2+
 release from cardiac sarcoplasmic reticulum 
(SR) vesicles, which may contribute directly to digoxin‟s inotropic effects (McGarry & 
Williams 1993).  
   Cardiac effects of digoxin include increased rate and peak force of contraction, as well as 
reduced time for generation of the peak force. Due to alterations in vagal and sympathetic 
function, digitalis therapy leads to reduced formation of impulses by the sinoatrial (SA) node 
and depression of conduction by the AV node, accompanied by an increase in the effective 
refractory period (Jortani & Valdes 1997). Its main use is in human and veterinary patients 
with congestive heart failure (CHF), where digitalization results in a broad scope of 
haemodynamic adjustments, including increased myocardial contractility and    , diuresis and 
diminution of oedema, control of cardiac arrhythmias and reductions in blood volume, venous 
pressures, heart size and HR. The improved myocardial contractility is the most important 
effect and the primary action on which the other effects depend (Adams 2001). Prophylactic 
preoperative digitalization has been used in humans to protect the heart against the negative 
inotropic effect of certain anaesthetic agents (Goldberg et al. 1961). Similarly, preanaesthetic 
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digitalization in dogs offered some protection against the negative inotropic and hypotensive 
effects of 1 and 2 % halothane (Goldberg et al. 1962) and high doses of thiopental (45 and 60 
mg/kg), although this could not be reproduced with smaller doses (15 and 30 mg/kg) 
(Goldberg et al. 1961). Prophylactic preoperative digitalization is not only useful for patients 
with overt heart failure, but has also been recommended in the late 1960‟s for patients with 
any history of cardiac failure (even when well compensated at the time of surgery), cardiac 
enlargement, ventricular hypertrophy, coronary artery disease or episodic atrial fibrillation 
(AF) or flutter, and for any patient undergoing cardiac surgery or for people over the age of 
50 years undergoing major pulmonary surgery (Deutsch & Dalen 1969). Later on, 
preoperative digitalization of patients with coronary artery disease (but without cardiac 
failure) has indeed been shown to prevent the impairment in cardiac function during recovery 
from anaesthesia (Pinaud et al. 1983). 
   Despite possible protective effects against the negative inotropic effects of anaesthetic 
drugs, cardiac glycosides are rarely used in patients without a history or clinical evidence of 
cardiovascular abnormalities. Possible reasons include problems related to the 
pharmacokinetic profile of digoxin, its propensity to induce toxic side effects and perhaps the 
apparently lower effectiveness in healthy patients. As mentioned earlier, an inotropic drug for 
perianaesthetic use is preferred to have a rapid onset but short duration of action, two 
properties which digitalis glycosides do not appear to have. Although the positive inotropic 
response to digoxin and digitoxin can be detected within 15-30 minutes after intravenous (IV) 
administration in dogs, the maximal pharmacological effect is typically not obtained until 60 
minutes after administration (Hamlin et al. 1971). This might make the drug sufficiently 
suitable for preoperative prophylactic use, but much less for treatment of cardiovascular 
depression occurring during anaesthesia. Digoxin disposition after IV injection in horses was 
reported to be tri-exponential. Both a rapid and slow distributive phase with half-lives of 15 
minutes and 4.1 hours respectively, followed by a biological disposition phase with a half-life 
of 23.1 hours have been calculated (Button et al. 1980). Based on these data, prolonged 
effects can be expected after administration of these drugs. It has been stated that „The basic 
procedure for digitalization usually involves the initial administration of a large amount of 
digitalis divided in several doses over a period of 24 – 48 hours to achieve the desired 
therapeutic effect quickly, but because of marked interpatient variation in the response to 
therapeutic and toxic actions of the glycosides, digitalization of each patient should be viewed 
as an individual and separate project involving some degree of trial and error during the 
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search for an efficacious dose without toxic side effects‟ (Adams 2001). From this description, 
it seems reasonable to say that, even if these drugs can be used during preoperative 
preparation of patients with cardiac disease facing elective surgery, they are not suitable for 
peroperative use in emergency cases, nor feasible for routine use before elective surgery. 
Furthermore, cardiac glycosides are typically administered orally and although IV 
administration is justified during acute decompensation, this increases the likelihood for toxic 
arrhythmias (Adams 2001). 
   The narrow safety margin between the therapeutic and toxic levels of digoxin is a major 
drawback. Toxicity is initially manifested in horses as signs of anorexia, colic, and diarrhoea, 
but cardiac arrhythmias are another common and potentially life-threatening result of digitalis 
intoxication (Sage 2002). Digoxin is capable of producing paroxysmal atrial tachycardia, 
atrial fibrillation and flutter, AV block and junctional rhythm with slow rate (Jortani & Valdes 
1997). Close monitoring of the clinical response and plasma digoxin concentration are needed 
in horses under digoxin treatment to avoid toxicity (Sage 2002), again rendering this drug less 
suitable for routine use during anaesthesia. Also, accurate measurement of digoxin 
concentrations has proven to be technically difficult and challenging (Jortani & Valdes 1997). 
Furthermore, hypokalaemia, -magnesaemia, and -calcaemia, can occur in anaesthetized 
patients and make the patient more sensitive to the toxic effects of digitalis glycosides. At the 
same time, digoxin also interacts with other drugs commonly used in the perioperative period, 
including phenylbutazone, quinidine, erythromycin, tetracyclines, omeprazole, etc. (Sage 
2002). Digoxin further accentuates the cardiotoxicity of local anaesthetics (Roitman et al. 
1993). Digitalis is not indicated in cases of circulatory shock because it may intensify tissue 
hypoxia by causing peripheral vasoconstriction in patients without congestive failure 
syndrome (Adams 2001). 
   Finally, digoxin was proven to be more effective in the diseased than in the normal heart, 
where     increases minimally and may even decrease slightly due to an increase in systemic 
vascular resistance (SVR), thus augmenting outflow impedance (Adams 2001). Although 
digitalis increases the contractility not only of the failing, but also of the normal heart (Adams 
2001), the degree to which cardiac glycosides augment contractility is inversely related to the 
baseline contractile state (Braunwald 1985). Despite these observations, it may be argued that, 
during anaesthesia, contractility is depressed and should therefore be higher with prior 
digitalization, even in healthy patients. However, there is clear evidence suggesting that the 
effects of digoxin are diminished by certain anaesthetic drugs. Halothane was shown to 
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increase the tolerance of the heart to digitalis, so digitalization may be less effective in 
patients anaesthetized with halothane, while the effects of an excessive dose of digitalis given 
during halothane anaesthesia may not become apparent until the patient awakens (Morrow 
1970). Also, preoperative digitalization did not attenuate cardiac and haemodynamic changes 
occurring after induction and during balanced anaesthesia with phenoperidine, thiopentone, 
suxamethonium, pancuronium and N2O/O2 in patients with ischaemic heart disease (Blanloeil 
et al. 1980).  
   In horses, digoxin can be used during treatment for CHF (Brumbaugh et al. 1982, 
Staudacher 1989) and AF (Reef et al. 1995, Gray 1999) and remains the most commonly used 
digitalis glycoside in the horse (Sage 2002). However, digitalis is best reserved for therapy of 
CHF and should not be used in attempts to treat cardiovascular depression during anaesthesia 
in healthy patients. To the authors‟ knowledge, reports in literature about perianaesthetic use 
of digoxin in equids are sparse, being limited to one experimental study about the combined 
use of digoxin and dopamine in ponies (Gasthuys et al. 1991b) and a case report about the use 
of digoxin during preoperative preparation of a horse with AF and reduced contractility 
(Schauvliege et al. 2005).  
 
Sympathomimetics 
When ß-adrenergic sympathomimetics bind to the β1-receptor, a stimulatory protein (Gs), 
which is a heterotrimer of α, β and γ subunits, is activated (Hall 1993) and undergoes a 
conformational change. This results in high-affinity binding of guanosine triphosphate (GTP) 
(Gilman 1984) and dissociation of the α subunit – GTP complex, which in turn stimulates 
adenylate cyclase. The latter enzyme converts adenosine triphosphate (ATP) to cyclic 
adenosine monophosphate (cAMP) (Power & Kam 2008). Cyclic AMP then binds to a protein 
kinase comprised of two regulatory and two catalytic subunits, causing a dissociation of the 
regulatory subunits from the catalytic subunits. This activated protein kinase phosphorylates 
specific substrate proteins in the cells, including sarcolemmal proteins, phospholamban and 
troponin-I (TnI) (Evans 1986).  
   Phosphorylation of sarcolemmal proteins results in increased Ca
2+ 
influx through slow 
channels in response to membrane depolarization (Evans 1986). More specifically, the 
probability of slow Ca
2+
 (L-type) channel opening and the mean open time of the channel are 
increased, an effect mediated by protein kinase A (Sperelakis et al. 1994). In addition to the 
slower, indirect, cAMP/protein kinase A pathway, a faster and more direct mechanism also 
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follows β receptor activation, which likely involves direct modulation of the L-type Ca2+ 
channel activity by the α subunit of the Gs-protein (Sperelakis et al. 1994). Because Ca2+ flux 
across myocardial cell plasma membranes is facilitated (Osterrieder et al. 1982), intracellular 
Ca
2+
 levels increase, stimulating the release of more Ca
2+
 from the SR („Ca2+ induced Ca2+ 
release‟) (Fabiato 1983). This results in an increase of the contractile forces (Vernon et al. 
1991). 
   Phosphorylation of phospholamban, a protein that regulates the Ca
2+
 pump of the SR, 
results in an increased velocity of Ca
2+
 reuptake by SR vesicles, an increased affinity of the 
transport protein for Ca
2+
 and an increased turnover of elementary steps of the ATPase 
reaction (Kranias & Solaro 1983). Consequently, Ca
2+
 transport by the cardiac SR is 
stimulated (Tada et al. 1975) and occurs at an increased rate (Davis et al. 1990, Luo et al. 
1994), thus augmenting calcium sequestration by the SR (Tada et al. 1983). Because more 
Ca
2+
 is available for release during the next action potential, the net result is a higher force 
and rate of contraction (Luo et al. 1994). In phospholamban-deficient mice, contractility was 
as high as in wild-type mice maximally stimulated by the β agonist isoproterenol, while 
isoproterenol administration in the knockout mice did not further increase contractility (Luo et 
al. 1994). It ha s therefore been suggested that increases in the Ca
2+
 sensitivity of the SR 
transport system, through phosphorylation of phospholamban, might even be the main 
mechanism by which β-adrenergic agonists mediate a contractile response. A second 
consequence of the rise in the Ca
2+
 transport rate by the SR is an increased rate of myocardial 
relaxation, i.e. a positive lusitropic effect (Luo et al. 1994, Li et al. 2000).  
   Protein kinase A in ventricular myocytes also phosphorylates TnI, which helps to explain 
the positive lusitropic effects of catecholamines (Kögler & Rüegg 1997). Phosphorylation of 
TnI leads to a decreased affinity of troponin C for Ca
2+
 (Kranias & Solaro 1983, Kögler & 
Rüegg 1997) and an increased rate of Ca
2+
 dissociation from the myofilaments, thus 
accelerating myocardial relaxation (Li et al. 2000).  
   Negative aspects of ß-adrenergic sympathomimetics are the increases in cardiac work and 
myocardial oxygen demand occurring after their administration (Notterman 1991), as well as 
sinus tachycardia, cardiac arrhythmias, muscular tremor and disturbances of organ perfusion 
caused by vasoconstriction (Swanson et al. 1985, Trim et al. 1985, Gasthuys et al. 1991c, Lee 
et al. 1998). The increase in HR seen after administration of β1-adrenergic agonists is related 
to acceleration of voltage-sensitive sarcolemmal currents (the so-called „voltage clock‟) and 
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Ca
2+ release from the SR (the „calcium clock‟) in cardiac pacemaker cells, such as the SA 
node (Eisner & Cerbai 2009, Joung et al. 2009). Individual differences between drugs do 
exist, not only in their pharmacokinetic properties but also in their selectivity for the different 
types of adrenergic receptors. Two classic examples of catecholamines are adrenaline and 
noradrenaline. However, dobutamine and dopamine are undoubtedly the most widely used 
agents in equine anaesthesia. A short overview of some β-sympathomimetics is presented in 
Table 1. 
Adrenaline 
Adrenaline or epinephrine is an endogenous catecholamine secreted into the bloodstream by 
the adrenal medulla during stress periods. It exerts powerful α and β1 and moderate β2 effects 
(Barnard & Linter 1993). At lower doses (0.04 – 0.1 µg/kg/min), the effects on β-
adrenoreceptors predominate and HR, contractility and conduction velocity are increased (β1 
effect), while SVR is lowered (β2 effect) or unchanged (Morrill 2000, Calvey & Williams 
2001b). Consequently, systolic arterial pressure (SAP) increases, while diastolic arterial 
pressure (DAP) may even decrease due to vasodilation (Sanders et al. 1991, Calvey & 
Williams 2001b). At higher doses, the α-effects become more dominant so both SVR and 
blood pressure increase (Barnard & Linter 1993, Morrill 2000). In halothane anaesthetized 
horses, IV administration of a bolus of adrenaline (3 µg/kg) resulted in a pronounced increase 
in blood pressure during approximately 8 minutes; HR initially increased markedly, but 
decreased when the pressor response became maximal (Lees & Tavernor 1970). The plasma 
half-life of adrenaline is very short (10-15 seconds) (Power & Kam 2001b), explaining the 
short duration of the effects. Consequently, adrenaline can be administered as a CRI, which 
has been described in halothane anaesthetized horses. Significant increases in blood pressure 
and HR were seen at rates of 0.25-1.2 µg/kg/min, but ventricular premature contractions 
occurred at the higher end of the dose range (Gaynor et al. 1992). 
   In human medicine, adrenaline is mainly indicated for treatment of anaphylaxis, pulseless 
electrical activity, asystole and ventricular fibrillation (Morrill 2000) and plays an important 
role during cardiopulmonary resuscitation (Wenzel et al. 2006). The drug can be useful in 
cases of ventricular fibrillation where fine fibrillation (high-frequency, low-amplitude waves) 
needs to be coarsened prior to direct current cardioversion (Calvey & Williams 2001b). 
Adrenaline is also indicated in patients irresponsive to dobutamine or dopamine and in 
patients with life threatening hypotension, because its maximal effects are greater than those 
of other β agonists (Lees & Tavernor 1970, Barnard & Linter 1993). 
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Table 1: Dose-dependent effects of frequently used β- sympathomimetic agents (continues).  
  
Abbreviations used: heart rate (HR), arterial blood pressure (ABP), systemic vascular resistance (SVR), oxygen (O2), systolic (SAP) and 
diastolic (DAP) arterial pressure, ventricular premature contraction (VPC), dopamine 1 and 2 receptor (DA1 and DA2 respectively), 
glomerular filtration rate (GFR), sodium (Na
+
), cardiac output (   ). 
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Table 1: Dose-dependent effects of frequently used β- sympathomimetic agents (continued).   
 
 
Abbreviations used: cardiac index (CI), mean arterial pressure (MAP), systemic vascular resistance (SVR), cardiac output (   ), arterial 
blood pressure (ABP), heart rate (HR), dopamine 1 and 2 receptor (DA1 and DA2 respectively).  
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Table 1: Dose-dependent effects of frequently used β- sympathomimetic agents (continued).  
 
 
Abbreviations used: systemic vascular resistance (SVR), cardiac index (CI), mean arterial pressure (MAP), stroke volume (SV), heart 
rate (HR), packed cell volume (PCV), arterial blood pressure (ABP), cardiac output (   ), atrioventricular (AV), atrial premature 
contraction (APC), diastolic arterial pressure (DAP), oxygen (O2).  
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   Adrenaline additionally produces many other effects throughout the body, including 
mydriasis, bronchodilation, lipolysis, glycogenolysis, increased blood glucose levels, 
sweating, etc. (Anderson & Aitken 1977, Morrill 2000). Traditionally, there has been concern 
about the association of adrenaline with tachycardia, vasoconstriction and myocardial 
ischaemia (Schechter et al. 1983). Adrenaline constricts coronary vessels due to its effects on 
α adrenoceptors and although this direct effect is overshadowed by the dilatory effect of 
metabolic changes induced by the increased work of the heart (Calvey & Williams 2001b), 
myocardial oxygen consumption rises due to increases in HR, contractility and SVR (Fawaz 
& Tutunji 1960). Myocardial oxygen supply may therefore become inadequate (Barnard & 
Linter 1993). 
   Another concern during treatment with adrenaline is its propensity to induce arrhythmias 
(Lenel et al. 1948), including premature ventricular depolarizations, ventricular tachycardia 
and atrial or ventricular fibrillation (Gaynor et al. 1992). Intravenous administration of 3 
µg/kg adrenaline produced ectopic beats of ventricular origin in 8 out of 13 conscious horses 
(Lees & Tavernor 1970). The arrhythmogenic activity of adrenaline is also influenced by the 
anaesthetic protocol. As an example, the risk for arrhythmias in response to adrenaline 
infusions in dogs was significantly higher with halothane compared to isoflurane or 
sevoflurane (Imamura & Ikeda 1987). Furthermore, halothane not only increased the 
incidence, but also the duration of ventricular arrhythmias occurring after IV adrenaline 
administration in horses (Lees & Tavernor 1970). In the latter study, 3 µg/kg of adrenaline 
caused ventricular ectopic beats in all horses and ventricular or nodal tachycardia in 4 of 11 
animals (Lees & Tavernor 1970). When hypercapnia occurs, this will further increase the risk 
of adrenaline-induced ventricular arrhythmias in halothane anaesthetized horses (Gaynor et al. 
1993). Beside the choice of the inhalant agent, drugs used during premedication may also 
influence the arrhythmogenicity of adrenaline. Xylazine was reported to reduce the dose of 
adrenaline required to induce fibrillation in anaesthetized dogs (Muir et al. 1975). However, 
more recent studies in dogs (Lemke et al. 1993a & 1993b) and horses (Gaynor et al. 1992) 
failed to show significant alterations in the arrhythmogenic dose of adrenaline after xylazine 
administration (Gaynor et al. 1992). On the other hand, premedication with acepromazine 
may protect against the occurrence of arrhythmias in response to adrenaline (Muir et al. 
1975). Consequently, low doses of acepromazine are often included in the premedication 
protocols of horses for elective surgical procedures. 
Chapter 1.2: Inotropes 
 
 41 
Noradrenaline 
Although noradrenaline or norepinephrine is a β1 agonist which increases myocardial 
contractility (Garb 1950), it is a more potent α agonist and is therefore best seen as a 
vasopressor with some inotropic properties. For this reason, the drug will be discussed later. 
 
Dopamine 
Dopamine is a naturally occurring sympathetic amine and the precursor of noradrenaline. It is 
formed by metabolization of L-dihydroxyphenylalanine (= L-dopa) by dopa decarboxylase 
and is metabolized by dopamine β hydroxylase to noradrenaline (Blaschko 1939). Dopamine 
exerts a complex, dose-dependent action on the cardiovascular system since it stimulates a 
variety of receptors, including presynaptic dopamine 2 (DA2) and α2 receptors and 
postsynaptic dopamine 1 (DA1), α1, α2 and β1 receptors (Murphy & Elliott 1990). Dopamine 
achieves part of its effects by causing the release and preventing the re-uptake of 
noradrenaline (Via et al. 2003). Because of the effects at postsynaptic β1 receptors, mediated 
by inducing noradrenaline release, dopamine has positive inotropic and chronotropic effects. 
Postsynaptic DA1 receptors on vascular smooth muscle cells mediate vascular relaxation and 
promote sodium excretion by the kidneys.  Dopamine causes vasoconstriction by the effects 
exerted at postsynaptic α1 and α2 receptors. Presynaptic α2 and DA2 receptors both inhibit 
noradrenaline release (Murphy & Elliott 1990). The half-life of dopamine is 2 minutes with a 
time to onset of action of 5 minutes and duration of effect of approximately 10 minutes 
(Morrill 2000). 
   In humans, low doses (< 2-4 µg/kg/min) predominantly activate DA1 and DA2 receptors, 
increasing renal plasma flow, glomerular filtration rate and sodium excretion (Murphy & 
Elliott 1990, Barnard & Linter 1993, Morrill 2000). Such „renal‟ doses can be used to increase 
renal blood flow, e.g. during heart failure or acute tubular necrosis (Morrill 2000). However, 
this is no longer recommended as a routine strategy in human medicine. Although low-dose 
dopamine indeed augmented renal blood flow, glomerular filtration rate and natriuresis in 
different experimental models of ischaemic and nephrotoxic acute renal failure (ARF), most 
clinical studies in humans have failed to demonstrate convincingly that it prevents ARF in 
high risk patients, or improves renal function or outcome in patients with established ARF 
(Denton et al. 1996, Friedrich et al. 2005). Intermediate doses (3-10 µg/kg/min) 
predominantly stimulate β1 receptors, resulting in an increased HR and     (Murphy & Elliott 
1990, Morrill 2000, Via et al. 2003). The inotropic effect is usually more pronounced than the 
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chronotropic effect, but tachycardia can sometimes be a problem, particularly in 
underhydrated patients (Calvey & Williams 2001b). These moderate doses are used primarily 
to increase contractility in CHF (Morrill 2000). Higher doses (> 10 µg/kg/min) mainly 
stimulate α receptors, leading to vasoconstriction (Murphy & Elliott 1990, Morrill 2000), 
while arrhythmias become more likely (Calvey & Williams 2001b). Dopamine increases 
automaticity in Purkinje fibres, affects action potential duration and has been reported to 
induce sinus tachycardia and ventricular ectopic activity.  However, the latter is usually 
asymptomatic and dopamine-associated ventricular tachycardia is relatively rare in humans 
(Tisdale et al. 1995). High dosages are mainly used to increase blood pressure in cases of 
hypotension or shock with evidence of hypoperfusion (e.g. mental status changes, oliguria, 
poor tissue perfusion). Dopamine administration is usually initiated when SAP is below 90 
mm Hg (Morrill 2000). It should be remembered that the mentioned dose ranges are 
approximate and doses at which the different receptors are activated can vary considerably, 
depending largely on the patient‟s clinical status and particularly on the pre-existing level of 
sympathetic activity (Murphy & Elliott 1990). 
   Numerous authors reported on the cardiovascular effects of dopamine in conscious or 
anaesthetized ponies or horses. In conscious horses, dopamine at 1 and 2.5 µg/kg/min did not 
affect HR, carotid arterial pressure (Clark & Moore 1989a, Trim et al. 1989), lateral caecal 
arterial blood flow (Clark & Moore 1989a) or fractional excretion of sodium and potassium, 
although a rate of 2.5 µg/kg/min did increase renal blood flow (Trim et al. 1989). In the study 
by Clark & Moore (1989a), significant increases in lateral caecal arterial blood flow and HR 
and decreases in carotid arterial pressure were found when dopamine was administered at a 
rate of 5 µg/kg/min. In contrast, Trim et al. (1989) did not observe any changes in HR, blood 
pressure or fractional excretion of sodium and potassium with a similar dose, although 
increases in renal blood flow and urine volume, decreases in urine osmolality and 
dysrhythmias occurred. 
   In halothane anaesthetized ponies, dopamine CRI‟s at doses of 2.5 and 5.0 µg/kg/min failed 
to induce any significant cardiovascular changes (Gasthuys et al. 1991c, Lee et al. 1998). 
Higher doses (10 – 20 µg/kg/min) decreased SVR and increased CI, MAP and intramuscular 
blood flow in the dependent muscles of halothane anaesthetized ponies, but the highest dose 
(20 µg/kg/min) was associated with tachyarrhythmias and muscular tremor (Lee et al. 1998). 
After pretreatment with digoxin, dopamine did not produce significant changes in 
cardiovascular function at doses of 1.25 and 2.5 µg/kg/min, but administration of 5 µg/kg/min 
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caused increases in blood pressure and    , while SVR tended to decrease and HR and total 
pulmonary resistance remained constant (Gasthuys et al. 1991b). 
   In halothane anaesthetized healthy horses, a dopamine CRI at rates between 0.5 and 3 
µg/kg/min also failed to produce any cardiovascular effects (Swanson et al. 1985, Trim et al. 
1985), except for an increase in     and a decrease in SVR at a dose of 2.5 µg/kg/min (Trim et 
al. 1985), which was not detected at 3 µg/kg/min (Swanson et al. 1985). Using a CRI rate of 4 
µg/kg/min, Young et al. (1998a) reported significant decreases in mean aortic pressure and 
increases in    , together with a small but significant increase in HR. Using a CRI of 5 
µg/kg/min, dopamine had no effect on blood pressure, most likely because it reduced SVR 
while increasing     by augmenting the rate of increase in left ventricular pressure (dP/dt) 
(Swanson et al. 1985). At 10 µg/kg/min, increases in blood pressure were recorded, mainly 
because of an increase in     and dP/dt, while SVR returned to baseline values. Heart rate was 
not affected by either of these doses. Robertson et al. (1996), using the same administration 
rates, reported variable effects on HR, with either no change, an increase or a decrease in 
individual horses. In the study of Swanson et al. (1985), 2
nd
 degree AV blocks, in some cases 
accompanied by increases in HR, were noted in 1 out of 9 horses receiving 5 µg/kg/min and 
in 3 of 9 horses receiving 10 µg/kg/min. Other authors have also reported arrhythmias in 
halothane anaesthetized horses receiving dopamine, including supraventricular premature 
contractions (Trim et al. 1985, Robertson et al. 1996) and episodes of tachycardia at 5 
µg/kg/min (Trim et al. 1985), as well as sino-atrial block, atrial premature contractions, 
ventricular premature contractions, ventricular tachycardia and ventricular fibrillation with 
death in 1 horse at 10 µg/kg/min (Robertson et al. 1996). 
   Based on the available data from literature, it can be concluded that the situation in equids is 
comparable to human medicine, i.e. the cardiovascular effects of dopamine are dose-
dependent and results between various studies are not always consistent. Low dose rates (≤ 3 
µg/kg/min) do not produce clear changes, while higher doses can be used to increase     and 
perhaps also blood pressure. However, by increasing the dose, the risk of inducing 
arrhythmias becomes higher. As in human medicine, the response of each individual patient to 
dopamine may vary depending on the degree of sympathetic stimulation and the health status 
of the patient. After infusion with Escherichia coli endotoxins in anaesthetized horses, 
dopamine appeared to produce more pronounced effects than previously mentioned. A CRI of 
5 µg/kg/min increased CI and blood pressure and decreased diastolic pulmonary arterial 
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pressure (PAP), SVR and pulmonary vascular resistance (PVR), although it had no effect on 
the development of metabolic acidosis (Trim et al. 1991). One more possible indication for 
the use of dopamine was mentioned in a case report where 4 anaesthetized foals with AV 
block unresponsive to atropine sulphate and supportive treatment were treated successfully 
with dopamine hydrochloride (Whitton & Trim 1985). 
 
Dopexamine 
Dopexamine is a synthetic catecholamine with agonistic activity at β2 adrenoreceptors and 
peripheral dopamine receptors (Brown et al. 1985, Calvey & Williams 2001b). The drug‟s 
potency at β2 receptors is approximately 60 times higher than that of dopamine, but the 
activity at dopamine receptors is lower. Nevertheless, dopexamine causes a fall in renal 
vascular resistance and reduces neurogenic vasoconstriction through its activity at vascular 
DA1 and prejunctional DA2 receptors respectively (Brown et al. 1985). Although it is only a 
weak β1 receptor agonist, dopexamine has positive inotropic effects, partly due to its direct 
effects on cardiac β2 adrenoreceptors, but also by inhibiting the neuronal reuptake of 
noradrenaline (Uptake1), which increases the effects of released noradrenaline at β1 receptors 
(Calvey & Williams 2001b, Via et al. 2003). 
   Dopexamine was reported to increase HR and CI and to reduce SVR and PVR (Leier et al. 
1988). In humans, it can be used as an alternative to dobutamine to increase     and produce 
vasodilation, hereby increasing splanchnic blood flow and urinary output (Barnard & Linter 
1993, Via et al. 2003). Besides sinus tachycardia, dopexamine can also induce 
tachyarrhythmias in humans (Calvey & Williams 2001b). 
   In halothane anaesthetized ponies and horses, the cardiovascular effects of dopexamine 
CRI‟s varying between 0.5 and 20 µg/kg/min were usually characterized by increases in CI, 
MAP, HR and maximal rate of increase in left ventricular pressure (dP/dtmax), together with 
a reduction in SVR (Muir 1992a & b, Young et al. 1997, Lee et al. 1998). It was also 
demonstrated that dopexamine infusions of 1 and 5 µg/kg/min in anaesthetized ponies 
increased intramuscular blood flow in the nondependent limb (Lee et al. 1998). However, 
several undesirable side effects have been associated with dopexamine administration in 
equids, including muscular tremor (Lee et al. 1998), profuse sweating during administration, 
excitement and violent shivering during recovery and signs of colic a few hours after 
anaesthesia (Young et al. 1997, Lee et al. 1998). At the higher end of the dose range (10 – 20 
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µg/kg/min), several authors also reported sinus tachycardia, tachyarrhythmias and ventricular 
arrhythmias (Muir 1992a, Lee et al. 1998). 
 
Fenoldopam 
Fenoldopam, a DA1 receptor agonist with no α or β effects, increases CI, but reduces SVR 
and blood pressure dose-dependently (Barnard & Linter 1993). Lateral caecal arterial blood 
flow (Clark & Moore 1989b), renal blood flow (Aronson et al. 1990) and urine output (Hollis 
et al. 2006a) also increase during administration of fenoldopam. However, the drug was 
reported to induce hypotension and tachycardia in anaesthetized rats (Sengupta & 
Lokhandwala 1985), dogs (Aronson et al. 1990), horses (Clark & Moore 1989b) and foals 
(Hollis et al. 2006a). Consequently, fenoldopam seems less useful for cardiovascular support 
in anaesthetized horses. 
 
Dobutamine 
Dobutamine, a synthetic catecholamine chemically related to dopamine (Calvey & Williams 
2001b), is one of the most potent positive inotropes available (Morrill 2000). It was developed 
by systematic modification of isoproterenol‟s chemical structure to reduce its chronotropic, 
arrhythmogenic and vascular side effects (Tuttle & Mills 1975). The resulting drug, 
dobutamine, was shown to have an inotropic efficacy in dogs as great as the one of 
adrenaline, due to a direct action on β1 cardiac receptors, combined with only a slight effect 
on α and β2 vascular receptors (Tuttle & Mills 1975). The drug is marketed as a racemic 
mixture, in which the (-) isomer has some β agonist properties but is predominantly an α 
agonist, while the (+) isomer is a β1 and β2 agonist and a competitive α blocker (Ruffolo et al. 
1981). The racemic mixture has a predominant β1 activity and a balanced peripheral β2 and α1 
effect (Via et al. 2003). Therefore, lower dosages mainly stimulate β1 receptors, while both β1 
and β2 effects are seen at higher dosages (> 7.5 µg/kg/min). The effects at α1 receptors 
(vasoconstriction) are usually antagonized by the drug‟s β2 effects (vasodilation) (Morrill 
2000). In humans, the plasma half-life of dobutamine is very short (2 – 3 minutes), due to 
rapid metabolism in the liver (Calvey & Williams 2001b). The time to onset of action is 1 to 
10 minutes, with a peak effect seen within 10 to 20 minutes (Morrill 2000). 
   In humans, dobutamine is administered to increase     in patients with CHF and other states 
of decreased     (Morrill 2000). This increase in     is the result of an increase in stroke 
volume (SV) and, at higher doses, HR (Barnard & Linter 1993). Dobutamine has been 
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suggested as the agent of choice in septic shock patients with low     despite adequate fluid 
resuscitation, but should be combined with vasopressor therapy when blood pressure is low 
(Beale et al. 2004). The drug is contraindicated in human patients with hypovolaemia and is 
usually not administered if the patient‟s SAP is below 90 mm Hg (Morrill 2000), because 
dobutamine can decrease blood pressure slightly because of its vasodilating properties. This 
vasodilatory effect is mainly observed at higher dosages, which activate β2 receptors, causing 
a decrease in afterload, SVR (Morrill 2000) and total pulmonary resistance (Thuillez et al. 
1993). Nonetheless, dobutamine restored blood pressure despite reducing SVR slightly in 
dogs with experimentally induced hypotension and low     and contractility (Tuttle & Mills 
1975). Dobutamine has also been shown to increase myocardial oxygen supply and coronary 
blood flow, but this favourable effect may be lost when the drug causes tachycardia (Via et al. 
2003), which is mainly observed at higher dosages (Morrill 2000). Dobutamine may also 
induce arrhythmias, but its arrhythmogenic activity has been shown to be weaker than that of 
other catecholamines such as dopamine, isoproterenol and noradrenaline (Ueda et al. 1977). 
   In equine anaesthesia, dobutamine is undoubtedly the most widely used catecholamine for 
cardiovascular support. Many authors have reported on the cardiovascular effects of different 
doses of dobutamine in both ponies and horses, usually under experimental circumstances. In 
halothane anaesthetized ponies, dobutamine (1.25, 2.5 & 5.0 µg/kg/min) did not significantly 
alter SVR but dose-dependent increases in cardiac index (CI), MAP, mean PAP and SV were 
reported. This was in contrast with dopamine infusions of 2.5 and 5.0 µg/kg/min, which did 
not affect any of these variables. At the 2 highest doses of dobutamine, packed cell volume 
(PCV) and HR also increased, and in some ponies a severe tachycardia was observed 
(Gasthuys et al. 1991c). Lee et al. (1998) obtained similar results in ponies, with dose-
dependent increases in CI and MAP and decreases in SVR at CRI rates of 2.5, 5.0 and 10 
µg/kg/min. In 2 out of 8 ponies, the highest dose caused tachycardia and ventricular 
arrhythmias. Additionally, it was shown that dobutamine increased intramuscular blood flow 
in both the dependent and nondependent forelimbs more consistently than dopamine, 
dopexamine or phenylephrine (Lee et al. 1998). 
   In halothane or isoflurane anaesthetized healthy horses, blood pressure invariably increased 
in response to dobutamine infusions at doses ranging between 0.5 and 10 µg/kg/min 
(Swanson et al. 1985, Dyson & Pascoe 1990, Young et al. 1998b, Raisis et al. 2000a, Gehlen 
et al. 2006). As reported in ponies, these increases occurred at lower infusion rates of 
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dobutamine compared to dopamine and were not accompanied by changes in SVR (Swanson 
et al. 1985). Although     does not seem to be affected by doses of 0.5 (Raisis et al. 2000a) 
and 1.0 µg/kg/min (Swanson & Muir 1986), higher doses of dobutamine (3 – 10 µg/kg/min) 
have been shown to increase     (Swanson et al. 1985, Swanson & Muir 1986, Dyson & 
Pascoe 1990, Young et al. 1998b). In agreement with these findings, no changes were found 
in left ventricular systolic function when dobutamine was administered at a rate of 0.5 
µg/kg/min (Raisis et al. 2000a), while doses between 3 and 10 µg/kg/min were shown to 
increase the maximal rate of left ventricular pressure development (dP/dtmax) (Swanson et al. 
1985), maximal acceleration and velocity of aortic blood flow and left ventricular velocity 
time integral, while left ventricular pre-ejection period and ejection time significantly 
decreased (Young et al. 1998b). Dobutamine‟s effect on HR in anaesthetized normotensive 
horses appears to be variable, with some authors reporting increases (Gehlen et al. 2006) and 
others decreases (Swanson et al. 1985) at doses of 3 – 5 µg/kg/min. At 10 µg/kg/min, HR was 
not significantly different from baseline values (Swanson et al. 1985). Most likely, the actual 
effect in an individual horse will depend on the prevailing autonomic nervous system activity, 
blood pressure and HR of the horse before initiating dobutamine administration. In contrast to 
reports in human medicine, most authors found only small and non-significant effects of 
dobutamine on SVR in horses (Swanson et al. 1985, Raisis et al. 2000a). Other effects of 
dobutamine administration include increased pulmonary capillary wedge pressure (PCWP) 
(Gehlen et al. 2006), PAP (Young et al. 1998b) and PCV (Dyson & Pascoe 1990). 
Additionally, low dose dobutamine infusions (0.5 µg/kg/min) significantly increased femoral 
arterial flow, most likely due to local vasodilation, which may however not be associated with 
improved perfusion of skeletal muscles since microvascular perfusion, recorded using laser 
Doppler flowmetry, was not altered (Raisis et al. 2000a). Although dobutamine CRI‟s are 
usually found to have a quick onset and short duration of action, Young et al. (1998b) 
demonstrated that, in halothane anaesthetized horses, dobutamine at a dosage of 4 µg/kg/min 
did not achieve peak effects on many haemodynamic variables within 40 minutes of the start 
of the infusion while effects of a 60-minute infusion persisted for at least 30 minutes after the 
infusion was discontinued (Young et al. 1998b). 
   Dobutamine is a weaker proarrhythmic drug than most other catecholamines (Ueda et al. 
1977). Arrhythmias have been reported with the use of dobutamine in horses under 
experimental conditions, including supraventricular tachycardia in 2 of 8 horses receiving 
dobutamine at a rate of 4 µg/kg/min (Young et al. 1998b). However, in most horses the 
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arrhythmias observed during dobutamine administration are limited to bradyarrhythmias, 2
nd
 
degree AV blocks and isorhythmic AV dissociation at doses of 3 – 5 µg/kg/min (Swanson et 
al. 1985, Light et al. 1992). This agrees with the results of a study involving 200 horses 
anaesthetized for elective or emergency surgery, where a CRI of 1.5 to 3.2 µg/kg/min 
dobutamine as treatment of hypotension effectively increased blood pressure, while a cardiac 
arrhythmia developed in 28 % of the horses (60 % sinus bradycardia, 32 % AV block, 4 % 
premature atrial contractions and 4 % AV dissociation) (Donaldson 1988). 
   Caution is advised when combining parasympatholytic drugs with dobutamine. After prior 
atropine administration, the risk for tachyarrhythmias in response to dobutamine 
administration was higher (Light et al. 1992), while the dose of dobutamine required to induce 
repeated premature ventricular complexes or sustained narrow-complex tachyarrhythmia was 
almost threefold lower (Light & Hellyer 1993). 
   Many authors investigated the effects of dobutamine in anaesthetized horses under 
experimental conditions, but only a few reports describe the effects during routine clinical 
use. In horses anaesthetized for different surgical procedures, 1 – 4 µg/kg/min dobutamine 
significantly increased blood pressure and PCV, while HR tended to decrease (Hellyer et al. 
1998). No arrhythmias were noted in the latter study. In another clinical study, in isoflurane 
anaesthetized horses, dobutamine administered to effect (average dose of 1 µg/kg/min) 
effectively increased blood pressure, CI and HR, although some of these changes may have 
been accentuated by surgical stimulation (De Vries et al. 2009). Because the increase in CI 
was only significant 30 minutes but not 15 minutes after the start of the infusion, the authors 
suggested that the initial increase in blood pressure may have resulted from the peripheral 
vasoconstrictive (α1) effects of dobutamine; since SVR was not measured or calculated, this 
hypothesis could not be confirmed. 
   Dobutamine appears to be an effective and rather safe drug for cardiovascular support in 
horses and seems to be more effective than dopamine at improving blood pressure and    . 
Some additional evidence favouring dobutamine over dopamine in equine anaesthesia was 
provided by Duke et al. (2006), who reported that a combination of high-volume fluid therapy 
and dobutamine for cardiovascular support, with the aim to maintain MAP above 70 mm Hg, 
reduced the increase in muscle enzymes after halothane anaesthesia compared to the use of 
low-volume fluid therapy and dopamine with the aim to maintain MAP above 60 mm Hg. 
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Xamoterol 
Xamoterol is a selective partial agonist of the β1 adrenoreceptors and produces dose-
dependent positive inotropic and chronotropic effects upon the dog heart (Nuttall & Snow 
1982). In pigs, a more potent positive inotropic than chronotropic effect was illustrated under 
basal conditions (Galiè et al. 1989). However, the drug is also a competitive antagonist of the 
chronotropic and vasodilator effects of isoprenaline on the heart and blood vessels and of the 
chronotropic effects on noradrenaline on the heart (Nuttall & Snow 1982). When sympathetic 
tone is low, xamoterol has additive effects with released noradrenaline, but when it is high, it 
wil antagonize the effects of the neurotransmitter, such that xamoterol has moderate inotropic 
effects at rest, but partly attenuates the β-adrenergic response during exercise (Calvey & 
Williams 2001b). In pigs with a maximal sympathetic tone, xamoterol indeed antagonized the 
chronotropic, though not the inotropic, effect of noradrenaline, while increasing SVR and 
blood pressure, possibly through a β2 vascular blocking action (Galiè et al. 1989). In humans, 
xamoterol may be beneficial in patients with poor left ventricular function but can cause 
clinical deterioration in patients with extremely poor left ventricular function when 
sympathetic drive is high (Molajo & Bennett 1985). To the authors‟ knowledge, the use of 
xamoterol has not been described in horses or ponies. 
 
Ephedrine 
For more than 5000 years, the Chinese have used a vegetable drug, derived from a plant 
called Ma Huang (= Ephedra sinica), as a circulatory stimulant, antipyretic and cough 
suppressant. Towards the end of the 19
th
 century, an alkaloid, named ephedrine, was isolated 
from this plant by a Japanese chemist and subsequently shown to have marked chemical and 
pharmacological similarity with adrenaline (Stehle 1925). Like adrenaline, ephedrine 
increases HR, contractility and blood pressure (Stehle 1925). Ephedrine occurs naturally in 
various other plants, but nowadays it is usually synthesized (Calvey & Williams 2001b). The 
drug has direct and indirect sympathomimetic activity (Trendelenburg et al. 1962). It directly 
stimulates postsynaptic α1-receptors, but is also actively taken up by sympathetic nerve 
endings (Uptake1), where it displaces noradrenaline from its storage granules into the synapse 
and inhibits the intraneuronal metabolism of noradrenaline by mitochondrial monoamine 
oxidase (Calvey & Williams 2001b). Tachyphylaxis occurs with the continued use of 
ephedrine (Valette et al. 1960), because of depletion of noradrenaline stores in sympathetic 
neurones (Calvey & Williams 2001b). Similarly, the effect of ephedrine may be diminished 
when the sympathetic nervous system is already maximally stimulated before administration. 
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Compared to most other sympathomimetics, the cardiovascular effects of ephedrine are more 
prolonged, e.g. the effect on blood pressure usually lasts at least 15 minutes (Stehle 1925). 
Therefore this drug is often administered as a bolus instead of a CRI. 
   In halothane anaesthetized horses, ephedrine (0.06 mg/kg IV) increased    , SV and blood 
pressure, without affecting HR or cardiac rhythm (Grandy et al. 1989). Ephedrine (0.06 mg/kg 
IV, 1 – 2 boluses) significantly increased blood pressure without significantly altering HR or 
inducing arrhythmias (Hellyer et al. 1998). In the latter study, dobutamine 1 – 4 µg/kg/min 
tended to increase MAP to a greater extent than ephedrine, suggesting that dobutamine is 
more efficacious than ephedrine at increasing arterial blood pressure in anaesthetized horses. 
However, the study was not designed to compare equipotent doses of the two drugs. 
Ephedrine did not affect PCV, in contrast to dobutamine (Hellyer et al. 1998). 
 
Isoprenaline 
Isoprenaline or isoproterenol (N-isopropylnorepinephrine) is a synthetic catecholamine which 
differs from adrenaline in that it has an isopropyl group substituted for the methyl group of 
adrenaline (Nathanson & Miller 1952). Of all catecholamines available to the clinician, 
isoprenaline has the most potent direct β1 and β2 effects, but no α effects (Barnard & Linter 
1993). The drug therefore increases     and myocardial contractility and produces a 
pronounced increase in HR (Mueller 1978, Chamberlain et al. 1980, Mansell et al. 1988), in 
some cases even an excessive tachycardia (Morrill 2000). The β2 activity leads to peripheral 
and bronchial vasodilation, resulting in a reduction in SVR (Mueller 1978, Chamberlain et al. 
1980), DAP (Mansell et al. 1988, Barnard & Linter 1993) and MAP (Morrill 2000, Calvey & 
Williams 2001b). The potent β1 activity leads to a significant increase in myocardial oxygen 
consumption (Parratt & Wadsworth 1970, Mueller 1978), while coronary perfusion may 
become compromised because of tachycardia and reduced DAP (Parratt & Wadsworth 1970). 
Undesirable effects include tachycardia, arrhythmias (Mueller 1978, Morrill 2000) and a 
diversion of blood flow from vital organs to muscle and skin (Barnard & Linter 1993). 
Isoprenaline is nevertheless useful in patients with bradycardia and AV block (Nathanson & 
Miller 1952, Barnard & Linter 1993), as well as in patients with pulmonary hypertension and 
right ventricular failure (Barnard & Linter 1993). The half-life of isoproterenol is 2.5 to 5 
minutes with an onset of action after 30 to 60 seconds and a duration of action of 8 to 50 
minutes (Morrill 2000). 
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   To the authors‟ knowledge, only one study reported the use of isoprenaline during 
anaesthesia in horses. Intravenous injection of 0.85 µg/kg isoprenaline to 6 halothane 
anaesthetized horses produced great increases in HR, with a much slower return to baseline 
compared to adrenaline. Ventricular ectopic beats were observed in all animals and 
ventricular or nodal tachycardia in 3 cases. In most horses, blood pressure increased slightly 
(Lees & Tavernor 1970). 
 
Calcium salts 
As indicated earlier, inotropic drugs usually act by increasing the availability of Ca
2+
 to the 
contractile apparatus, but an alternative approach is to directly increase circulatory calcium 
levels (Choudhury & Saxena 2003). Total calcium in the blood consists of three distinct 
forms: protein bound, ionized (free) and complexed with ions such as phosphate and citrate 
(Simesen 1980). In the open-chest dog, differences in ionized calcium levels accounted for 
significant alterations in dP/dt, suggesting that fluctuations in ionized calcium were primarily 
involved in the regulation of the contractile state of the heart (Bristow et al. 1977). This 
finding led the authors to propose that ionized calcium should replace total calcium as a 
routine clinical test. It is now indeed generally accepted that ionized calcium is the 
biologically active form. Intravenous therapy that is aimed at increasing circulatory calcium 
levels is therefore best done by administering calcium salts which increase serum ionized 
calcium levels. Typically, CaCl2 or calcium gluconate are used. The choice between both 
forms may depend on considerations regarding differences in urinary excretion, rapidity of 
dissociation, concentration of the salt in solution and bioavailability of the calcium ion 
provided (Cote et al. 1987). However, in both dogs and children, Cote et al. (1987) 
demonstrated that equal elemental calcium doses of calcium gluconate and CaCl2 were 
equivalent in their ability to raise ionized calcium levels, rapidity of ionization and 
cardiovascular effects. On the other hand, Hempelmann et al. (1978) found that, while both 
CaCl2 and calcium gluconate significantly increased blood pressure, left ventricular pressure, 
SVR, CI, stroke index (SI), peak dP/dt and myocardial oxygen consumption, the positive 
inotropic effects of CaCl2 were more pronounced. 
   In man, CaCl2 effectively improved cardiac function when it was depressed by anaesthesia, 
underlying cardiac disease, or both (Eriksen et al. 1983). Similarly, calcium salts produced 
positive inotropic effects in cats (Bosnjak and Kampine 1986), dogs (Pagel et al. 1993), calves 
(Stanley et al. 1976) and horses (Grubb et al. 1996, Grubb et al. 1999a) and attenuated or 
Cardiovascular stimulant drugs 
 
52 
 
completely reversed the negative lusitropic actions of halothane and isoflurane in horses 
(Grubb et al. 1999b). Furthermore,     and/or SV increased when calcium salts were 
administered in conscious (Grubb et al. 1996) and anaesthetized horses (Grubb et al. 1999a) 
and ponies (Gasthuys et al. 1991a), hypocalcaemic dogs (Drop and Scheidegger 1980) and 
human patients with cardiac disease (Eriksen et al. 1983). In anaesthetized dogs, calcium 
gluconate increased myocardial contractility and myocardial oxygen consumption, but in 
contrast to the adrenergic stimulation induced by isoprenaline, myocardial uptake of free fatty 
acids remained low, indicating a possibly lower oxygen cost for similar haemodynamic 
performance (Bugge-Asperheim 1972). Heart rate decreased in halothane anaesthetized 
ponies (Gasthuys et al. 1991a) and horses (Grubb et al. 1999a) during the administration of 
calcium, while blood pressure increased when calcium was administered to anaesthetized 
ponies (Gasthuys et al. 1991a), horses (Grubb et al. 1999a), dogs (Drop and Scheidegger 
1980) and humans (Marone et al. 1981, Eriksen et al. 1983, Zaloga et al. 1990, Butterworth et 
al. 1992, Royster et al. 1992). In most of these reports, the increase in blood pressure was not 
due to an increase in    , but rather to an increase in SVR. 
   However, while calcium administration may slightly improve MAP, it significantly 
increased mortality associated with endotoxic shock (Malcolm et al. 1989) and septic 
peritonitis (Zaloga et al. 1992) in rats. Furthermore, several researchers failed to demonstrate 
significant changes in cardiovascular function after calcium administration. Calcium 
gluconate infusion did not influence blood pressure in conscious horses (Grubb et al. 1996) 
and     was not affected by calcium administration in dogs (Scheidegger et al. 1980), healthy 
people (Marone et al. 1981, Eriksen et al. 1983) or patients recovering from cardiac surgery 
(Zaloga et al. 1990, Butterworth et al. 1992, Royster et al. 1992). Possibly, these conflicting 
results may be explained by differences in health status, cardiovascular function and pre-
existing serum calcium concentrations between the different studies. Indeed, serum calcium 
concentrations were found to be lower during inhalation anaesthesia than in conscious horses 
(Gasthuys et al. 1985, Grubb et al. 1999a). Also, Drop and Scheidegger (1980) reported 
significant increases in     and SV when calcium was administered in hypocalcaemic, but not 
in normocalcaemic dogs. Similarly, Mathru et al. (1993) found that during normocalcaemia, 
the predominant effect of CaCl2 is peripheral vasoconstriction, while calcium infusion during 
hypocalcaemia significantly increased left ventricular contractile performance. It can be 
concluded that the usefulness of calcium salts for cardiovascular support differs between 
individual patients. 
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Calcium sensitizers 
Most cardiotonic agents, such as digitalis, catecholamines and phosphodiesterase III 
inhibitors, induce a positive inotropic effect by facilitating Ca
2+
 mobilization through cAMP-
dependent or -independent mechanisms in myocardial cells. These agents are therefore 
sometimes referred to as „Ca2+ mobilizers‟. On the other hand, „Ca2+ sensitizers‟ increase the 
Ca
2+
 binding affinity of troponin C or stability of the Ca
2+
-troponin C complex and/or 
facilitate thin filament regulation of cross-bridge cycling and/or directly facilitate cross-bridge 
cycling (Endoh 2008). Some of these agents (e.g. EMD 57033, CGP 48506) are pure Ca
2+ 
sensitizers, while others also weakly (Org 30029, SCH00013) or clearly (pimobendan, 
levosimendan) inhibit PDE III, hereby increasing intracellular cAMP levels in the 
myocardium (Endoh 2008). Advantages of Ca
2+ 
sensitizers include the stimulation of cardiac 
contractility without increasing myocardial oxygen demand (Parissis et al. 2008), without the 
risks for arrhythmias, cell injury, apoptosis or necrosis due to Ca
2+ 
overload. Even more, these 
agents are able to reverse contractile dysfunction under pathophysiological conditions where 
other agents may be less effective (Endoh 2008). Levosimendan enhances myocardial 
contractility by Ca
2+
 sensitization and causes peripheral vasodilation through ATP-dependent 
potassium channels (Perrone & Kaplinsky 2005); it also has immunomodulatory, antioxidant 
and anti-apoptotic properties, whereby lower levels of oxidative stress markers have been 
reported compared to placebo treatment (Parissis et al. 2008). In dogs with CHF secondary to 
dilated cardiomyopathy or chronic degenerative valvular disease, pimobendan was found to 
be safe and well tolerated. Pimobendan enhanced the quality of life when used in combination 
with furosemide or other conventional therapies and reduced mortality from CHF associated 
with dilated cardiomyopathy (Gordon et al. 2006). Although Ca
2+
 sensitizers appear 
promising for use in patients with heart failure, they do have long-lasting haemodynamic 
effects (Lehtonen et al. 2004) and are quite expensive. It appears unlikely that these specific 
drugs will ever be used for routine cardiovascular support during anaesthesia in patients 
without cardiac disease. To the authors‟ knowledge, the effects of pimobendan and 
levosimendan have not been investigated in horses or ponies. 
 
Phosphodiesterase III inhibitors 
As explained earlier, the inotropic and chronotropic effects of β sympathomimetics are 
mediated by increasing the synthesis of cAMP by adenylate cyclase. At the same time 
however, cAMP is broken down by phosphodiesterase enzymes, which in this way play an 
important role in modulating the amplitude and duration of the cyclic nucleotide second 
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messenger signal, the response of cells to prolonged agonist stimulation and cross-talk 
between different second messenger signalling pathways (Beavo 1995). More than 25 PDE‟s 
of 7 different families have been recognized in humans (Beavo 1995). Some drugs, including 
the methylxanthines theophylline, theobromine and caffeine (Butcher & Sutherland 1962), but 
also papaverine (Kukovetz & Pöch 1970) and pentoxifylline (Cortijo et al. 1993), 
nonselectively inhibit PDE‟s of the different families. One example of the clinical use of 
methylxanthines is as bronchodilators for treatment of asthma (Shenfield 1982). However, 
these agents also affect the central nervous system, gastrointestinal tract and cardiovascular 
system (Slapke et al. 1988). Other drugs more specifically inhibit a certain family of PDE 
enzymes and produce effects that depend on the type of PDE inhibited. There is some 
evidence to suggest that selective PDE I inhibitors increase cognitive function (Beavo 1995) 
and certain PDE IV inhibitors may have antidepressant (Bobon et al. 1988) or anti-
inflammatory (Teixeira et al. 1994) effects. PDE V inhibitors such as sildenafil can have a 
role in the treatment of pulmonary hypertension (Michelakis et al. 2002). However, the 
greatest number of commercially available compounds, including e.g. amrinone, milrinone, 
vesnarinone, enoximone, pimobendan, etc. primarily inhibit the PDE III family. These drugs 
have been developed as antithrombotic (reduction of platelet aggregation) (Shintani et al. 
1985), antihypertensive (vasodilation) and/or inotropic agents (Beavo 1995). 
   The inotropic effects of PDE III inhibitors result from increased cAMP levels in the 
myocardial cell, the effects of which have already been described for the β sympathomimetic 
agents. However, PDE III inhibitors also increase the cAMP levels in vascular smooth muscle 
cells, causing a vasorelaxation through three different mechanisms. Cyclic AMP decreases 
myoplasmic Ca
2+
 concentrations (McDaniel et al. 1991, Itoh et al. 1993) by inhibiting the 
slow, L-type Ca
2+
 channels (Sperelakis et al. 1994), reducing Ca
2+
 influx in vascular smooth 
muscle cells (Ishikawa et al. 1993, Orlov et al. 1996) and enhancing Ca
2+
 pump activity by 
phosphorylation of phospholamban (Kimura et al. 1991, Sasaki et al. 1992). Secondly, PDE 
inhibitors may decrease the Ca
2+
 sensitivity of contractile elements in vascular smooth muscle 
cells (Itoh et al. 1993). Finally, a cAMP-dependent protein kinase catalyzes the 
phosphorylation of myosin light chain kinase, which interferes with the binding of Ca
2+
-
calmoduline to myosin light chain kinase, reducing the activity of this enzyme (Adelstein et 
al. 1982). In turn, this causes reduced myosin light chain phosphorylation, which is needed for 
actin-myosin interaction and vascular smooth muscle contraction. 
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   There are three groups of PDE III inhibitors: the bipyridines (amrinone, milrinone), 
imidazole derivatives (enoximone, piroximone) and benzimidazole derivatives (sulmazole, 
pimobendan, adibendan) (Barnard & Linter 1993). Comparative studies failed to show 
clinically relevant differences between most PDE III inhibitors (Via et al. 2003). They all 
induce an inotropic effect, pulmonary and systemic vasodilation, less chronotropic effects 
than dobutamine, no increase in myocardial oxygen consumption (Baim 1989) and improved 
diastolic properties of the left ventricle, such as relaxation, compliance and filling (Barnard & 
Linter 1993). Because of their inotropic and vasodilating effects, PDE III inhibitors such as 
amrinone, milrinone and enoximone are sometimes referred to as inodilators. These drugs 
cause peripheral vasodilation and therefore reduce ventricular wall stress and counteract the 
increased oxygen requirement normally needed to support enhanced contractility (Colucci 
1991). Their lusitropic effect appears to be more pronounced than that of the β 
sympathomimetics, e.g. the lusitropic action of milrinone was greater than that of adrenaline 
(Lobato et al. 2000). Potential drawbacks include the long duration of action and a possibly 
excessive vasodilator effect associated with bolus administration (Via et al. 2003). High doses 
may indeed substantially reduce MAP, but this effect can be minimized by volume expansion, 
slower administration of loading doses and the administration of vasopressors (Barnard & 
Linter 1993). In human medicine, the main indications of these drugs are in patients with 
heart failure and during weaning from cardiopulmonary bypass (Lehtonen et al. 2004). 
Reports about the use of PDE III inhibitors in horses are sparse, only the effects of milrinone 
have been described in this species (Muir 1995). Because of the abundance of information 
about the many PDE III inhibitors available, only a short overview of some properties of three 
well known inodilators will be provided here, i.e. amrinone, milrinone and enoximone. 
 
Amrinone 
Amrinone was the first PDE III inhibitor approved for clinical human use. In 1978, Benotti et 
al. investigated its cardiovascular effects and found significant increases in CI and dP/dtmax 
together with decreases in left ventricular end-diastolic, pulmonary capillary and right atrial 
pressures, without a change in HR and only a slight decline in mean aortic pressure. 
Amrinone also improved myocardial systolic and diastolic function in endotoxaemic rabbits 
and even reduced the systemic inflammatory response syndrome after IV administration of 
endotoxins (Takeuchi et al. 1999). Amrinone has a half-life of more than 3 hours in humans 
(Park et al. 1983). Reported side effects include thrombocytopenia, gastrointestinal effects, 
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hypotension, fever, liver enzyme elevation and anaphylactoid responses (Treadway 1985). 
Accumulation can also occur in critically ill patients (Notterman 1991). Although the 
incidence and/or importance of most of these side effects appear to be limited (Treadway 
1985), amrinone is used less frequently compared to newer agents such as milrinone and 
enoximone. 
 
Milrinone 
Milrinone is a second generation bipyridine derivative of amrinone and is 15 times more 
potent (Barnard & Linter 1993). Milrinone increases left ventricular dP/dt, ameliorates cardiac 
pump function, improves diastolic filling and accelerates isovolumic myocardial relaxation, 
without altering myocardial oxygen demand (Colucci 1991). Milrinone was also shown to 
have less proarrhythmic effects than dobutamine (Caldicott et al. 1993) and may even have 
anti-inflammatory properties (Möllhoff et al. 1999). Slow administration over 10-15 minutes 
is recommended for all PDE III inhibitors to avoid sudden decreases in SVR and venous 
return, which may result in hypotension, especially in hypovolaemic patients (Choudhury & 
Saxena 2003). When milrinone was administered to halothane anaesthetized horses, increases 
in HR, MAP,    , ejection fraction and maximum rate of increase and decrease of left 
ventricular pressure were observed (Muir 1995). 
 
Enoximone 
Enoximone (MDL 17,043) is an imidazole derivative which mainly inhibits PDE III, although 
PDE IV inhibition may also contribute to the observed inotropic effects (Szilágyi et al. 2005). 
Beside the positive inotropic effect, enoximone increases coronary blood flow and reduces 
SVR and PVR in humans, without significant increases in myocardial oxygen consumption 
(Dage and Okerholm 1990, Ghio et al. 2003). Myocardial oxygen consumption, as reflected 
by heart rate-pressure product, was indeed significantly lower in patients after the 
administration of enoximone compared to patients receiving dobutamine following 
cardiopulmonary bypass (Lancon et al. 1990). In patients with moderate to severe CHF, 
enoximone infusion markedly improved left ventricular performance while HR tended to rise 
and MAP to decrease (Vernon et al. 1991). In similar populations of patients, oral (Leier et al. 
1987) and intravenous (Winkle et al. 1990) enoximone increased     and decreased SVR, but 
had minimal or no effects on HR and blood pressure. Furthermore, Leier et al. (1987) reported 
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that, while the flow through and resistance of the renal and hepatic-splanchnic vascular beds 
were not altered, enoximone seemed to preferentially reduce limb vascular resistance and 
augment blood flow to the peripheral musculoskeletal system. 
   In patients with cardiogenic shock persisting despite the use of adrenergic agents, the 
addition of enoximone resulted in significant increases in CI and SI and a significant decrease 
in PCWP, without consistent changes in MAP (Vincent et al. 1990). Of perhaps greater 
interest for equine practitioners are the effects of inotropic drugs in patients with other types 
of shock. In contrast to dobutamine, enoximone improved hepatosplanchnic function and had 
anti-inflammatory properties in fluid-optimized septic shock patients (Kern et al. 2001). In 
patients with severe and prolonged catecholamine and volume refractory endotoxin shock, 
even with electromechanical uncoupling and complete myocardial arrest, enoximone was able 
to immediately restore myocardial contractility and blood pressure (Ringe et al. 2003). In a rat 
endotoxaemia model, despite contributing to systemic hypotension, enoximone prevented 
mucosal hypoperfusion (Schmidt et al. 2001). 
   In humans, enoximone is extensively metabolized into enoximone sulphoxide, very little 
unchanged drug appears in the urine (Okerholm et al. 1987). Enoximone sulphoxide has the 
same inotropic and vasodilator activities as the parent molecule, but is only 0.13-0.14 times as 
potent (Dage & Okerholm 1990). The terminal half-lives of both enoximone and its 
sulphoxide metabolite were 2.0-2.7 hours and did not appear to be dose related (Morita et al. 
1995). Administering 4 consecutive doses at 3h-intervals did not affect pharmacokinetic 
parameters and no accumulation was observed (Morita et al. 1995). 
   Adverse effects associated with long term oral enoximone therapy include central nervous 
(insomnia, headache and anxiety), gastrointestinal (diarrhoea, dyspepsia, vomiting, nausea, 
abdominal pain, increased liver enzymes mainly in patients with previous liver disease or 
diabetes) and cardiovascular side effects (usually mild ventricular or supraventricular 
arrhythmias) (Gilfrich & Dieterich 1991, Vernon et al. 1991). Vernon et al. (1991) mentioned 
that the gastrointestinal effects were the most common and could be resolved with a reduction 
in dosage, while Gilfrich & Dieterich (1991) found that cardiovascular side effects were the 
most frequent (10 % of patients), followed by gastrointestinal complaints in 3 % of the 
patients. On the other hand, Treese et al. (1991) found that in most patients with advanced 
chronic heart failure, even long-term enoximone therapy was not associated with an important 
increase in the incidence of ventricular arrhythmias. 
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   Most studies investigating the safety and side effects of enoximone have been performed in 
cardiac patients receiving the drug orally for prolonged periods of time, but its short-term use, 
e.g. in the intensive care unit (Sicignano et al. 1994) or following cardiac surgery (Gonzalez 
et al. 1988, Zeplin et al. 1990) was usually reported to be safe, with a low incidence of side 
effects. In patients with acute myocardial infarction, enoximone was tolerated better and 
produced fewer side-effects than dobutamine using doses which produced similar increases in 
    (Caldicott et al. 1993). When used during weaning from cardiopulmonary bypass, one of 
the main concerns with PDE III inhibitors is the occurrence of excessive vasodilation, which 
can be reduced by slow administration, but often has to be compensated for by volume 
supplementation and alpha-mimetic stimulation (Kruger et al. 1996). After extracorporeal 
circulation, enoximone reduced platelet levels and was associated with supraventricular 
arrhythmias and ventricular tachyarrhythmias (Ferrara et al. 1993). However, an inhibitory 
effect on platelet aggregation might in fact be beneficial in patients with cardiovascular 
disease (Buerke et al. 1997). On the other hand, Boldt et al. (1992) reported that platelet 
aggregation after cardiopulmonary bypass decreased to a similar extent with enoximone 
treatment as in the control group and concluded that enoximone did not affect platelet 
function in cardiac surgery patients. In contrast with the report of Ferrara et al. (1993), Pop et 
al. (1986), who investigated the electrophysiologic effects of enoximone, concluded that, 
despite its positive chronotropic and dromotropic effects, enoximone did not appear to be 
arrhythmogenic. Similarly, Brembilla-Perrot et al. (1990) found that enoximone has no 
supraventricular arrhythmogenic effects and does not facilitate the induction of ventricular 
arrhythmias in subjects without inducible sustained ventricular tachycardia under basal 
conditions, although it can accelerate the ventricular tachycardia rhythm in patients who have 
inducible sustained ventricular tachycardia under basal conditions. 
 
Vasopressors 
Vasopressors cause vasoconstriction and can be used to increase blood pressure through an 
increase in SVR. Many vasopressors are also positive inotropes and/or chronotropes at the 
same time. However, even pure vasopressors, which do not affect HR or myocardial 
contractility, may still have an influence on    . When vasoconstriction mainly occurs on the 
venous side of the circulation, mean systemic filling pressure and venous return will increase 
and this will tend to augment     through an increased preload. On the other hand, arterial 
Chapter 1.2: Vasopressors 
 
 59 
vasoconstriction will increase afterload and may actually reduce    , especially when 
contractility is already compromised, e.g. by underlying cardiac disease, sepsis or anaesthetic 
drugs. With regard to tissue perfusion, the effect of vasopressors will depend on the pre-
existing arteriolar tone. Arteriolar vasoconstriction will increase blood pressure but reduce 
perfusion of the tissues distal to constricted arterioles. This may lead to ischaemia of 
vulnerable organs such as the kidneys and the gut. However, arterial hypotension can be 
associated with a collapse of vessels perfusing tissues with high extravascular 
(intracompartmental) pressures, such as the muscles of recumbent horses (Lindsay et al. 
1980), because transmural pressure becomes inadequate. Under these circumstances, 
vasopressors may help to increase transmural pressure and actually restore patency of blood 
vessels and peripheral tissue perfusion. Vasopressors are therefore usually reserved for 
situations where hypotension is caused by a reduction in SVR (e.g. due to drug- or endotoxin-
induced vasodilation), myocardial contractility and     are normal (or already increased by 
sympathetic stimulation, fluids and inotropic support) and vascular transmural pressure needs 
to be restored to maintain (or re-establish) vessel patency and assure tissue perfusion. 
   Different types of vasopressors are available, which can largely be subdivided into three 
groups, i.e. vasopressin, calcium salts and sympathomimetics. Although the exact mechanism 
of action differs somewhat between these groups, they all increase intracellular Ca
2+
 levels in 
vascular smooth muscles. Calcium induces vascular smooth muscle contraction by binding to 
calmodulin and activating the enzyme myosin light chain kinase, which then phosphorylates 
myosin, initiating contraction. Calcium would further enhance smooth muscle contractile 
activity by binding directly to myosin and finally by activating protein kinase C, which 
phosphorylates smooth muscle myosin at a different site than myosin light chain kinase 
(Adelstein & Sellers 1987). 
 
Vasopressin analogues 
Endogenous vasopressin or antidiuretic hormone is synthesized in the hypothalamus and 
stored and released into the bloodstream by the posterior pituitary, mainly in response to 
increases in plasma osmolarity, but also when the arterial baroreceptors detect large decreases 
in blood pressure (Power & Kam 2001b). The most important physiological effects of 
vasopressin are water retention by the kidneys, mediated via V2 receptors on the basolateral 
surface of cells of the distal convoluted tubules and medullary collecting ducts in the kidney, 
and vasoconstriction, mediated via V1 receptors on vascular smooth muscle cells (Mutlu & 
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Factor 2004). Activation of V1 receptors stimulates phospholipase C, promoting hydrolysis of 
phosphatidylinositol 4,5-biphosphate (PIP2), which results in formation of inositol 
triphosphate (IP3) and diacylglycerol (DAG). Inositol triphosphate in turn promotes 
mobilization of Ca
2+
 from the endoplasmic reticulum, leading to vascular smooth muscle 
contraction (Mutlu & Factor 2004). Diacylglycerol stimulates protein kinase C, an enzyme 
which increases the influx of extracellular Ca
2+
 through L-type Ca
2+
 channels (Marshall et al. 
1999). Vasoconstriction mainly occurs in nonvital organ systems such as the skin, skeletal 
muscles and intestines (Vanhoutte et al. 1984, Rajani et al. 2009), while vasodilation occurs in 
other vessels such as the cerebral and coronary arteries (Vanhoutte et al. 1984). Vasopressin 
may additionally have some inotropic effects after stimulation of myocardial V1 receptors 
(Fujisawa & Iijima 1999), but this is usually overshadowed by a baroreflex-mediated 
reduction in    . This baroreflex is even facilitated by vasopressin, both through a central 
action of the hormone and a sensitizing influence on arterial baroreceptors and cardiac 
afferents (Abboud et al. 1990). 
   The time required for synthesis, transport and storage of vasopressin in the neurohypophysis 
is about 1 to 2 hours (Sklar & Schrier 1983), while the plasma half-life of endogenous 
vasopressin is short, only 6-10 minutes (Morelli et al. 2009). Prolonged stimulation, e.g. 
during haemorrhagic shock, exhausts the endogenous supply of vasopressin in approximately 
1 hour, which leads to vasodilation and hypoperfusion of end organs and may be a 
contributing factor to the morbidity and mortality associated with haemorrhagic shock (Rajani 
et al. 2009). Similarly, endogenous vasopressin plasma levels were found to be 
inappropriately low in vasodilatory septic shock. Except for depletion of endogenous 
vasopressin stores, it has been suggested that this may also be due to an impaired baroreflex-
mediated secretion of vasopressin (Landry et al. 1997). Administering vasopressin or one of 
its analogues may thus be useful in patients with refractory shock despite adequate fluid 
resuscitation and high-dose conventional vasopressors (Beale et al. 2004). Furthermore, 
vasopressin receptors remain available despite maximal binding of adrenoreceptors by 
endogenous or exogenous catecholamines. 
   Examples of arginine vasopressin (AVP) analogues are terlipressin and F-180. Terlipressin 
is a non-selective, synthetic AVP analogue, which has the nonapeptide sequence of the natural 
hormone lysine-vasopressin (Morelli et al. 2009). It has a somewhat greater preference for 
vascular V1 receptors than vasopressin, which has equal affinity for V1 and V2 receptors 
(Mutlu & Factor 2004). It is less expensive than vasopressin and has a long half-life, making 
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single bolus dosing possible (Mutlu & Factor 2004). Another, perhaps less known vasopressin 
analogue is F-180, a long-acting drug with selective effects on the V1 receptor (Bernadich et 
al. 1998). 
   Although arginine vasopressin and terlipressin are potent adjunct vasopressor agents which 
effectively increase SVR and blood pressure and reduce catecholamine requirements in 
patients with advanced vasodilatory or haemorrhagic shock, who remain hypotensive despite 
adequate fluid resuscitation and infusions of catecholamines (Jochberger et al. 2005, 
Tsuyenoshi et al. 2005, Krismer et al. 2006, Ertmer et al. 2008), the influence on the final 
outcome will remain uncertain until large scale, prospective studies have been performed 
(Jochberger et al. 2005). A second possible indication for vasopressin is during treatment of 
cardiac arrest. Vasopressin‟s effects were similar to those of adrenaline in the management of 
ventricular fibrillation and pulseless electrical activity and were even superior to those of 
adrenaline in patients with asystole (Krismer et al. 2006). Furthermore, vasopressin followed 
by adrenaline resulted in significantly higher rates of survival to hospital admission and 
discharge (Krismer et al. 2006). In a porcine cardiac arrest model, with severe hypotension 
induced by blood loss, vasopressin redirected blood from bleeding sites to more vital organs 
and resulted in sustained vital organ perfusion, less metabolic acidosis and prolonged 
survival, in contrast with large-dose adrenaline or saline administration (Voelckel et al. 2000). 
   Nevertheless, AVP should not be used as the sole vasopressor agent (Krismer et al. 2006). 
Especially when used in higher doses, AVP and terlipressin can reduce    , oxygen delivery 
(DO2) and mixed venous oxygen saturation, with impaired perfusion and ischaemic injury of 
tissues such as the gut, liver and skin (Ertmer et al. 2008). Also, while the efficacy of 
catecholamines is often markedly reduced in vasodilatory shock states, exogenous vasopressin 
receptor agonists appear to be more efficacious and even moderate doses may lead to an 
exaggerated increase in SVR (Ertmer et al. 2008). In septic rats, high dose AVP infusion 
severely compromised gut mucosal blood flow, which may be related to arteriolar 
vasoconstriction, a reduction in    , or both (Westphal et al. 2004). The inflammatory response 
to the septic injury was also increased (Westphal et al. 2004). On the other hand, during long-
term hyperdynamic endotoxaemia in pigs, a 12 hour low-dose infusion of terlipressin 
increased MAP and SVR and decreased     and global oxygen consumption, without any 
detrimental effect on hepatosplanchnic perfusion, oxygen exchange and metabolism. 
Nevertheless, a marked hyperlactataemia occurred, which did not originate from the 
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hepatosplanchnic organs, but from other tissues, possibly muscles and skin (Asfar et al. 2005). 
Ischaemic skin lesions are indeed another common complication during continuous infusion 
of AVP in patients with catecholamine-resistant vasodilatory shock (Dünser et al. 2003). 
Hyponatraemia and tissue oedema in response to anti-diuresis and water reabsorption may 
also occur, as well as decreases in platelet counts and increases in aminotransferase activity 
and bilirubin concentrations (Ertmer et al. 2008). 
   To avoid side effects, high volume fluid therapy is recommended when infusing AVP or 
terlipressin (Ertmer et al. 2008). When using terlipressin, a continuous infusion appears to be 
superior to bolus administration, since intermittent bolus injections of terlipressin caused 
decreases in HR and CI and increases in PVR, while continuous low-dose infusion of the drug 
stabilized haemodynamics and improved myocardial performance in endotoxaemic sheep 
(Lange et al. 2007). Platelet count, surrogate variables of hepatic dysfunction, electrolytes and 
osmolality should also be strictly monitored in patients treated with vasopressin analogues 
(Ertmer et al. 2008). 
   Literature describing the cardiovascular effects of exogenous AVP or its analogues in 
equids is scarce. In hypotensive, isoflurane anaesthetized foals, vasopressin (0.3 and 1.0 
mU/kg/min) increased SVR and blood pressure without affecting CI and DO2, but increased 
the gastric to arterial CO2 gap, which is indicative for reduced splanchnic perfusion (Valverde 
et al. 2006). 
 
Calcium salts 
As already mentioned, calcium chloride or gluconate administration increased blood pressure 
in anaesthetized ponies (Gasthuys et al. 1991a), horses (Grubb et al. 1999a), dogs (Drop and 
Scheidegger 1980) and humans (Marone et al. 1981, Eriksen et al. 1983, Zaloga et al. 1990, 
Butterworth et al. 1992, Royster et al. 1992). In most of these reports this was not due to an 
increase in    , but rather to an increase in SVR, illustrating the vasoconstrictive effects of 
calcium administration. 
 
Sympathomimetics 
Many sympathomimetics have vasoconstrictive properties through their effects at α1 
adrenergic receptors, which are G-protein coupled receptors. Many different types of α1 
adrenoceptors exist in different tissues and many different intracellular signaling effectors 
have been described, including phosholipase A2, phospholipase D and activation of Ca
2+
 and 
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K
+
 channels (Marshall et al. 1999). However, most α1 adrenoceptors, including those on 
vascular smooth muscle cells, are linked to phospholipase C via a G protein. When activated, 
the α subunit of the heterotrimeric G protein, Gq, binds GTP and dissociates from the βγ 
subunits and activates phospholipase C, which hydrolyzes PIP2 to IP3 and DAG (Marshall et 
al. 1999), with effects on Ca
2+
 transients as already described for vasopressin. Many 
sympathomimetic drugs not only induce vasoconstriction but also have inotropic and/or 
chronotropic properties. Furthermore, the vasoconstrictive effect of some drugs, such as 
adrenaline and dopamine, depends on the dose administered. Subdivision of the 
catecholamines as pure inotropes or pure vasopressors is therefore not always possible. Only 
the agents with clear vasoconstrictive and less inotropic effects will be discussed (Table 2). 
 
Noradrenaline 
Noradrenaline or norepinephrine is an endogenous catecholamine secreted by the adrenal 
medulla and is the main neurotransmitter at sympathetic postganglionic fibres. It is a rather 
potent β1 and very potent α1 and α2 agonist which mainly functions as a vasopressor (Barnard 
& Linter 1993, Morrill 2000). Systemic vascular resistance and arterial pressure are raised 
because of generalized vasoconstriction. This causes a vagally mediated baroreceptor 
response, which usually obscures the direct effects of noradrenaline on the heart and rather 
tends to cause slight bradycardia (Barnard & Linter 1993, Calvey & Williams 2001b). Also, 
noradrenaline directly increases myocardial contractility (Garb 1950), but     may in fact 
decrease due to the substantial increase in SVR (Barnard & Linter 1993, Morrill 2000).  
   Noradrenaline is used when the importance of increasing perfusion pressure outweighs the 
disadvantages of a lower    , or to counterbalance the vasodilatory effects of other agents 
(Barnard & Linter 1993, Via et al. 2003). Additionally, the effects of noradrenaline on α and 
β1 receptors in the myocardium may complement the positive inotropic effects of other drugs, 
and when relatively low doses are used (0.5-1.5 µg/kg/min), excessive vasoconstriction is not 
a problem and there are no deleterious effects on renal function (Calvey & Williams 2001b). 
Time to onset of action of noradrenaline is 1 to 2 minutes and because the half-life is very 
short (20-30 seconds) (Power & Kam 2001b), the duration of the effect is limited to 1-2 
minutes (Morrill 2000).  
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Table 2: Sympathomimetic agents with primarily a vasopressor action.  
 
Abbreviations used: systemic vascular resistance (SVR), arterial blood pressure (ABP), cardiac output (   ), oxygen (O2), mean arterial 
pressure (MAP), heart rate (HR), cardiac index (CI), oxygen delivery (DO2), right atrial pressure (RAP), systolic (SAP) and diastolic 
arterial pressure (DAP), packed cell volume (PCV), stroke volume (SV), atrioventricular (AV), central venous pressure (CVP).  
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   However, caution is advised when using this drug. Like adrenaline, noradrenaline has 
arrhythmogenic properties (Friedrichs & Merrill 1991). Myocardial oxygen consumption is 
invariably increased (Barnard & Linter 1993, Morrill 2000), ischaemia may be exacerbated 
and ventricular function can be compromised (Barnard & Linter 1993). Because of 
generalized vasoconstriction, renal, abdominal visceral and skeletal muscle ischaemia may 
also occur (Morrill 2000) and, if used in shock patients, the state of shock may actually be 
worsened (Calvey & Williams 2001b). In human medicine, noradrenaline is usually not 
recommended for patients with hypovolaemia, because “There must be adequate volume to 
generate pressure, and clinicians should remember to ‘fill up the tank‟ before attempting to 
constrict the vessels” (Morrill 2000).  
   Although some clinicians commonly use noradrenaline in anaesthetized horses when blood 
pressure is not responsive to dobutamine and/or in vasodilatory shock states (e.g. 
endotoxaemia), little information is available on the effects in adult horses. A bolus of 
noradrenaline (3 µg/kg) in halothane anaesthetized horses increased MAP during 6 minutes, 
but this increase was less pronounced than with adrenaline at the same dose. Heart rate 
initially increased slightly, followed by a more pronounced bradycardia shortly after the time 
of the maximal pressor response. In 2 of 4 animals receiving noradrenaline, ventricular 
arrhythmias were observed (Lees & Tavernor 1970). Using a total dose of 50 – 200 µg in 
conscious adult horses, Sanders et al. (1991) reported increases in blood pressure and 
decreases in bronchial artery flow after noradrenaline administration.  
   In contrast to the paucity of data in adult horses, several researchers have studied the effects 
of noradrenaline in young foals (Hollis et al. 2006b, Valverde et al. 2006, Craig et al. 2007, 
Hollis et al. 2008). Noradrenaline (0.1–0.3 µg/kg/min) increased blood pressure and SVR and 
decreased HR and CI compared to a placebo treatment with saline in normotensive conscious 
foals (Hollis et al. 2006b, Hollis et al. 2008). No significant differences in urine output, 
creatinine clearance or fractional excretion of electrolytes were found using a dose of 0.1 
µg/kg/min in Thoroughbred foals (Hollis et al. 2006b), but urine output and creatinine 
clearance increased when administering a dose of 0.3 µg/kg/min in pony foals (Hollis et al. 
2008). In the latter report, the authors concluded that noradrenaline may be useful for 
hypotensive foals, because it increases SVR and blood pressure without negatively affecting 
renal function. Similar results were found in 1 – 2 week old, isoflurane anaesthetized foals, 
where noradrenaline (0.05-0.40 µg/kg/min) increased blood pressure, PAP, SVR and PVR, 
while HR decreased (Craig et al. 2007). Cardiac index and DO2 also decreased, but the 
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changes were not significant. Oxygen consumption, oxygen extraction, mixed venous oxygen 
tension and standard base excess, all markers of inadequate tissue perfusion, did not change 
(Craig et al. 2007). In neonatal hypotensive foals during deep isoflurane anaesthesia, 
noradrenaline (0.3 and 1.0 µg/kg/min) increased not only SVR and blood pressure, but also CI 
and DO2, while the oxygen extraction ratio decreased. However, as would be expected, the 
increases in CI and DO2 were much less pronounced than after dobutamine administration 
(Valverde et al. 2006).  
    
Phenylephrine 
Phenylephrine is closely related structurally to adrenaline and noradrenaline. It is a selective 
α1-adrenergic agonist (Calvey & Williams 2001b) and has little effect on β adrenoreceptors of 
the heart (Kee 2003). It therefore has minimal direct effects on HR and contractility, but 
bradycardia can be observed in response to the increase in blood pressure (Hardy et al. 1994). 
In septic shock patients, hepatosplanchnic blood flow and oxygen delivery were lower during 
treatment with phenylephrine compared to noradrenaline (Reinelt et al. 1999). 
   Phenylephrine infusion (1, 3 or 6 µg/kg/min) in conscious horses significantly increased 
PAP, RAP, SAP, DAP, MAP and PCV and significantly decreased HR and    , but SV did not 
change significantly. At the highest dosage, the rate-pressure product increased. At all doses, 
bradycardia was observed, while 2
nd
 degree AV block was present in 88 % of horses (Hardy 
et al. 1994). In halothane anaesthetized ponies, doses of 0.25-2 µg/kg/min dose-dependently 
increased MAP, central venous pressure (CVP), PVR, PCWP and SVR, without improving 
intramuscular blood flow or CI (Lee et al. 1998). Similarly, Raisis et al. (2000b) reported that 
phenylephrine decreased femoral arterial and venous blood flow and     and increased MAP, 
SVR and PCV in anaesthetized horses. Besides its use as a vasopressor, phenylephrine is also 
commonly used in horses during treatment of nephrosplenic entrapment of the large colon, 
where splenic contraction is the therapeutic target (Hardy et al. 2000).  
 
Methoxamine 
Methoxamine has similar effects to phenylephrine because of its highly selective agonist 
effects on α-adrenoceptors. The drug is commonly used in the management of untoward 
hypotension occurring during anaesthesia, particularly following subarachnoid or extradural 
blockade or when ganglion-blocking drugs have been employed (Calvey & Williams 2001b). 
Only a few reports are available about the use of methoxamine in horses or ponies. When
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given before induction of anaesthesia, methoxamine 40 µg/kg did not significantly affect 
cardiopulmonary function during halothane anaesthesia in horses (Dyson & Pascoe 1990). 
However, when given during anaesthesia in halothane anaesthetized ponies, methoxamine 13 
µg/kg followed by 5 µg/kg/min was able to maintain normotension, while     was lower and 
SVR higher compared to the saline goup (Brodbelt et al. 1998).  
 
Metaraminol 
Metaraminol is a sympathomimetic drug with a direct effect on vascular-adrenergic receptors 
and an indirect mechanism of action related to the stimulation of noradrenaline release 
(Holmes 2005). It can be used for the prevention and treatment of acute hypotension, e.g. 
caused by epidural or spinal anaesthesia, surgical complications or drug reactions (Calvey & 
Williams 2001b, Kee 2003). To the authors‟ knowledge, the use of metaraminol in horses has 
not been described. 
 
Combinations 
Under certain circumstances, it may be advantageous to combine agents which exert different 
effects (e.g. vasopressors and inotropic drugs) or agents which exert similar effects through a 
different mechanism of action (e.g. sympathomimetics with calcium salts, phosphodiesterase 
inhibitors with sympathometics, vasopressin analogues with sympathomimetic vasopressors, 
etc.). Since extensive research has been performed in this area, it is only possible to give a 
few examples here.   
   During treatment of vasodilatory shock, increased myocardial contractility, peripheral 
vasoconstriction and preservation of renal function are concomitant objectives which might be 
achieved using CRI‟s of noradrenaline (inotropic and vasoconstrictor) and low dose dopamine 
(renal and splanchnic blood flow) (Schaer et al. 1985). However, it remains uncertain whether 
this combination is superior to dopamine alone (Beale et al. 2004). Similarly, „renal doses‟ of 
dopamine are sometimes used in combination with dobutamine in the treatment of shock 
states with a low     (e.g. septic or cardiogenic shock) in an attempt to improve both renal and 
cardiac function (Calvey & Williams 2001b). Another example of combined use of different 
sympathomimetic agents is the administration of noradrenaline (0.1 µg/kg/min) with 
dobutamine (5 µg/kg/min), which increased blood pressure and SVR and decreased HR and 
CI compared to saline administration in normotensive neonatal foals, without differences in 
urine output, creatinine clearance or fractional excretion of electrolytes (Hollis et al. 2006b). 
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   Because inotropic drugs exert their effect through increased Ca
2+
 influx in the myocardium, 
the effects of -adrenergic agonists might be enhanced when these drugs are administered 
together with Ca
2+
 (d‟Hollander et al. 1982, Abernethy et al. 1995). However, calcium salts 
rather tended to attenuate the cardiotonic effects of -adrenergic agonists in man (Zaloga et al. 
1990, Butterworth et al. 1992, Abernethy et al. 1995), most likely due to a negative effect of 
free Ca
2+
 ions on the activity of adenylyl cyclase in the myocardial cells (Drummond & 
Duncan 1970, Colvin et al. 1991, Yu et al. 1993, Abernethy et al. 1995). At the same time, 
Ca
2+
 decreased the inotropic effects of milrinone in rat heart preparations (Goyal and McNeill 
1986), possibly by stimulating the activity of PDE, thereby increasing cAMP degradation 
(Teo & Wang 1973). 
   Because inotropic ß-sympathomimetics and PDE III inhibitors increase the intracellular 
concentration of cAMP through independent mechanisms, they may produce more powerful 
increases in contractility when used in combination. At the same time, PDE III inhibitors have 
vasodilatory properties, while many ß-sympathomimetics act as vasopressors, which may be 
useful to prevent or treat exaggerated decreases in SVR after administration of PDE III 
inhibitors. In humans, a combination of adrenaline and amrinone produced additive effects on 
SV after cardiopulmonary bypass surgery (Royster et al. 1993). Also, enoximone‟s 
cardiovascular effects were additive to those produced by dobutamine, with larger increases in 
CI, left ventricular stroke work index and HR and more pronounced decreases in RAP, PAP, 
PCWP, SVR and PVR (Gilbert et al. 1995). Other authors have described beneficial effects of 
combinations of amrinone with dobutamine (Uretsky et al. 1987), noradrenaline (Robinson & 
Tchervenkov 1987) and dopamine (Olsen et al. 1988). 
 
Conclusions  
In anaesthetized horses, adequate perfusion of peripheral tissues is important to avoid possibly 
lethal complications such as myopathies. Although balanced anaesthesia and fluid support are 
useful, cardiovascular stimulant drugs are often needed to achieve this. These include 
antimuscarinics, inotropic drugs and vasopressors. Antimuscarinic drugs are preferably used 
to treat bradycardia unrelated to hypertension and are not suitable to augment     under other 
circumstances, for many reasons. Vasopressors are useful in patients with hypotension caused 
by vasodilation, e.g. induced by drugs or endotoxins, where myocardial contractility and     
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are normal or high. Under such circumstances, the benefit of restoring vascular transmural 
pressure often outweighs the disadvantage of not improving     and possibly compromising 
perfusion of certain tissues because of excessive vasoconstriction. However, in most cases, 
inotropic drugs are preferable to improve tissue perfusion. Digitalis glycosides, calcium salts 
and calcium sensitizers are less suitable for routine cardiovascular support during anaesthesia, 
because of different reasons including a lack of effectiveness, cost, toxicity and/or 
pharmacokinetic considerations. Extensive research has been performed on the β 
sympathomimetic agents, of which dobutamine appears to remain the most useful agent for 
clinical use in anaesthetized horses. In humans, dobutamine typically causes inotropic effects, 
combined with some vasodilation, effects which are quite similar to those of PDE III 
inhibitors in humans. These agents therefore might be useful during equine anaesthesia, but 
have received very little attention in literature.  
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Treatment of cardiovascular depression is important to reduce anaesthetic related mortality in 
horses. However, to detect cardiovascular depression and to monitor the response to 
treatment, an easily applicable, continuous, noninvasive and reliable method to measure 
cardiac output in anaesthetized horses is needed. Pulse contour analysis using the LiDCO-
Plus
®
 monitor appears attractive for this purpose. The first aim of the experimental part of 
this PhD thesis was therefore to evaluate the reliability of this monitor in ponies or horses. 
   When cardiac output is low, treatment with positive inotropes is often needed during 
anaesthesia in horses. While extensive literature is available on the effects of 
sympathomimetic drugs in horses, there is very limited information on the effects of 
phosphodiesterase III inhibitors. In humans, these agents are potent inotropes and induce little 
serious side effects during short term use. As described in chapter 1.2, amrinone may induce 
some side effects and is used less frequently compared to milrinone and enoximone in human 
medicine. Since the effects of milrinone had already been investigated in horses, the second 
aim of the present PhD thesis was to evaluate the cardiovascular effects and safety of 
enoximone in ponies and/or horses, alone or combined with other inotropic and vasoactive 
drugs.  
 
   To achieve these aims, both an experimental and a clinical study were set up. The specific 
aims of the experimental trial were to: 
- assess the reliability of the Pulse Contour analysis logarithm used in the LiDCO-Plus® 
monitor to measure cardiac output by comparing it to the lithium dilution technique. 
- evaluate the cardiovascular effects and side effects of a bolus of enoximone in 
isoflurane anaesthetized ponies, alone or in combination with dobutamine or calcium 
chloride. 
    
   The aim of the clinical study was to 
- explore enoximone‟s usefulness in horses undergoing colic surgery. 
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SUMMARY 
Cardiac output (   ) measurements using lithium dilution (LiDCO) and pulse contour 
analysis (PulseCO) techniques were compared in isoflurane anaesthetized ponies before 
and during the administration of different inotropic/vasoactive drugs. Six ponies aged 
5.0 ± 1.6 years and weighing 286 ± 53 kg were enrolled in a prospective, randomized, 
experimental cross-over trial. After sedation (romifidine) and induction (midazolam + 
ketamine), anaesthesia was maintained with isoflurane in oxygen. After 90 minutes (= 
T0), 1 of 4 treatments was administered: saline 0.1 mL/kg
 
(S), enoximone 0.5 mg/kg 
intravenously
 
(E), enoximone followed by dobutamine (0.5 µg/kg/min for 120 minutes) 
(ED) or enoximone followed by a calcium chloride infusion (0.5 mg/kg/min for 10 
minutes) (EC). Data were recorded for 120 minutes after T0. The PulseCO (recorded 
from carotid artery) was calibrated before T0, no further recalibrations were 
performed.     was determined with LiDCO (   LiDCO) and PulseCO (   PulseCO) 
simultaneously at T5, T10, T20, T40, T60, T80, T100 and T120. Systemic vascular 
resistances (SVRLiDCO and SVRPulseCO) were calculated.  
   In the saline group,    PulseCO was 4.9 ± 12.3 % lower than    LiDCO (P < 0.01), whereas 
SVRPulseCO was 6.9 ± 14.4 % higher than SVRLiDCO (P < 0.01). These differences 
increased over time,     by 0.06 % per minute (P=0.042) and SVR by 0.08 % per minute 
(P=0.018).    PulseCO was higher than    LiDCO in the EC group (1.8 ± 23.3 %), but lower 
than    LiDCO in groups E (-11.7 ± 20.4 %) and ED (-10.0 ± 25.9 %) (significant 
difference between treatments, P < 0.01). The differences in SVR in groups E (20.4 ± 
32.0 %) and ED (20.7 ± 35.3 %) were significantly higher than in groups S (6.9 ± 14.4 
%) and EC (3.1 ± 22.2 %) (P < 0.01). It can be concluded that the PulseCO values 
deviated significantly from the LiDCO measurements in isoflurane anaesthetized ponies 
and that this difference was influenced by inotropic/vasoactive drugs. 
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Introduction 
During equine anaesthesia, cardiovascular monitoring usually consists of an 
electrocardiogram and invasive measurement of arterial blood pressure. Indeed, supporting 
mean arterial blood pressure (MAP) is important in the prevention of severe complications, 
such as myopathies. However, measurement of cardiac output (   ) would allow an even 
better assessment of cardiovascular function. Ideally, the measurement technique must be 
easy to perform, accurate, continuous and minimally invasive. Numerous techniques have 
been described, such as the Fick principle (Fick 1870), electromagnetic flowmetry (Brunsting 
et al. 1970), indicator dilution methods (Lagerlof et al. 1950), Doppler echocardiography 
(Steingart et al. 1980), thoracic electrical bioimpedance (Mattar et al. 1986), pulse contour 
analysis (Kouchoukos et al. 1970) and rebreathing of carbon dioxide (Klausen 1965). While 
many of these methods have been used in horses (Waugh et al. 1980, Evans et al. 1988, 
Young et al. 1996, Giguère et al. 2005), the indicator dilution techniques have been used 
most frequently (Muir et al. 1976), but only allow an intermittent assessment of    . A 
continuous thermodilution method has been developed (Luchette et al. 2000), but its response 
time was reported to be rather slow (Siegel et al. 1996) and to the authors‟ knowledge, the 
use of the technique has not been described in depth in the horse. Transoesophageal 
echocardiography has also been reported as an effective and non-invasive method for 
measurement of     in anaesthetized horses (Young et al. 1996), but this technique requires 
experience and a long, expensive device is needed in horses.  
   Several other techniques have been developed, but one of the most attractive alternatives 
was the estimation of     based on an analysis of the arterial pressure wave, which would 
allow continuous, beat-to-beat assessment of     and only requires the insertion of an arterial 
catheter. Most of these pulse contour analysis methods are based on the “Windkessel” theory 
(Kouchoukos et al. 1970) and relate the arterial pressure or pressure difference to a flow or 
volume by taking the impedance through which the flow is driven into account (Jansen et al. 
1990). Numerous researchers developed countless linear models to assess stroke volume (SV) 
or     based on this theory, with rather disappointing results (Alderman et al. 1972, Starmer et 
al. 1973, Verdouw et al. 1975, Wesseling et al. 1976). Later, an extended version of the 
Windkessel model was developed: the “Modelflow” method (Wesseling et al. 1993). This 
nonlinear, time-varying, three-element model was able to maintain reliable determinations of 
    for a 24 hour period in humans, provided that no profound fluctuations in blood pressure 
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occurred (Gödje et al. 1999). An improved version of this algorithm has been implemented in 
the current PiCCO
®
 software (Pulsion Medical Systems AG, Munich, Germany) (Gödje et al. 
2002).  
   In the LiDCO-Plus
®
 monitor (LiDCO-plus Hemodynamic Monitor
®
, LiDCO Ltd., London, 
UK), continuous arterial pulse contour analysis is performed using a different formula 
compared to the previous methods. Cardiac output is calculated during each heart beat from 
the beat duration, ejection duration, MAP and the modulus and phase of the first harmonic of 
the waveform (Fig. 2 Chapter 1.1). The PulseCO
®
 technique incorporates a model of the 
pressure transfer from the aorta to the radial artery and uses a model of the arterial system in 
which wave reflections are well represented. The technique was therefore expected to be 
more accurate and less sensitive to changes in systemic vascular resistance (SVR) than the 
“Windkessel” model, where aorta and radial artery pressures are assumed to be equal and 
wave travel phenomena are not characterized (Linton & Linton 2001). Compared to 
thermodilution and LiDCO
®
, PulseCO
®
 reliably tracked changes in     in haemodynamically 
stable patients for at least 8 hours after cardiac surgery in humans, without performing 
recalibration (Hamilton et al. 2002).  
   As the PulseCO
®
 algorithm was developed for use in humans, the reliability in animals can 
be questioned. In anaesthetized dogs, the PulseCO
®
 provided directional tracking of    
 
measurements but poor accuracy when the haemodynamic conditions were altered 
appreciably from those during the initial calibration with the LiDCO
®
 system (Chen et al. 
2005). Although Martin-Bouyer et al. (2006) did not report significant differences between 
LiDCO
®
 and PulseCO
®
 in anaesthetized dogs after epidural administration of romifidine, the 
difference between the two methods gradually increased over time. One study in 24 horses 
undergoing elective or colic surgery reported a good correlation between LiDCO
®
 and 
PulseCO
®
 (Hallowell & Corley 2005). The objective of the present investigation was to 
further evaluate the accuracy of the PulseCO
®
 software in ponies by comparing LiDCO
®
 and 
PulseCO
®
 measurements under changing haemodynamic conditions.  
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Materials & Methods 
Animals 
After approval by the Ethical Committee of the Faculty of Veterinary Medicine of the 
University of Ghent (EC 2005/48), 6 ponies were used for the study: 5 geldings and 1 mare, 
aged 5.0 ± 1.6 years and weighing 286 ± 53 kg.  The left carotid artery had been transposed 
to a subcutaneous position at least two months before the experiment. Based on a physical 
and general blood examination, all ponies were regarded as ASA (American Society of 
Anesthesiologists) class I (normal and healthy).  
 
Anaesthetic protocol and instrumentation 
The ponies were fasted for 12 hours before anaesthesia. After sedation (80 µg/kg romifidine 
intravenously (IV) (Sedivet
®
, Boehringer Ingelheim, Brussels, Belgium)), a 12 gauge catheter 
(Intraflon 2
®
, Vygon, Ecouen, France) was placed in the right jugular vein. Fifteen minutes 
later, general anaesthesia was induced with 0.06 mg/kg
 
midazolam IV (Dormicum
®
, Roche, 
Brussels, Belgium) and 2.2 mg/kg ketamine IV (Anesketin
®
, Eurovet, Heusden-Zolder, 
Belgium). After endotracheal intubation (24 - 26 mm OD Soft rubber tracheal tube, Rüsch 
AG, Kernen, Germany), the ponies were placed in right lateral recumbency. The endotracheal 
tube was connected to a large animal anaesthetic unit (Matrix medical inc., Orchard Park, 
New York, USA + Sulla 909V
®
, Dräger, Lübeck, Germany) with a large animal respirator 
(Smith respirator LA 2100
®
, model 2002, Veterinary Technics/BDO-Medipass, Hoogezand, 
the Netherlands). 
   General anaesthesia was maintained with isoflurane (Isoflo
®
, Abbott Laboratories Ltd., 
Queenborough, Kent, United Kingdom) in oxygen, delivered through an out-of-circuit 
vaporizer (Drägerwerk AG, Lübeck, Germany). During the first 10 minutes of anaesthesia, 
the oxygen flow was set at 6 L/min, after which it was decreased to 10 mL/kg/min. 
Inspiratory and expiratory CO2, O2 and isoflurane concentrations were monitored with a 
calibrated, methane-insensitive, multi-gas analyzer (HP M1025B
®
, Hewlett Packard 
Company, Houston, USA). The end - tidal isoflurane concentration was maintained at 1.7 %. 
Respiration mode was assisted-controlled, with a tidal volume of 10 mL/kg, a respiratory 
frequency of 10 breaths/min, a peak inspiratory pressure of 1.96 kPa (20 cm H2O) and an 
inspiration time of 2 seconds. When necessary, these settings were adapted to maintain 
PaCO2 between 4.66 and 6.00 kPa (35 - 45 mm Hg). Lactated Ringer‟s solution 
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(Haemofiltration Formula E2, Clear-Flex
®
, Bieffe Medital, Grosotto, Italy) was infused at a 
rate of 3 mL/kg/hour.  
   After preparation of the skin over the left jugular vein and transposed carotid artery, a 20 
gauge catheter (Vasocan
®
 Braunüle Luer Lock, B. Braun Melsungen AG, Melsungen, 
Germany) was placed in the left carotid artery. Using the Seldinger technique, a 7 French 
thermodilution catheter (3-lumen, Abbott Laboratories, North Chicago, IL60064, USA) was 
placed in the left jugular vein, with the distal port in the right atrium to measure right atrial 
pressure (RAP). Correct positioning of the catheter was confirmed by the characteristic 
waveforms. Both the arterial and right atrial catheters were connected to a pressure 
transducer, zeroed at the level of the right atrium. Both catheters were regularly flushed 
during anaesthesia using a heparinized saline solution (100 IU heparin per mL (Heparine 
LEO
®
, Leo Pharma B.V., Breda, the Netherlands)). Pressures were monitored with a CMS-
Patientenmonitor
®
 (HP M1165A
®
, model 56S, Hewlett-Packard GmbH, Böblingen, 
Germany), which was also used to record the electrocardiogram (ECG) (base-apex lead), to 
perform pulse-oximetry (probe placed on tongue) and to measure body temperature using an 
oesophageal probe. The pressure monitoring system was calibrated against a mercury 
manometer before each experiment.  Cardiac output was determined with both the lithium 
dilution technique (   LiDCO) and with Pulse Contour Analysis (   PulseCO) (LiDCO-plus 
Hemodynamic Monitor
®
, LiDCO Ltd., London, UK). For LiDCO measurements, a 1 to 1.5 
mmol bolus of lithium chloride was injected through the proximal port of the thermodilution 
catheter, while arterial blood for detection of lithium chloride by the LiDCO sensor (CM10 
LiDCO sensor
®
, LiDCO Ltd.) was withdrawn from the carotid artery by the LiDCO Flow 
Regulator. The LiDCO-plus
®
 monitor then calculated     using the following formula:     = 
(LiCl dose x 60)/[Area x (1 – PCV)] (where Area =  integral of primary concentration versus 
time curve and PCV = packed cell volume). The monitor requires the user to enter the blood 
haemoglobin (Hb) concentration and calculates PCV from this value (PCV(L/L) = Hb 
(g/dL)/34) (Linton et al. 2000). Since we measured PCV by centrifugation before each 
LiDCO determination, but not the Hb concentration, we calculated Hb from PCV using the 
same formula. The plasma sodium concentration is also required by the LiDCO-plus
®
 
monitor and was determined on a blood sample withdrawn from the right jugular vein before 
sedation (AVL 9180 Electrolyte Analyzer
®
, AVL scientific corporation, Roswell, Georgia, 
USA 30076). Dilution curves rejected by the LiDCO-plus
®
 software were repeated 
immediately. For Pulse Contour Analysis, the pressure waveform from the catheter in the 
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carotid artery was analyzed by the LiDCO-plus
®
 monitor. During LiDCO measurements, 
PulseCO values were temporarily unavailable, as the arterial catheter had to be disconnected 
from the pressure transducer to allow blood flow towards the lithium sensor. Therefore, 
   PulseCO was taken as the mean of the PulseCO values during the last 5 seconds before and 
the first 5 seconds after each LiDCO measurement. PulseCO calibration, based on a LiDCO 
measurement, was performed after 60 minutes of anaesthesia and repeated 10 and 20 minutes 
later if LiDCO and PulseCO values differed by more than 5%. No further recalibrations were 
performed during the remaining anaesthetic period (120 minutes). At each of these three time 
points (T-30, T-20 and T-10), baseline values for heart rate (HR), systolic (SAP), diastolic 
(DAP) and mean arterial pressure (MAP) and RAP were also recorded.  
 
Experimental design 
Ninety minutes after induction, 1 of 4 treatments was administered: an IV bolus of 0.5 mg/kg 
enoximone 0.5%  at a rate of 20 mL/min (treatment E), an equivalent volume of saline (0.1 
mL/kg) at 20 mL/min (treatment S), an IV bolus of enoximone 0.5 mg/kg at 20 mL/min, 
followed by a constant rate infusion of 0.5 µg/kg/min dobutamine (Dobutamine Mayne
®
, 
Mayne Pharma, Brussels, Belgium) for 120 minutes (treatment ED) or an IV bolus of 
enoximone 0.5 mg/kg at 20 mL/min, followed by an infusion of calcium chloride at 0.5 
mg/kg/min (Calcii chloridum 10%, Federa, Brussels, Belgium) from T5 to T15 (treatment 
EC). T0 was defined as the end of the injection of saline or enoximone, after which data were 
recorded for 120 minutes. In a randomized order, each pony received all 4 treatments in a 
crossover trial setting, with a wash-out period of at least 2 weeks between treatments. 
   Heart rate, SAP, DAP, MAP, RAP,    LiDCO and    PulseCO were recorded at T5, T10, T20, 
T40, T60, T80, T100 and T120 (time expressed in minutes), except in the EC group, where 
LiDCO measurements were not performed at T5.  
   Stroke volume (SVLiDCO and SVPulseCO) and SVR (SVRLiDCO and SVRPulseCO) were 
calculated as follows: 
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Statistical analysis 
Statistical analysis was performed using a statistical software programme (S-Plus
®
 7.0 for 
Windows, Insightful Corp., Seattle, USA). Data are expressed as mean ± 1 standard deviation 
(SD). For each pair of    
 
measurements after T0, the absolute and relative differences in     
(AbsDiff   
 
and RelDiff   
 
respectively) were calculated as: 
                                                       
                     
                                  
               
 
                         
                      
                          
   
                     
                    
                          
  
                      
 
   To assess whether these differences were significant during treatment with saline, a paired 
t-test was performed. The evolution of these differences over time in the control group was 
assessed using a mixed model ANOVA with pony as random effect and time as continuous 
fixed effect.  
   The influence of treatment was analyzed using a mixed model ANOVA with pony as 
random effect, treatment as categorical fixed effect and time and its interaction with treatment 
as continuous fixed effects. To further document bias and precision, Bland-Altman plots were 
obtained and mean bias and limits of agreement between LiDCO and PulseCO techniques 
were calculated for each treatment group (Bland & Altman 1986). 
   To assess whether RelDiff    during treatment S was influenced by changes in HR, SAP, 
DAP, MAP, RAP, PCV or SVRLiDCO, mixed models were fitted with pony as random effect 
and the respective variable as continuous fixed effect.  Differences were considered 
significant if P < 0.05.  
 
Results  
In total, 186 comparisons between LiDCO and PulseCO values for     and SVR were 
obtained. The mean total lithium chloride dose per pony was 0.056 ± 0.011 mmol/kg, with a 
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maximum of 0.068 mmol/kg in one pony. Overall, during saline treatment (Fig. 1 & 2, Table 
1), PulseCO understimated    LiDCO by 0.70 ± 1.33 L/min (P < 0.001) (mean bias 4.9 ± 12.3 
%, limits of agreement -19.7 and +29.5 %) and overestimated overall SVR by 22.0 ± 58.0 
dyne.sec/cm
5
 (P = 0.011) or 6.9 ± 14.4 % (P = 0.002) (mean ± SD). The difference also 
increased over time: each minute, the absolute difference between    LiDCO and    PulseCO 
increased by 0.007 L/min (P = 0.023), while the relative difference increased by 0.06 % per 
minute (P = 0.042). The difference between SVRLiDCO and SVRPulseCO increased by 0.29 
dyne.sec/cm
5
 (P = 0.027) or 0.08 % (P = 0.018) each minute. 
    While    PulseCO was usually lower than    LiDCO during treatments S and E, PulseCO 
initially overestimated LiDCO values in groups ED and EC, but gradually became lower than 
LiDCO values during the remaining period of the anaesthesia (Fig. 1 & 2, Table 1). 
Consequently, there were significant differences between treatments in AbsDiff    (P < 
0.001), AbsDiffSVR (P = 0.009), RelDiff    (P = 0.001) and RelDiffSVR (P = 0.006).  
 
Fig. 1:  Cardiac output (   ) measured using lithium dilution (LiDCO) and Pulse Contour 
Analysis (PulseCO) in 6 anaesthetized ponies, receiving a bolus of enoximone (E), 
saline (S), enoximone followed by a dobutamine infusion during 120 minutes (ED) or 
enoximone followed by a calcium chloride infusion during 10 minutes (EC). T0 = end 
of administration of saline or enoximone; PulseCO calibration performed at T-30, T-
20 and T-10.  
Data are represented as mean ± 1 standard deviation.    
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Table 1:  Cardiac output (   ), stroke volume (SV) and systemic vascular resistance (SVR) measured by lithium dilution (LiDCO) and pulse contour 
analysis (PulseCO) in 6 anaesthetized ponies, during treatment (Trt) with saline (S), enoximone (E), enoximone followed by a dobutamine 
infusion (ED) or enoximone followed by a calcium chloride infusion (EC).  
 
Data are represented as mean ± SD. 
T0 = end of administration of saline or enoximone 
PulseCO calibration performed at T-30, T-20 and T-10. 
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Overall, the largest absolute difference in     was in the enoximone/dobutamine treatment, 
with PulseCO understimating    LiDCO (mean bias 2.28 ± 5.90 L/min, limits of agreement -
9.52 and +14.08 L/min), especially from T40 onwards, when     was also clearly higher 
compared to the other treatments. However, when looking at the relative differences, the 
largest overall difference in     was found after treatment E, where    PulseCO was lower than 
   LiDCO (mean bias 11.7 ± 20.4 %, limits of agreement -40.8 and +52.5 %). Mean bias during 
treatment ED was 10.0 ± 25.9 %. The smallest relative difference was found in the 
enoximone/calcium combination group, where overall PulseCO overestimated LiDCO values 
(mean bias -1.8 ± 23.3 %, limits of agreement -48.4 and +44.8%). RelDiffSVR in groups ED 
(20.7 ± 35.3 %) and E (20.4 ± 32.0 %) was significantly higher than in groups S (6.9 ± 14.4 
%) (P < 0.01) and EC (3.1 ±  22.2 %) (P < 0.001).   
 
Fig. 2:  Bland-Altman plots of cardiac output measured using lithium dilution (LiDCO) and 
Pulse Contour Analysis (PulseCO) in 6 anaesthetized ponies, receiving a bolus of 
enoximone (E), saline (S), enoximone followed by a dobutamine infusion during 120 
minutes (ED) or enoximone followed by a calcium chloride infusion during 10 minutes 
(EC).  
Mean bias (middle line) and limits of agreement (upper and lower line) are indicated. 
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   Systolic arterial pressure, DAP and MAP had a significant effect on RelDiff    during 
treatment S: as these pressures increased, RelDiff    became higher (P < 0.001) (Fig. 3). No 
significant influence of HR, RAP, PCV or SVR on RelDiff    could be detected.   
 
Fig. 3:  Mean arterial pressure and relative differences between lithium dilution and pulse 
contour analysis measurements of cardiac output (RelDiff   ) in 6 anaesthetized ponies 
receiving a bolus of saline at T0 (treatment S). Values are represented as mean ± SD.  
 
Discussion 
In the present study, significant differences between LiDCO and PulseCO estimations of both 
the     and the SVR were found in isoflurane anaesthetized ponies, even when no drugs were 
administered. Furthermore, these differences significantly increased over time and were 
influenced by the different treatments. These results indicate that in a clinical setting, relevant 
differences may occur if recalibration is not performed regularly, especially in 
haemodynamically unstable patients receiving inotropic/vasoactive drugs.     
   Although the thermodilution technique (TDCO) is widely used for     measurements in 
horses, the LiDCO technique was chosen as reference to validate PulseCO measurements in 
the present study. Indeed, comparison of TDCO and LiDCO measurements has demonstrated 
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that the LiDCO technique is reliable, not only in humans (Linton et al. 1997), but also in 
anaesthetized horses (Linton et al. 2000) and foals (Corley et al. 2002). Although it has been 
shown in pigs that a peripheral injection site can be used for lithium chloride administration, 
a better correlation with an electromagnetic flowmeter around the aorta was found using a 
central injection site (Kurita et al. 1999). Therefore, a central venous injection of lithium 
chloride was preferred in the present study, in order to increase the accuracy of the reference 
technique. 
   In dogs and foals, LiDCO progressively exceeded TDCO over time. This was attributed to  
a decrease in the sensitivity of the older types of the LiDCO sensor (which had a relatively 
thin membrane) over time (Mason et al. 2001, Corley et al. 2002). However, newer sensors 
(as used in the present study) have a thicker membrane, which should increase their 
performance over longer time periods (Mason et al. 2001). Alternatively, increased 
background serum lithium concentrations can reduce the sensitivity of the sensor, leading to a 
smaller lithium peak and a consequent overestimation of true    . In the present study, 11 
measurements were performed over 150 minutes. Although 20 successive 3 mmol bolus 
injections given at 3-minute intervals to adult Standardbred horses did not interfere with the 
performance of the LiDCO, Hatfield et al. (2001) recommended a maximum of 10 
measurements in 2 hours. According to the manufacturer of LiDCO-plus
®
, increased 
background serum lithium only becomes important when serum lithium concentrations 
increase above 0.2 mmol/L. Corley et al. (2002) reported that the cumulative lithium dose to 
achieve this concentration in foals was approximately 0.08 ± 0.03 mmol/kg. In the present 
study, this mean dose was never exceeded, even in the pony receiving the highest dose (0.068 
mmol/kg).  
   It is also possible that the use of plasma sodium concentrations of the standing non-sedated 
ponies for LiDCO measurements during anaesthesia would affect the accuracy of the LiDCO 
measurements. However, plasma sodium concentrations have not been reported to change 
after induction of anaesthesia in horses (Tevik et al. 1968, Gasthuys et al. 1986). 
Furthermore, plasma sodium concentrations during anaesthesia should have been stable after 
the initial calibration, since none of the treatments should have affected plasma sodium 
concentrations. Therefore, the comparison between the 2 techniques should be reliable. 
Finally, calculation is less accurate than measurement of the haemoglobin concentration. 
However, as explained in the materials and methods section, the LiDCO-plus
®
 monitor uses 
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PCV and not haemoglobin in the formula applied to calculate    
 
 and actually derives PCV 
from the entered haemoglobin value using the same formula as the one used in the present 
study to calculate haemoglobin from PCV (Linton et al. 2000). In conclusion, the LiDCO 
measurements in the present study can be assumed to be as accurate as previously described 
(Linton et al. 2000, Corley et al. 2002). Consequently, the actual     was likely to be 
progressively underestimated by the PulseCO software. 
   During saline treatment, isoflurane anaesthesia was kept stable using the expiratory 
isoflurane concentration and a constant PaCO2. Nevertheless,    PulseCO became significantly 
lower than    LiDCO with a mean bias of 4.9%. Relative differences between the 2     
measurement techniques were calculated because Critchley and Critchley (1999) argued that 
these are more relevant compared to absolute differences. According to their report, limits of 
agreement of ± 30 % between the new and the reference technique  are acceptable. The limits 
of agreement were -19.7 and 29.5 % in the control treatment of the present study. As the 
difference was significantly larger during the other treatments (limits of agreement during 
enoximone treatment -40.8 and +52.5 %), PulseCO became more unreliable as the 
haemodynamic conditions changed. 
   Several hypotheses are possible to explain why PulseCO values were lower than LiDCO 
measurements during saline treatment and why this difference became larger over time. In the 
saline group, gradual but significant increases in SVRLiDCO and blood pressure and decreases 
in HR occurred over time (Chapter 4.1). Changes in blood pressure and especially in SVR 
were proven to affect the accuracy of various linear pulse contour analysis techniques 
(Kouchoukos et al. 1970, Starmer et al. 1973). Even the Modelflow method, although it takes 
aortic characteristic impedance, arterial compliance and SVR into account (Wesseling et al. 
1993), was found to be less accurate when pronounced changes in blood pressure and/or SVR 
occurred (Gödje et al. 1999, Rödig et al. 1999). The PulseCO software incorporates a model 
of pressure transfer from the aorta to peripheral arteries, takes wave reflection into account 
and should therefore be less sensitive to changes in SVR, as backward flow, resulting in 
augmentation of the pressure but retardation of the flow, is partly determined by SVR. In 
humans, PulseCO
®
 was accurate in conditions when the SVR changed but MAP remained 
constant and in conditions where the changes in SVR were small compared to changes in 
MAP (Linton & Linton 2001). In the present study, no significant influence of SVR on the 
difference between LiDCO and PulseCO could be demonstrated, although SVR increased 
LiDCO & PulseCO in ponies 
 
102 
 
substantially and significantly during saline treatment (see chapter 4.1). However, statistical 
analysis confirmed that the difference in     estimated by the 2 methods became larger when 
blood pressure increased, possibly because aortic compliance decreased substantially in a 
non-linear way when pressure increased (Jansen et al. 2001). The respective curves during 
treatments E, ED and EC illustrated the same trend: after an initial increase in     following 
administration of enoximone, which was reliably tracked by the PulseCO, blood pressure 
gradually increased in all groups, accompanied by an increasing difference between LiDCO 
and PulseCO values. Similar to the present study, Chen et al. (2005) reported an 
underestimation of     by the PulseCO when blood pressure increased in dogs.  
   To the authors‟ knowledge, there is only one report about the accuracy of the PulseCO 
software in horses (Hallowell & Corley 2005). These authors reported a mean difference 
between LiDCO and PulseCO of 0.2%, with limits of agreement of -10.6 to + 11%, which 
was far better than the results of the present study. Although we did not use a continuous 
flushing device for the arterial catheter, it was frequently flushed manually using a 
heparinized saline solution and no obvious  signs of dampening of the arterial waveform were 
observed in any of the ponies. Secondly, blood pressure was recorded from the carotid artery, 
while either the facial or metatarsal arteries were used by Hallowell and Corley (2005). To a 
certain degree, the accuracy of pulse contour analysis techniques may differ according to the 
artery from which it is recorded (Gödje et al. 2002). However, PulseCO was designed for use 
with radial artery pressure in man, because it incorporates a model of the pressure transfer 
from the aorta to the radial artery (Linton & Linton 2001). Therefore, inaccuracy would 
mainly be expected with pressures monitored from the hind limb, as the most important sites 
of wave reflection are the vascular beds of the trunk (Karamanoglu et al. 1994). Changes in 
the reflection coefficient of these beds might change the relationship between the pressures in 
the ascending and abdominal aorta as well as arteries distal to this vessel (Linton & Linton 
2001). The accuracy of pulse contour analysis from the carotid artery should thus be 
comparable to the one from the facial artery.  
   Results of the present study indicated that the difference between the 2 methods increased 
over time. In the study of Hallowell and Corley (2005), LiDCO measurements were 
performed at 20-30 minute intervals and compared to the PulseCO readings immediately 
before each measurement. However, it is not mentioned whether the PulseCO was 
recalibrated with each LiDCO measurement. If recalibration was performed at 20-30 minute 
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intervals, differences between both techniques would be minimized. Furthermore, the number 
of comparisons per horse varied between 2 and 6, with 20 to 30 minute intervals between 
recordings, indicating that even if no recalibrations were performed, a large part of the 
comparisons was performed within the first hour after the initial calibration. As the present 
study was performed over a longer time period (120 minutes after calibration), a larger 
difference between the two methods was expected. Other factors which may affect PulseCO 
measurements, such as an aortic aneurysm or aortic valve abnormalities, were not present in 
these experimental ponies.  
   The LiDCO-plus
®
 user‟s manual recommends checking the calibration in humans every 8 
hours and each time a significant change is instituted in the haemodynamic management of 
the patient, when the arterial catheter or pressure line is changed or when the patient is moved 
to a new location. However, despite such measures, clinically relevant differences between 
TDCO and PulseCO (Linton and Linton 2001, Yamashita et al. 2005) or PiCCO (Halvorsen 
et al. 2006) have been reported in human patients during and after coronary artery bypass 
surgery and it has been recommended to check or redo the calibration before major clinical 
decisions are taken (Linton & Linton 2001). Based on the results of the present study, this can 
also be recommended in horses, since the accuracy of the PulseCO was significantly different 
between treatments, indicating that possible differences may be magnified in case of 
pronounced haemodynamic changes. Especially in these animals, where accurate knowledge 
of     would be of great value to the clinician, the PulseCO may thus become less reliable if 
recalibration is not performed.  
   Significant differences in SVR were expected between treatments, because enoximone 
induced vasodilation in humans (Vernon et al. 1991), dobutamine tended to reduce SVR in 
ponies (Gasthuys et al. 1991, Lee et al. 1998) and may increase SVR at higher doses in horses 
(Taylor & Clarke 1999), a combination of enoximone and dobutamine potentiated the 
systemic vasodilator effects of both drugs in humans (Thuillez et al. 1993) and administration 
of calcium increased SVR in anaesthetized ponies (Gasthuys et al. 1991). Nevertheless, in the 
present study, the only significant difference in SVR was found during treatment with 
enoximone and dobutamine, where SVRLiDCO was lowest. Although the largest absolute 
difference between LiDCO and PulseCO values was also found during treatment ED, no 
significant correlation was found between SVR and the difference between both techniques. 
Most likely, the large absolute difference found during treatment ED can simply be explained 
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by the fact that     values were also highest during this treatment. When relative differences 
were analyzed, the differences during treatments E and ED were comparable. 
   The smallest relative difference overall was found during treatment with a combination of 
enoximone and calcium chloride. PulseCO overestimated     in this group, especially during 
and immediately after calcium administration. It might be hypothesized that alterations in the 
concentration of ionized calcium have an influence on the voltage of the lithium sensor, 
thereby influencing LiDCO measurements. However, this is most unlikely, as the sensor 
should only be sensitive to ions with a single positive charge (like lithium and sodium) and 
not to ionized calcium, which carries a double positive charge. On the other hand, as HR, 
arterial blood pressure and SVRLiDCO were all comparable in groups E and EC, it remains 
unclear how calcium administration influenced PulseCO readings. During treatment EC, 
standard deviation of the LiDCO measurements was higher than during treatment E. This 
indicates that, compared to treatment E, there was more variation in the response to treatment 
EC between the different ponies. As a result, standard deviation of the PulseCO 
measurements was also increased. The overestimation of     by the PulseCO might therefore 
simply be the result of statistical coincidence. The large overlap of the PulseCO 
measurements during treatments E and EC confirms this hypothesis. 
   In conclusion, the present study indicated that, over a period of 120 minutes after 
calibration, PulseCO can significantly differ from LiDCO measurements in 
haemodynamically stable, isoflurane anaesthetized ponies. Furthermore, this difference 
gradually increased over time and was influenced by inotropic/vasoactive drugs and by 
changes in arterial blood pressure. It is therefore recommended to check the calibration 
before major clinical decisions are taken.             
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SUMMARY 
The cardiovascular effects of enoximone were examined in six healthy, isoflurane 
anaesthetized ponies, aged 5.0 ± 1.6 years and weighing 286 ± 52 kg. After sedation with 
romifidine (80 µg/kg intravenously (IV)), anaesthesia was induced with midazolam (0.06 
mg/kg IV) and ketamine (2.2 mg/kg IV) and maintained with isoflurane in oxygen 
(FE´Iso 1.7%). The ponies were ventilated to maintain normocapnia (PaCO2 4.66-6.00 
kPa). Each pony was anaesthetized twice to receive either enoximone 0.5 mg/kg IV (E) 
or saline (S) 90 minutes after induction, with a minimal interval of 3 weeks between 
treatments. Heart rate (HR), arterial blood pressure and right atrial pressure (RAP), 
cardiac output (   ) (lithium dilution technique) and blood gases (arterial and central 
venous samples) were recorded at regular intervals during a period of 120 minutes after 
treatment. Stroke volume (SV), systemic vascular resistance (SVR), venous admixture 
(       ) and oxygen delivery (DO2) were calculated.  
   Enoximone induced significant increases in HR,    , SV,         and DO2 and a 
significant decrease in RAP. No significant differences were detected for arterial blood 
pressure, SVR and blood gases. No cardiac arrhythmias or other side effects were 
observed. These results suggest that in isoflurane anaesthetized ponies, enoximone has 
beneficial effects on     and SV without significantly affecting blood pressure. Despite 
increases in        , DO2 to the tissues was improved.  
          
Enoximone in ponies 
 
114 
 
Introduction 
Johnston et al. (2002) pointed out that most causes of perianaesthetic death in horses are 
linked with cardiovascular depression. Horses appear to be more susceptible to the 
cardiovascular and respiratory depressant effects of the inhalation anaesthetics than other 
species (Eberly et al. 1968, Gillespie et al. 1969, Hall 1971). This results in hypotension and 
poor tissue perfusion. As a result, tissue oxygen supply is often inadequate in anaesthetized 
horses, as delivery of oxygen (DO2) to the tissues is determined not only by the arterial 
oxygen content (CaO2) (which is often low in the recumbent horse) but also, and even more 
important, by the cardiac output (   ). In order to prevent postanesthetic myopathy, 
preventing myocardial depression and maintaining tissue blood flow are of major importance 
in the equine patient. 
   Reduction in anaesthetic depth, high-volume fluid therapy and inotropic support to 
maintain mean arterial pressure (MAP) above 70 mm Hg are recommended to reduce the 
severity of myopathy (Duke et al. 2006). Available inotropic drugs include digitalis 
glycosides, beta-adrenergic agonists, calcium sensitizers and phosphodiesterase (PDE) 
inhibitors (Notterman 1991, Via et al. 2003). Sympathomimetics are most frequently used in 
anaesthetized horses, although side-effects can occur, including sinus tachycardia, cardiac 
arrhythmias, muscular tremor and in some cases severe vasoconstriction (Swanson et al. 
1985, Trim et al. 1985, Gasthuys et al. 1991, Lee et al. 1998). 
   PDE III inhibitors (amrinone, milrinone, enoximone) are nonglycoside, noncatecholamine 
agents with positive inotropic and vasodilating effects (Vernon et al. 1991) and less 
proarrhythmic effects than dobutamine (Caldicott et al. 1993).  These drugs exert their action 
through inhibition of the enzymatic hydrolysis of cAMP. This leads to positive inotropic and 
lusitropic effects in the myocardium (Vernon et al. 1991) and systemic vasodilation (Evans 
1989). Amrinone is used less frequently in man, because accumulation can occur in critically 
ill patients and thrombocytopenia has been observed (Notterman 1991). Fewer side effects 
have been reported in man using the newer PDE III inhibitors, such as milrinone and 
enoximone (Kikura et al. 1995). The haemodynamic effects of milrinone have been 
investigated in halothane anaesthetized horses, whereby increases in heart rate (HR), MAP, 
   , ejection fraction and maximum rate of increase and decrease of left ventricular pressure 
(+/- dP/dtmax) were observed (Muir 1995).  
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   In man, enoximone increases coronary blood flow, reduces vascular resistances and has a 
positive inotropic effect, without significant increases in myocardial oxygen consumption 
(Dage and Okerholm 1990, Ghio et al. 2003). Myocardial oxygen consumption, as reflected 
by heart rate-pressure product, was significantly lower in patients who received enoximone 
than in patients receiving dobutamine following cardiopulmonary bypass (Lançon et al. 
1990). Even more, in patients with acute myocardial infarction, enoximone was tolerated 
better and produced fewer side-effects than dobutamine using doses which produced similar 
increases in     (Caldicott et al. 1993). The aim of the present study was to determine the 
effects of a single bolus of enoximone in isoflurane anaesthetized ponies.
 
Materials & Methods 
Animals 
After approval by the Ethical Committee of the Faculty of Veterinary Medicine of the 
University of Ghent (EC 2005/48), six ponies, aged 5.0 ± 1.6 years and weighing 286 ± 52 
kg, were selected for this study (5 geldings and 1 mare). The left carotid artery was 
transposed to a subcutaneous position at least two months before the experiment. The ponies 
were regularly vaccinated and dewormed. Based on a physical and general blood 
examination, they were regarded as ASA (American Society of Anesthesiologists) class I 
(normal, healthy patient).  
 
Determination of baseline values in the standing ponies 
In the first phase of the experiment, values for HR, arterial blood pressure and     were 
determined in the standing, unsedated ponies. A 14 gauge catheter (Vasocan
®
 Braunüle Luer 
Lock, B. Braun Melsungen AG, Melsungen, Germany) was placed in the right jugular vein 
and blood was withdrawn for measurement of plasma sodium level (AVL 9180 Electrolyte 
Analyzer
®
, AVL scientific corporation, Roswell, Georgia, USA 30076) and packed cell 
volume (PCV) (Haemofuge
®
, Heraeus Instruments, Osterode, Germany). A 20 gauge catheter 
(Vasocan
®
 Braunüle Luer Lock) was placed in the left carotid artery and connected to a 
pressure transducer (ST-33
®
, PVB Critical Care GmbH, Kirchseeon, Germany), zeroed at the 
level of the right atrium. A haemodynamic monitor (CMS Patientenmonitor HP M1165A
®
, 
model 56S, Hewlett-Packard GmbH, Böblingen, Germany) was used to record the 
electrocardiogram (ECG, base-apex lead) and systolic, diastolic and mean arterial pressures 
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(SAP, DAP and MAP respectively). The pressure monitoring system was calibrated against a 
mercury manometer before the experiment. Cardiac output measurements were performed 
with the lithium dilution technique (LiDCO-plus Haemodynamic Monitor
®
, LiDCO Ltd., 
London, UK): a 1.5 mmol bolus of lithium chloride was injected through the jugular catheter, 
while arterial blood for detection of lithium chloride by the LiDCO sensor (CM10 LiDCO 
sensor
®
, LiDCO Ltd.) was withdrawn from the carotid artery by the LiDCO Flow Regulator 
(4.5 mL/min). Haemoglobin (Hb) concentration, required by the LiDCO-plus
®
 monitor, was 
calculated from PCV (Hb (g/dL) = 34 * PCV (L/L) (Linton et al. 2000)). 
   The ponies were placed in a stock in a quiet environment. After 30 minutes of 
accommodation, values for HR, SAP, DAP, MAP and     were recorded twice with an 
interval of 10 minutes. Arterial blood samples were withdrawn anaerobically and analyzed 
immediately for oxygen and carbon dioxide partial pressures (PaO2 and PaCO2 respectively) 
and pH (ABL5
®
, Radiometer, Copenhagen, Denmark). Corrections for body temperature and 
inspiratory O2 fraction (FIO2) were performed. Haemoglobin saturation (SO2), bicarbonate, 
standard bicarbonate (SBC), total carbon dioxide (tCO2) and actual and standard base excess 
(ABE and SBE respectively) were calculated automatically by the ABL5
®
 Radiometer. PCV 
was obtained by centrifugation. 
 
General anaesthesia 
At least one week later, the second part of the study was performed in the anaesthetized 
ponies. Each pony was anaesthetized four times to receive one of four treatments 90 minutes 
after induction. The same anaesthetic protocol was used on all occasions. Food, but not water, 
was withheld during 12 hours before anaesthesia. Blood was withdrawn from the right 
jugular vein for measurement of plasma sodium level. Subsequently, the ponies were sedated 
with 80 µg/kg romifidine IV (Sedivet
®
, Boehringer Ingelheim, Brussels, Belgium) and a 12 
gauge catheter (Intraflon 2
®
, Vygon, Ecouen, France) was placed in the right jugular vein. 
Fifteen minutes after sedation, anaesthesia was induced with 0.06 mg/kg
 
midazolam IV 
(Dormicum
®
, Roche, Brussels, Belgium) and 2.2 mg/kg ketamine IV (Anesketin
®
, Eurovet, 
Heusden-Zolder, Belgium). An orotracheal tube (24-26 mm OD, Soft rubber tracheal tube, 
Rüsch AG, Kernen, Germany) was placed and the pony was positioned in right lateral 
recumbency, on a surgery table, with the legs upwards at an angle of 40° to the horizontal. 
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   General anaesthesia was maintained with isoflurane (Isoflo
®
, Abbott Laboratories Ltd., 
Queenborough, Kent, United Kingdom) in oxygen, using a large animal anaesthetic unit 
(Matrx medical inc., Orchard Park, New York, USA + Sulla 909V
®
, Dräger, Lübeck, 
Germany) with an out-of-circuit vaporizer (Drägerwerk AG, Lübeck, Germany) and a large 
animal ventilator (Smith respirator LA 2100
®
, model 2002, Veterinary Technics/BDO-
Medipass, Hoogezand, the Netherlands). The oxygen flow was started at 6 L/min and 
decreased to 10 mL/kg/min after 10 minutes. Respiration mode was assisted-controlled, with 
a tidal volume of 10 mL/kg. Respiratory frequency was set at 10 breaths/min, peak 
inspiratory pressure at 1.96 kPa (20 cm H2O) and inspiration time at 2 seconds. When 
necessary, these settings were adapted to maintain PaCO2 between 4.66 and 6.00 kPa (35-45 
mm Hg). Lactated Ringer‟s solution (Haemofiltration Formula E2, Clear-Flex®, Bieffe 
Medital, Grosotto, Italy) was infused throughout anaesthesia at a rate of 3 mL/kg/h. Air 
conditioning in the operating theatre maintained room temperature at 21 °C. 
   The skin over the left jugular vein and transposed carotid artery was surgically prepared. A 
20 gauge catheter (Vasocan
®
 Braunüle Luer Lock) was placed in the left carotid artery and 
connected to a pressure transducer, placed at the level of the right atrium. Using the Seldinger 
technique, a 7 French thermodilution catheter (3-lumen, Abbott Laboratories, North Chicago, 
IL60064, USA) was placed in the left jugular vein, with the distal port of the catheter in the 
right atrium to measure right atrial pressure (RAP). Correct positioning of the catheter was 
guided by the characteristic waveforms. The pressure monitoring system was zeroed at the 
level of the right atrium and calibrated against a mercury manometer before each experiment.  
   Inspiratory and expiratory CO2, O2 and isoflurane concentrations were monitored with a 
calibrated, methane-insensitive, multi-gas analyzer (HP M1025B
®
, Hewlett Packard 
Company, Houston, USA). The CMS-Patientenmonitor (HP M1165A
®
, model 56S, Hewlett-
Packard GmbH) was used to record the electrocardiogram (ECG) (base-apex lead), to 
monitor SAP, DAP, MAP and RAP and to measure body temperature. Cardiac output was 
measured with the lithium dilution technique (LiDCO-plus Haemodynamic Monitor
®
), using 
a 1.5 mmol bolus of lithium chloride, injected through the proximal port of the 
thermodilution catheter. As in the standing ponies, Hb concentration was estimated from the 
PCV, which was measured before each LiDCO determination. Plasma sodium level 
(determined before each anaesthetic episode) was entered into the LiDCO-plus
® 
monitor. 
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   The first 60 minutes of anaesthesia served as an instrumentation and stabilisation period to 
achieve an end-tidal isoflurane concentration of 1.7 % and a PaCO2 between 4.66 and 6.00 
kPa (ABL5
®
 Radiometer). After this period, three baseline values were recorded for 
inspiratory and expiratory isoflurane, CO2 and O2, HR, SAP, DAP, MAP, RAP, body 
temperature and    . Arterial (a) and central venous (v) blood samples were collected 
anaerobically from the carotid artery and the right atrium respectively, over a period of three 
breaths (both samples simultaneously), for determination of pH, PCO2, PO2, haemoglobin 
saturation with oxygen (SaO2), bicarbonate, SBC, tCO2, ABE, SBE and PCV (ABL5
®
, 
Radiometer). Time between baseline measurements was 10 minutes. Baseline values were 
calculated as the mean of these 3 recordings for each variable.    
   Ninety minutes after induction, one of four treatments was administered. Treatment S 
consisted of an IV bolus of 0.1 mL/kg saline (S). During treatments E, ED and EC, 0.5 mg/kg 
enoximone 0.5% (Perfan
®
, Myogen GmbH, Bonn, Germany) was administered at a rate of 20 
mL/min using an infusion pump (Ohmeda 9000 Syringe Pump
®
, Ohmeda, West Yorkshire, 
England), followed by either no additional drugs (treatment E), a constant rate infusion (CRI) 
of 0.5 µg/kg/min dobutamine (Dobutamine Mayne
®
, Mayne Pharma, Brussels, Belgium) 
during 120 minutes (treatment ED) or an infusion of calcium chloride at 0.5 mg/kg/min 
(Calcii chloridum 10%, Federa, Brussels, Belgium) from T5 to T15 (treatment EC). For 
treatment ED, dobutamine was dissolved in saline to obtain a concentration of 0.5 mg/mL 
and was administered through the cathether in the right jugular vein using a standard infusion 
pump (Ohmeda 9000 Syringe Pump
®
). T0 was defined as the end of the injection of saline or 
enoximone. After T0, data were recorded during 120 minutes. Each pony received all 
treatments in a randomized crossover trial, with a wash-out period of at least 2 weeks 
between treatments. 
   Values for inspiratory and expiratory CO2 and O2, HR, SAP, DAP, MAP, RAP and body 
temperature were recorded at T5, T10, T15, T20, T25, T30, T40, T50, T60, T70, T80, T90, 
T100, T110 and T120 (time expressed in minutes),     at T5, T10, T20, T40, T60, T80, T100 
and T120. In the EC group, LiDCO measurements were not performed at T5. Simultaneous 
arterial and central venous blood samples were collected at T10, T20, T40, T60, T80, T100 
and T120 and analyzed immediately (ABL5
®
, Radiometer).  
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   The ponies recovered in a padded recovery box. The endotracheal tube was removed once 
the ponies were able to swallow. A recovery score was given (Table 1) and the times to 
regain sternal recumbency and to standing were recorded.  
Table 1: Scoring system used to grade recovery 
Score Description 
1 1 attempt to stand, no ataxia 
2 1 - 2 attempts to stand, some ataxia 
3 >2 attempts to stand, but quiet recovery 
4 >2 attempts to stand, excitation 
5 severe excitation/pony wounded 
 
 
Calculations 
   Stroke volume (SV) was calculated as: 
              
                 
              
 
   Cardiac index and stroke index were expressed in mL/kg/min and mL/kg respectively. 
   Systemic vascular resistance (SVR) was calculated using the formula:  
          
   
   
  
                           
           
 
   Alveolar oxygen partial pressure (PAO2), blood oxygen content (CzO2), DO2, oxygen 
consumption (  O2) and degree of venous admixture (       ) were calculated as follows 
(Lumb 2005): 
               
     
   
 
 Where 0.8 = respiratory quotient and PIO2 is partial pressure of inspired oxygen. 
 
                                                                 
     Where z = a, v or ć for arterial (CaO2), central venous (CvO2) and end-capillary pulmonary oxygen 
content (CćO2) respectively. PćO2 is taken as PAO2. Arterial haemoglobin concentration was 
used to calculate CaO2 and CćO2, while venous haemoglobin concentration was used to 
calculate CvO2. 
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   The alveolar dead space-to-tidal volume ratio (VD/VT) was calculated as: 
       
             
     
 
where PE´CO2 = end tidal carbon dioxide tension. 
 
Statistical analysis 
The standing values for HR, SAP, DAP, MAP,     and SV were compared to the overall mean 
during the 120 min period following treatments S and E by a mixed model with treatment as 
fixed categorical effect and pony as random effect, using a 5 % significance level. 
   The effects of enoximone and saline were compared using a mixed model with treatment, 
time and their interaction as fixed categorical effects and pony as random effect, comparing 
the treatments S and E both globally (at α = 0.05) and at 8 timepoints: T0 (= mean of the 3 
baseline measurements), T10, T20, T40, T60, T80, T100 and T120 (at Bonferroni-adjusted α 
= 0.00625).   
 
Results 
Cardiovascular system 
Standing values for    , HR and SV were 27.7 ± 7.4 L/min, 38 ± 2 beats/min and 731 ± 162 
mL respectively. Standing values for SAP, DAP and MAP are presented in Table 2. All of 
these parameters significantly decreased during inhalation anaesthesia, but were not 
significantly different between groups at T0 (baseline values during anaesthesia). 
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   Compared to saline treatment, administration of enoximone resulted in significant increases 
in     (Fig. 1), HR (Fig. 2), SV (Fig. 3), SAP, DAP and MAP (Table 2). For     and SV, this 
difference was significant up to T100 (except SV at T80). Heart rate was significantly 
increased for 40 minutes after enoximone administration. As     and HR decreased slowly but 
significantly over time in the saline group, the interaction between treatment and time was 
significant for both parameters.  
   In both groups, DAP, MAP and SVR gradually increased over time. RAP was more or less 
stable throughout the anaesthesia after treatment S. After treatment E however, an initial 
decrease in RAP (E 10 ± 2 vs. S 15 ± 2 mm Hg at T10) was followed by a gradual increase, 
although RAP remained significantly lower than in the S group throughout the anaesthesia 
(120 minutes). The different evolution over time in the two groups resulted in a significant 
interaction effect between treatment and time for RAP.  
 Fig. 1: Cardiac Output (   ) in 6 anaesthetized ponies receiving a bolus of enoximone or saline.  
Values are displayed as mean ± SD. Statistical analysis was performed at T10, T20, T40, 
T60, T80, T100 and T120.  
* indicates a significant difference between the 2 treatments (P<0.00625) 
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 Fig. 2: Heart Rate (HR) in 6 anaesthetized ponies after a bolus of enoximone or saline.  
Values are displayed as mean ± SD. Statistical analysis was performed at T10, T20, T40, T60, 
T80, T100 and T120.  
* indicates a significant difference between treatments (P<0.00625) 
 
 
 
 Fig. 3: Stroke Volume (SV) in 6 anaesthetized ponies after a bolus of enoximone or saline.  
Values are displayed as mean ± SD. Statistical analysis was performed at T10, T20, T40, 
T60, T80, T100 and T120.   
* indicates a significant difference between treatments (P<0.00625) 
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Table 2: Systolic (SAP), diastolic (DAP), mean arterial (MAP) and right atrial (RAP) pressures and systemic vascular resistance (SVR) in 6 anaesthetized ponies 
receiving a bolus of enoximone (E) or saline (S). 
 
 
 
Values at individual timepoints are represented as mean  ±  SD (SD calculated for each treatment group separately).  
Overall values are represented as mean ± SE (SE calculated assuming homogeneity of variances). 
* significant difference between E and S for the overall comparison (P<0.05)  
§ significant difference between E and S at individual timepoints (P<0.00625) 
  
Variable Unit Standing Trt Time after treatment (min)   
  Values  T0 T10 T20 T40 T60 T80 T100 T120 Overall 
SAP mm Hg 143 ± 16 E 83 ± 7 86 ± 14 84 ± 12 84 ± 11 88 ± 11 89 ± 10 87 ± 10 85 ± 10 86 ± 5 
   S 79 ± 8 78 ± 7 81 ± 9 85 ± 10 84 ± 13 82 ± 12 82 ± 11 83 ± 6 82 ± 5 
DAP mm Hg 90 ± 11 E 51 ± 6 54 ± 14 54 ± 14 56 ± 15 60 ± 14 62 ± 12 61 ± 9 60 ± 10 57 ± 4 
   S 49 ± 5 49 ± 3 53 ± 4 57 ± 7 57 ± 8 57 ± 7 57 ± 6 57 ± 3 55 ± 4 
MAP mm Hg 114 ± 11 E 63 ± 6 65 ± 14 65 ± 14 67 ± 14 72 ± 13 73 ± 11 71 ± 9 69 ± 9 68 ± 4 
   S 60 ± 6 60 ± 4 63 ± 7 68 ± 9 67 ± 11 66 ± 10 65 ± 12 67 ± 4 65 ± 4 
RAP mm Hg  E 15 ± 2 10 ± 2 10 ± 2 11 ± 3 11 ± 2 12 ± 3 13 ± 3 13 ± 3 11 ± 1 
   S 15 ± 2 15 ± 2 § 15 ± 2 § 15 ± 2 § 15 ± 2 § 15 ± 2 § 15 ± 2 § 15 ± 2 § 15 ± 1 * 
SVR dyne.sec/cm
5
  E 261 ± 63 232 ± 66 257 ± 85 282 ± 77 352 ± 90 394 ± 114 400 ± 143 395 ± 143 318 ± 33 
   S 275 ± 49 307 ± 77 344 ± 83 406 ± 133 429 ± 111 444 ± 97 436 ± 99 440 ± 126 386 ± 33 
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Blood gas analysis, packed cell volume and body temperature 
Baseline values during anaesthesia were not significantly different between groups for any of 
the parameters. After enoximone treatment, no significant differences were found for tCO2, 
ABE and SBE. SvO2, CvO2 and body temperature significantly decreased over time (Tables 3 
& 4). Administration of enoximone induced no significant differences in overall blood gas 
results, PCV or body temperature compared to saline treatment. A significant interaction 
between treatment and time was detected for SaO2: in the S group, SaO2 decreased over time, 
while in the E group, SaO2 was initially lower, but increased over time and became slightly 
higher than in the S group from T60 onwards. The differences in SaO2 were however not 
statistically significant between the 2 groups (data not shown).  
   Analysis of the individual differences at selected timepoints (T10, T20, T40, T60, T80, 
T100 and T120) revealed that after enoximone administration venous PCV was significantly 
higher at T40, CvO2 at T40 and T60, SvO2 at T80 and T120.  
 
  
Fig. 4: Oxygen delivery (DO2) in 6 anaesthetized ponies after a bolus of enoximone or saline.  
Values are displayed as mean ± SD. Statistical analysis was performed at T10, T20, T40, 
T60, T80, T100 and T120.  
* indicates a significant difference between the 2 treatments (P<0.00625) 
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Venous Admixture, Oxygen Consumption and Oxygen Delivery 
No significant differences in baseline values were detected between groups for any of these 
parameters (Table 4). Oxygen delivery (Fig. 4) significantly decreased over time during the  
course of the anaesthesia after treatment S, but increased significantly after administration of 
enoximone, despite significant increases in         (overall and at T10 and T40). The increase 
in DO2 remained significant until T100.  
   For   O2, the difference between treatments was small (0.01 ± 0.15 L/min) and not 
statistically significant. 
Recovery  
Recovery scores were comparable in both groups (Table 5). Time for complete recovery 
(standing up) was 24 ± 7 minutes in the enoximone group, compared to 26 ± 9 minutes in the 
saline group. 
 
 
Table 5: Recovery scores of 6 ponies, receiving either a bolus of enoximone or saline during 
anaesthesia.  
 
Pony Enoximone Saline 
1 2 3 
2 4 2 
3 2 4 
4 2 3 
5 4 1 
6 2 2 
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Table 3: Blood gas results, packed cell volume (PCV) and body temperature in 6 anaesthetized ponies receiving a bolus of enoximone (E) or saline (S).  
 
Values at individual timepoints are represented as mean  ±  SD (SD calculated for each treatment group separately).  
Overall values are represented as mean ± SE (SE calculated assuming homogeneity of variances). 
No significant differences were found between E and S for the overall comparison (P<0.05)  
§ significant difference between E and S at individual timepoints (P<0.00625) 
Variable Unit Standing Trt Time after treatment (minutes)   
   Values  T0 T10 T20 T40 T60 T80 T100 T120 Overall 
Body temperature °C   E 36.3 ± 0.3 35.8 ± 0.6 35.7 ± 0.6 35.5 ± 0.7 35.3 ± 0.8 35.1 ± 0.8 35.0 ± 0.9 34.9 ± 0.9 35.4 ± 0.2 
    S 36.1 ± 0.3 35.9 ± 0.3 35.8 ± 0.4 35.5 ± 0.4 35.4 ± 0.4 35.2 ± 0.4 35.2 ± 0.3 35.1 ± 0.3 35.5 ± 0.2 
Central venous blood             
 pH  7.40 ± 0.02 E 7.41 ± 0.05 7.42 ± 0.05 7.43 ± 0.05 7.44 ± 0.05 7.44 ± 0.04 7.43 ± 0.05 7.43 ± 0.05 7.43 ± 0.06 7.43 ± 0.01 
    S 7.41 ± 0.03 7.43 ± 0.03 7.43 ± 0.04 7.43 ± 0.03 7.43 ± 0.03 7.43 ± 0.03 7.41 ± 0.03 7.41 ± 0.04 7.42 ± 0.01 
 pCO2 kPa 6.15 ± 0.21 E 6.85 ± 0.89 6.51 ± 0.93 6.35 ± 0.97 6.29 ± 0.89 6.47 ± 0.52 6.58 ± 0.77 6.53 ± 0.73 6.60 ± 0.80 6.50 ± 0.19 
    S 6.82 ± 0.53 6.53 ± 0.15 6.49 ± 0.34 6.47 ± 0.37 6.60 ± 0.50 6.64 ± 0.36 7.00 ± 0.47 7.00 ± 0.52 6.70 ± 0.19 
 pO2  kPa 4.69 ± 0.55 E 4.86 ± 0.72 6.69 ± 5.13 4.78 ± 0.80 4.42 ± 0.76 4.20 ± 0.65 3.93 ± 0.54 3.73 ± 0.70 4.91 ± 2.62 4.70 ± 0.43 
    S 4.46 ± 0.66 4.27 ± 0.90 6.15 ± 5.89 3.71 ± 0.75 3.22 ± 0.73 3.18 ± 0.75 3.13 ± 0.59 3.18 ± 0.47 3.80 ± 0.43 
 SBC mmol/L 26.5 ± 1.8 E 29 ± 3 29 ± 2 29 ± 2 30 ± 2 30 ± 2 30 ± 2 30 ± 2 30 ± 2 30 ± 1 
    S 29 ± 2 30 ± 3 30 ± 3 29 ± 2 29 ± 2 29 ± 2 29 ± 1 29 ± 2 29 ± 1 
 PCV L/L 31.0 ± 2.4 E 0.27 ± 0.04 0.26 ± 0.05 0.26 ± 0.04 0.28 ± 0.05 0.26 ± 0.03 0.24 ± 0.02 0.24 ± 0.04 0.24 ± 0.02 0.25 ± 0.01 
    S 0.25 ± 0.02 0.25 ± 0.02 0.25 ± 0.03 0.24 ± 0.04§ 0.25 ± 0.03 0.24 ± 0.04 0.24 ± 0.04 0.24 ± 0.04 0.24 ± 0.01 
Arterial blood             
 pH  7.42 ± 0.03 E 7.45 ± 0.05 7.46 ± 0.06 7.47 ± 0.05 7.48 ± 0.05 7.47 ± 0.04 7.47 ± 0.04 7.48 ± 0.05 7.47 ± 0.05 7.47 ± 0.01 
    S 7.45 ± 0.03 7.49 ± 0.04 7.48 ± 0.05 7.50 ± 0.04 7.49 ± 0.05 7.49 ± 0.05 7.48 ± 0.04 7.47 ± 0.05 7.49 ± 0.01 
 pCO2 kPa 5.47 ± 0.74 E 5.93 ± 0.68 5.87 ± 0.73 5.71 ± 0.69 5.53 ± 0.72 5.80 ± 0.52 5.71 ± 0.44 5.64 ± 0.49 5.69 ± 0.54 5.70 ± 0.34 
    S 6.01 ± 0.51 5.49 ± 0.52 5.47 ± 0.29 5.22 ± 0.58 5.33 ± 0.61 5.42 ± 0.60 5.71 ± 0.44 5.87 ± 0.70 5.50 ± 0.34 
 pO2 kPa 12.62 ± 1.21 E 25.51 ± 13.85 18.62 ± 14.54 24.00 ± 19.74 24.62 ± 18.21 26.71 ± 17.66 25.69 ± 14.67 20.64 ± 7.49 20.80 ± 12.10 23.00 ± 4.98 
    S 31.86 ± 21.29 30.04 ± 19.66 33.44 ± 15.58 32.13 ± 13.53 29.49 ± 18.85 28.09 ± 18.69 24.53 ± 15.76 23.60 ± 17.33 28.80 ± 4.98 
 SBC mmol/L 26.0 ± 3.5 E 30 ± 2 30 ± 3 30 ± 3 30 ± 2 31 ± 2 30 ± 2 31 ± 2 31 ± 2 30 ± 1 
    S 30 ± 3 31 ± 3 31 ± 3 30 ± 2 31 ± 1 31 ± 2 31 ± 2 31 ± 1 31 ± 1 
 PCV L/L 0.312 ± 0.019 E 0.27 ± 0.03 0.25 ± 0.05 0.26 ± 0.04 0.26 ± 0.03 0.24 ± 0.03 0.27 ± 0.04 0.25 ± 0.03 0.24 ± 0.02 0.25 ± 0.01 
    S 0.25 ± 0.02 0.25 ± 0.03 0.25 ± 0.04 0.24 ± 0.03 0.25 ± 0.03 0.25 ± 0.03 0.23 ± 0.04 0.24 ± 0.04 0.24 ± 0.01 
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Table 4: Arterial (CaO2), central venous (CvO2) and end-capillary pulmonary oxygen content (CćO2), venous admixture, oxygen delivery (DO2) and oxygen 
consumption (  O2) in 6 anaesthetized ponies receiving a bolus of enoximone (E) or saline (S). 
 
Values at individual timepoints are represented as mean  ±  SD (SD calculated for each treatment group separately).  
Overall values are represented as mean ± SE (SE calculated assuming homogeneity of variances). 
* significant difference between E and S for the overall comparison (P<0.05)  
§ significant difference between E and S at individual timepoints (P<0.00625) 
Variable Unit Standing Trt Time after treatment (min)   
  values  T0 T10 T20 T40 T60 T80 T100 T120 Overall 
CaO2 mL/ L 145.3 ± 8.7 E 128 ± 7 118 ± 12 122 ± 10 122 ± 9 118 ± 9 129 ± 19 121 ± 13 116 ± 5 121 ± 4 
   S 124 ± 12 122 ± 14 123 ± 18 120 ± 14 118 ± 8 119 ± 16 111 ± 10 113 ± 9 118 ± 4 
CvO2 mL/ L  E 90 ± 11 90 ± 18 90 ± 10 93 ± 13 82 ± 6 72.1 ± 11 70 ± 16 76 ± 12 82 ± 5 
   S 81 ± 13 78 ± 14 79 ± 24 66 ± 19§ 59 ± 18§ 55.9 ± 18 54 ± 14 55 ± 9 64 ± 5 
CćO2 mL/L  E 145 ± 8 136 ± 14 140 ± 11 139 ± 10 134 ± 11 146 ± 20 139 ± 13 134 ± 5 138 ± 4 
   S 140 ± 10 138 ± 14 138 ± 18 136 ± 15 134 ± 8 135 ± 15 129 ± 12 131 ± 11 134 ± 4 
Venous admixture %  E 32 ± 7 47 ± 24 35 ± 8 43 ± 19 32 ± 5 24 ± 7 28 ± 8 35 ± 16 35 ± 2 
   S 26 ± 7 28 ± 6§ 33 ± 20 23 ± 4§ 23 ± 6 22 ± 7 23 ± 3 23 ± 3 25 ± 2* 
DO2  L/min 4.13 ± 1.27 E 1.93 ± 0.33 2.25 ± 0.31 2.16 ± 0.44 1.96 ± 0.26 1.66 ± 0.31 1.66 ± 0.41 1.53 ± 0.45 1.41 ± 0.33 1.80 ± 0.31 
   S 1.62 ± 0.25 1.46 ± 0.28§ 1.40 ± 0.30§ 1.35 ± 0.44§ 1.21 ± 0.38§ 1.14 ± 0.33§ 1.04 ± 0.30§ 1.12 ± 0.27 1.20 ± 0.31* 
  O2 L/min 1.31 ± 0.50 E 0.57 ± 0.23 0.51 ± 0.30 0.57 ± 0.18 0.46 ± 0.26 0.51 ± 0.19 0.73 ± 0.31 0.61 ± 0.22 0.51 ± 0.25 0.56 ± 0.13 
   S 0.57 ± 0.12 0.52 ± 0.17 0.48 ± 0.27 0.60 ± 0.21 0.58 ± 0.19 0.58 ± 0.12 0.51 ± 0.08 0.57 ± 0.13 0.55 ± 0.13 
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Discussion 
Inhalation anaesthesia produces a dose-related cardiovascular depression in horses (Steffey & 
Howland 1980). In the present study, comparison of the values in the standing, unsedated 
ponies with the baseline values during inhalation anaesthesia, revealed clear and significant 
decreases in SAP, DAP, MAP,     and SV. During the further course of the anaesthesia in the 
saline group, DAP, MAP and SVR increased slowly, while HR,    , SV and DO2 gradually 
decreased. The cellular mechanisms responsible for the negative effects of volatile 
anaesthetics on cardiac contractility are generally attributed to alterations in intracellular 
calcium homeostasis in the myocardium (Pagel et al. 1993). These alterations include 
reductions in the influx of calcium through slow channels (Komai & Rusy 1987, Rusy & 
Komai 1987), impaired calcium uptake and release by the sarcoplasmic reticulum (Casella et 
al. 1987, Housmans & Murat 1988) and decreased calcium sensitivity of the myofilaments 
(Rusy & Komai 1987, Housmans & Murat 1988).  
   The drugs most commonly used for inotropic support in horses are the β-adrenergic 
sympathomimetic agents (e.g. dobutamine). When these agents bind to the ß1 receptor, the G-
protein coupled to this receptor splits and stimulates adenylylcyclase, the enzyme responsible 
for the synthesis of cAMP. An increase in cAMP concentration in the cardiac muscle 
activates a cAMP-dependent protein kinase, which phosphorylates the L-type calcium 
channels, leading to an increase in the mean open probability of individual channels (Hove-
Madsen et al. 1996). The subsequent increase in intracellular calcium levels in turn causes 
calcium-induced calcium release from the sarcoplasmic reticulum (Fabiato 1983), which 
leads to an increase in the contractile forces (Vernon et al. 1991). Furthermore, cAMP 
augments calcium-ATPase activity in the sarcoplasmic reticulum, promoting increased 
calcium storage during diastole (Muir 1995) and facilitating relaxation of the heart (Vernon et 
al. 1991). 
   Another class of drugs, the PDE inhibitors, increase the intracellular levels of cAMP and/or 
cGMP in different tissues through inhibition of their breakdown by phosphodiesterase 
enzymes (Hall 1993). At least five different phosphodiesterase isoenzymes have been 
described, with each family containing at least 2 subfamilies. Selective inhibition of these 
isoenzymes produces partially tissue specific effects. This leads to different clinical 
applications for different isoenzyme selective PDE inhibitors, including stimulation of 
Chapter 4.1: Discussion 
 
 129 
myocardial contractility, vasodilation, inhibition of platelet aggregation, bronchodilation and 
the use as anti-inflammatory drugs or antidepressants (Hall 1993).  
   Enoximone is a selective inhibitor of the type III PDE isoenzyme (Vernon et al. 1991), 
which is principally present in the myocardium, smooth muscles and platelets and breaks 
down both cAMP and cGMP (Calvey & Williams 2001, Hall 1993). In the myocardium 
enoximone induces inotropic and lusitropic effects, with a significantly lower myocardial 
oxygen consumption than after dobutamine therapy in man (Lançon et al. 1990). In vascular 
smooth muscle, cAMP phosphorylates protein kinase and myosin-light-chain kinase and 
alters ion fluxes, resulting in vasodilation (Evans 1989, Calvey & Williams 2001). Because of 
an increase in platelet cAMP, platelet aggregation is diminished (Calvey & Williams 2001). 
Possible side-effects of enoximone are usually only seen after long term oral treatment in 
men and include tachyarrhythmias, hypotension, thrombocytopenia, nausea, dyspepsia, 
diarrhoea, vomiting, fever, oliguria and limb pain (Vernon et al. 1991, Calvey & Williams 
2001). Side effects using a bolus or constant rate infusion during anaesthesia are rare and 
were not observed in the ponies of the present study. Although adverse effects during 
recovery have been reported with some sympathomimetics, such as dopexamine in horses 
(Young et al. 1997, Lee et al. 1998), the recovery scores were comparable in the two 
treatment groups.   
   Enoximone‟s principal effects are positive inotropism and vasodilation (Dage and 
Okerholm 1990, Vernon et al. 1991, Hall 1993). In the present study, a bolus of 0.5 mg/kg 
enoximone significantly augmented     for a period of 100 minutes in healthy ponies during 
isoflurane anaesthesia. This increase in     is in agreement with the reported effects of 
enoximone in dogs (Dage et al. 1982) and milrinone in halothane anaesthetized horses (Muir 
1995). Cardiac output is determined by HR and SV, which both increased after the 
administration of enoximone (HR until T40, SV until T100).  
   Mild and transient chronotropic effects have also been reported in dogs (Dage et al. 1982) 
and humans (Amin et al. 1985, Installe et al. 1987) after enoximone administration and can 
be explained by the consistent electrophysiological changes with this drug. Indeed, this PDE 
inhibitor shortens basic sinus cycle length, sinus node recovery time and sinoatrial 
conduction time and decreases Wenckebach cycle length and atrioventricular and atrial 
refractoriness, leading to positive chronotropic and dromotropic effects. Despite these 
changes during bolus administration, enoximone did not appear to be arrhythmogenic (Pop et 
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al. 1986). Only chronic, long-term oral administration in humans has been associated with 
tachyarrhythmias (Calvey & Williams 2001). In the present study, no arrhythmias were 
observed in our ponies and the maximal difference in mean HR between treatments occurred 
5 minutes after administration of the bolus (7 ± 1 beats per minute). Heart rate remained 
below 50 beats per minute in all ponies, except in 1 animal where HR temporarily increased 
from 45 (T0) to 59 beats per minute at T5. After T5, the difference in HR between the two 
groups gradually decreased and was no longer significant from T40 onwards.  
   In the present study, enoximone significantly increased SV for 100 minutes.  The three 
parameters which determine SV are preload, contractility and afterload, which are all 
influenced by enoximone in man (Vernon et al. 1991). Muir (1995) observed a reduction in 
mean right atrial and pulmonary artery pressures during and after milrinone infusions in 
horses. In the present study, a significant decrease in RAP during at least 120 minutes after 
administration of enoximone to our ponies was also observed, indicating a reduction in 
preload of the right heart. This finding might be explained by venous pooling, which has been 
described in man after enoximone treatment (Boldt et al. 1993, Lehtonen et al. 2004). While 
RAP reflects preload of the right heart, preload of the left heart is reflected by pulmonary 
capillary wedge pressure, which was reported to decrease after administration of enoximone 
in man (Vernon et al. 1991). This reduction in left ventricular filling pressure was larger than 
the one produced by dobutamine (Amin et al. 1985).   
   Contractility, the second factor which influences SV, was enhanced by the positive 
inotropic effects of enoximone in both dogs and humans (Installe et al. 1987, Dage & 
Okerholm 1990, Vernon et al. 1991, Boldt et al. 1992, Hall 1993, Ghio et al. 2003, Lehtonen 
et al. 2004, Calvey & Williams 2001). Ringe et al. (2003) even stated that in patients with 
severe prolonged catecholamine and volume refractory endotoxin shock, enoximone could 
restore myocardial contractility. In the present study, we observed an increase in SV without 
a decrease in SVR. Although contractility was not measured directly in the present study, it 
was most likely also enhanced. 
   The third factor, namely the afterload, was reported to be reduced by enoximone in man 
(Lehtonen et al. 2004). A frequently used clinical index of left ventricular afterload is SVR 
(Lang et al. 1986), which decreased after enoximone administration in man because of 
vasodilation (Vernon et al. 1991, Boldt et al. 1992, Calvey & Williams 2001). Similary, SVR 
decreased in response to administration of enoximone in dogs (Dage et al. 1982) and 
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milrinone in horses (Muir 1995). In the present study, the decrease in SVR after enoximone 
treatment was not significant. It might be hypothesized that sedation with romifidine 
attenuated the vasodilating properties of enoximone, since α2 agonists induce 
vasoconstriction by binding to postsynaptic α2 receptors, leading to a reduced synthesis of 
cAMP in the vascular smooth muscle cells. However, it has been reported that the increase in 
SVR in standing horses after administration of romifidine at doses of 80 and 120 µg/kg IV 
was only significant with the highest dose and no longer than 15 minutes (Freeman et al. 
2002). In the present study, a low dose of romifidine (80 µg/kg) was used and the time 
between sedation and administration of enoximone was 105 minutes. It is therefore most 
unlikely that the pre-anaesthetic use of romifidine was responsible for the lack of a significant 
effect of enoximone on SVR.  
   On the other hand, SVR reflects only peripheral vasomotor tone. A better measure of  left 
ventricular afterload is left ventricular end-systolic wall stress (σes), which combines the 
effects of peripheral loading conditions and left ventricular chamber pressure, dimension and 
wall thickness (Lang et al. 1986). When afterload is decreased and contractility increased, 
SVR actually underestimates the decrease in left ventricular σes (up to 50% when dobutamine 
is administered) (Lang et al. 1986). This phenomenon may also have occurred in the present 
study, as enoximone was reported to cause both arterial vasodilation (Boldt et al. 1993) and 
increased myocardial contractility (Installe et al. 1987, Dage and Okerholm 1990, Vernon et 
al. 1991, Boldt et al. 1992, Hall 1993, Ghio et al. 2003, Lehtonen et al. 2004, Calvey & 
Williams 2001).  
   Because of its actions as smooth muscle relaxant, enoximone was responsible for a 
decrease in blood pressure in some studies (Dage et al. 1982, Installe et al. 1987, Boldt et al. 
1993, Hall 1993, Schmidt et al. 2001, Calvey & Williams 2001). However, several other 
authors could not detect significant influences of enoximone on arterial pressure (Vernon et 
al. 1991, Paulus et al. 1994), even in patients with severe cardiogenic shock (Vincent et al. 
1988). In the present study, using normovolemic ponies, arterial pressure even tended to be 
slightly higher after the enoximone bolus; none of the observed differences in blood pressure 
were however statistically significant. Nevertheless, in cases of severe hypotension or 
endotoxaemia with major vasodilation, enoximone should be used with caution until its 
cardiovascular effects in case of hypovolemia/endotoxaemia are fully investigated. At the 
same time, more studies are necessary to determine whether horses respond in a similar way 
as ponies. 
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   In the present study,         was significantly higher after enoximone treatment (overall and 
at T10 and T40). In the study of Muir (1995), no data was given about the influence of 
milrinone infusions on arterial blood gases or the degree of        . Although Boldt et al. 
(1992) did not detect any differences in intrapulmonary shunting, increased venous admixture 
after enoximone administration in man has been reported by other authors (Vincent et al. 
1988, Paulus et al. 1994) and was probably related to an increased cardiac index and the 
inhibition of hypoxic pulmonary vasoconstriction (HPV) (Lynch et al. 1979, Paulus et al. 
1994). In the present study,     was indeed significantly higher after enoximone treatment. An 
inhibition of HPV may also have occurred and could be explained by two factors, namely the 
administration of enoximone on itself and an induced increase in mixed venous oxygen 
content (C  O2). In man, enoximone reduces pulmonary vascular resistance, indicating 
vasodilation in the pulmonary circulation, which would counteract HPV. Secondly, C  O2 is a 
partial determinant of HPV: with increasing C  O2, the stimulus for HPV decreases (Domino 
et al. 1983). However, in the present study, the increase in         after enoximone treatment 
was attributable to extreme values for PvO2 at T10 in 1 pony and for venous PCV at T40 in 2 
ponies, which explains the large standard deviations for PvO2, PCV, CvO2 and         at the 
respective timepoints in tables 3 and 4. These extreme values were the main reason why 
venous PCV and CvO2 were also significantly higher at T40. In the authors‟ opinion, these 
findings are therefore probably incidental, as in all other ponies, the values were comparable 
to saline treatment.  
    Despite the increase in         after enoximone administration in the present study, no 
significant decrease in CaO2 was observed. As CvO2 was increased,         could indeed be 
expected to have less influence on CaO2. Also, although PaO2 was somewhat lower in the E 
group, mean PaO2 always remained in the range to fully saturate haemoglobin, which is the 
main determinant of CaO2. Possibly, in cases of severe hypoxemia, where a small reduction 
in PaO2 can result in a severe decrease in SaO2, the effects of increased        , if present, 
might be more pronounced. However, it must be noted that, although they are generally 
accepted, the equations for calculation of blood oxygen content and degree of         are 
based on a few assumptions which can lead to inaccuracy. Firstly, during calculation of 
oxygen content, standard values are routinely used for the oxygen solubility coefficient and 
the oxygen-combining capacity of haemoglobin, which may not always be constant under all 
circumstances and in all subjects. Secondly, the equation for the degree of         does not 
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take Thebesian and bronchial venous blood into account (Lumb 2005). It may also be argued 
that the use of central venous blood (taken from the right atrium) instead of true mixed 
venous blood led to inaccuracy, but different authors documented that central venous blood 
collected from the right atrium can replace mixed venous blood to calculate the degree of 
pulmonary shunt (Tahvanainen et al. 1982, López Escárcega et al. 1985). Finally, while 
haemoglobin saturation is required for calculation of blood oxygen content, the ABL5 
Radiometer
®
 does not measure haemoglobin saturation but calculates it, as it is not equipped 
with a co-oximeter. For all of these reasons, and especially because there was no significant 
difference in PaO2 in the present study, the importance of the increase in         should not be 
overinterpreted until further studies are performed in hypoxaemic horses. 
   Because     was increased without changes in CaO2, a significant increase in DO2 during 
100 minutes was found, which is in agreement with several reports in man (Teboul et al. 
1992, Paulus et al. 1994, Loick et al 1997, Kern et al. 2001). Especially in equine anaesthesia, 
where hypoxaemia and cardiovacular depression are common clinical findings and can have 
detrimental effects, improved oxygen delivery is one of the most important goals of the 
anaesthetist. Furthermore, in humans, enoximone increased organ perfusion and skin 
capillary blood flow (Boldt et al. 1992), while indications for an improved nutritive 
microcirculation have been reported (Boldt et al. 1993). During an early stage of sepsis in 
anaesthetized rats, enoximone prevented mucosal hypoperfusion of the ileum (Schmidt et al. 
2001). In fluid-optimized septic shock in man, enoximone also improved hepatosplanchnic 
function and helped to attenuate the inflammatory response (Kern et al. 2001). This PDE 
inhibitor additionally seemed to have a beneficial effect on tissue damage and barrier 
function of the gut, since it diminished the increase in endotoxin concentrations in liver 
venous blood following cardiopulmonary bypass (Loick et al. 1997). Limb blood flow was 
also increased in response to a single oral dose of enoximone in man (Vernon et al. 1991). 
However, before assumptions are made in ponies or horses, the effects of enoximone on 
peripheral perfusion should be studied in depth in these species. 
   In conclusion, a single bolus of enoximone in isoflurane anaesthetized ponies induced 
increases in HR,     and SV without obvious effects on arterial pressure or SVR. Right atrial 
pressure, a reflection of right heart preload, was significantly reduced. Despite significant 
increases in        , oxygen delivery to the tissues was higher. Further studies are needed to 
determine whether the effects of enoximone are similar in horses as in ponies, to detect 
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possible interactions with other drugs and to investigate the effects of enoximone in horses 
with hypoxaemia, when increased         may have more importance and in horses with 
hypovolemia and/or hypotension, when vasodilation might have more pronounced effects on 
blood pressure.    
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SUMMARY 
The cardiovascular and respiratory effects of dobutamine after a bolus of enoximone 
were examined in 6 healthy, isoflurane anaesthetized ponies, weighing 286 ± 52 kg and 
aged 5.0 ± 1.6 years. After sedation with romifidine [80 µg/kg intravenously (IV)], 
anaesthesia was induced with midazolam (0.06 mg/kg IV) and ketamine (2.2 mg/kg IV) 
and maintained with isoflurane in oxygen. The ponies were ventilated to maintain 
normocapnia. After 90 minutes (= T0), enoximone alone (0.5 mg/kg IV) (E) or 
enoximone followed by a constant rate infusion of dobutamine (0.5 g/kg/min) (ED) for 
120 minutes were administered. Each pony received both treatments in a crossover 
trial, with at least 2 weeks between treatments. Heart rate (HR), cardiac output (   ), 
stroke volume (SV), right atrial (RAP), systolic (SAP), diastolic (DAP) and mean 
arterial pressure (MAP), blood gases, systemic vascular resistance (SVR), oxygen 
delivery (DO2) and several respiratory gas exchange variables were obtained before 
treatment and until T120.  
   Compared to enoximone alone, ED treatment induced overall increases in HR,    , SV, 
RAP, SAP, DAP, MAP, packed cell volume (PCV) and DO2. The difference was 
significant from T60 to T120 (except at T80) for HR, throughout the observational 
period for    , SAP, MAP, PCV and DO2, from T40 to T120 for DAP, at T10, T60, T80 
and T120 for SV and at T10 and T20 for RAP. Overall values for SVR and dead space 
ventilation (VD/VT) were lower after treatment ED compared to treatment E. VD/VT was 
lower at T20 and from T80 to T120. Venous oxygen saturation was higher after 
treatment ED than after treatment E from T60 onwards. These results suggest that 
enoximone and dobutamine have additive cardiovascular effects and reduce VD/VT in 
isoflurane anaesthetized ponies. 
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Introduction 
To maintain oxygen delivery (DO2) to the tissues during equine anaesthesia, inotropic drugs 
are often needed. For this purpose ß-adrenergic sympathomimetics are used most frequently 
in horses. These agents increase the intracellular level of cyclic adenosine monophosphate 
(cAMP) through stimulation of adenylyl cyclase. As a result, myocardial contractility is 
enhanced. However, the administration of these drugs increases cardiac work and myocardial 
oxygen demand (Notterman 1991) and can be accompanied by several side-effects (Swanson 
et al. 1985, Trim et al. 1985, Gasthuys et al. 1991, Notterman 1991). The phosphodiesterase 
(PDE) III inhibitors, a second class of inotropic drugs, exert their action through inhibition of 
the enzymatic hydrolysis of cAMP (Vernon et al. 1991). In horses or ponies, only the effects 
of milrinone (Muir 1995) and enoximone (Chapter 4.1) have been described. 
   As ß-sympathomimetics and PDE III inhibitors both increase the intracellular concentration 
of cAMP through independent, additive mechanisms, their combined use has been studied in 
man. A combination of adrenaline and amrinone produced additive effects on stroke volume 
(SV) after cardiopulmonary bypass surgery (Royster et al. 1993). Also, enoximone‟s 
favourable cardiovascular effects were additive to those produced by dobutamine in patients 
with class IV heart failure. Larger increases in cardiac index (CI), left ventricular stroke work 
index and heart rate (HR) were observed, together with more pronounced decreases in right 
atrial pressure (RAP), pulmonary artery pressure, pulmonary wedge pressure, systemic 
vascular resistance (SVR) and pulmonary vascular resistance (Gilbert et al. 1995). 
   In horses, no studies have been performed on the combined use of a PDE III inhibitor with 
a ß-sympathomimetic. Therefore, the objective of the present study was to evaluate the 
effects on the cardiovascular system and on respiratory gas exchange of a constant rate 
infusion (CRI) of dobutamine after bolus administration of enoximone in isoflurane 
anaesthetized ponies.  
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Materials & Methods 
The experimental protocol has been described in chapter 4.1. For statistical analysis, 
treatments E and ED were compared using a mixed model with treatment, time and their 
interaction as fixed categorical effects and pony as random effect. This model was used to 
analyze the overall difference between the two treatments (at α = 0.05) and the difference at 8 
selected time points: Baseline, T10, T20, T40, T60, T80, T100 and T120 (at Bonferroni-
adjusted α = 0.00625).   
 
Results  
Cardiovascular system  
Compared to enoximone alone (treatment E), cardiac output (   ) (P=0.004) and SV (P=0.006) 
were higher during treatment with enoximone and dobutamine (treatment ED) (Table 1, Fig. 1 
& 2). Analysis at the selected time points revealed that the difference was significant 
throughout the observational time for     and at T10, T60, T80 and T120 for SV. Mean CI was 
54.08 ± 7.19 mL/kg/min with enoximone alone versus 82.40 ± 7.19 mL/kg/min when 
enoximone and dobutamine were combined. 
   Heart rate (Table 1) increased after administration of enoximone in both groups, but was 
higher during treatment ED (50.3 ± 3.3 beats/min) compared to treatment E (40.5 ± 3.3 
beats/min) (P=0.026). This difference was significant from T60 onwards (except at T80).    
   The addition of a CRI of dobutamine also resulted in increases in blood pressure (Table 1) 
compared to enoximone alone: overall systolic (SAP) (P=0.0015), diastolic (DAP) 
(P=0.0018) and mean (MAP) (P=0.0007) arterial pressures were higher during treatment ED. 
As this difference gradually became larger over time, a significant interaction effect between 
treatment and time was detected. On T10 and T20, RAP was also significantly larger during 
treatment ED compared to treatment E. 
   Systemic vascular resistance increased over time during both treatments (P<0.0001) (Table 
1). Analysis of the overall values revealed a lower SVR during treatment ED (ED 318 ± 65 vs 
E 274 ± 77 dynes.sec/cm
5
, P=0.0423). However, after Bonferroni correction, no significant 
differences between the two treatments could be detected at any of the selected time points.  
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Fig. 1: Cardiac index (CI) in 6 anaesthetized ponies receiving enoximone alone or enoximone 
followed by a CRI of dobutamine.  
Values are displayed as mean ± SD.  
* indicates a significant difference between the 2 treatments (P<0.00625). 
 
Fig. 2: Stroke volume index (SI) in 6 anaesthetized ponies receiving enoximone alone or 
enoximone followed by a CRI of dobutamine.  
Values are displayed as mean ± SD.  
* indicates a significant difference between the 2 treatments (P<0.00625) 
Body temperature, blood gas analysis and packed cell volume  
During the observational period, body temperature gradually decreased over time (P<0.0001) 
(Table 2). Although the overall values for body temperature were not significantly different 
between treatments, body temperature decreased more rapidly during treatment ED, leading to 
an interaction effect between the factors treatment and time (P<0.0001). 
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Table 1: Heart rate (HR), systolic (SAP), diastolic (DAP), mean arterial (MAP) and right atrial (RAP) pressures, cardiac output (   ), stroke volume 
(SV) and systemic vascular resistance (SVR) in 6 anaesthetized ponies receiving enoximone alone (E) or enoximone followed by a CRI of 
dobutamine (ED).  
 
Values at individual timepoints are represented as mean  ±  SD (SD calculated for each treatment group separately).  
Overall values are represented as mean ± SE (SE calculated assuming homogeneity of variances). 
* significant difference between E and ED for the overall comparison (P<0.05)  
§ significant difference between E and ED at individual timepoints (P<0.00625) 
 
Variable Unit Trt   Time after treatment (min)   
      Baseline T10 T20 T40 T60 T80 T100 T120 Overall 
HR beats/min E 39 ± 4 46 ± 6 44 ± 6 41 ± 5 39 ± 5 38 ± 4 37 ± 4 36 ± 3 41 ± 3 
  ED 39 ± 6 51 ± 5 49 ± 6 50 ± 9  51 ± 12 § 49 ± 14  51 ± 18 § 52 ± 19 § 50 ± 3 * 
SAP mm Hg E 83 ± 7 86 ± 14 84 ± 12 84 ± 11 88 ± 11 89 ± 10 87 ± 10 85 ± 10 86 ± 5 
  ED 80 ± 5 113 ± 8 § 112 ± 6 § 115 ± 13 § 119 ± 19 § 121 ± 22 § 121 ± 23 § 118 ± 23 § 115 ± 5 * 
DAP mm Hg E 51 ± 6 54 ± 14 54 ± 14 56 ± 15 60 ± 14 62 ± 12 61 ± 9 60 ± 10 57 ± 4 
  ED 47 ± 3 62 ± 8 63 ± 8  69 ± 9 § 77 ± 9 § 80 ± 15 § 80 ± 15 § 79 ± 15 § 71 ± 4 * 
MAP mm Hg E 63 ± 6 65 ± 14 65 ± 14 67 ± 14 72 ± 13 73 ± 11 71 ± 9 69 ± 9 68 ± 4 
  ED 59 ± 3 77 ± 7 § 79 ± 7 § 85 ± 9 § 92 ± 12 § 96 ± 17 § 97 ± 17 § 95 ± 17 § 87 ± 4 * 
RAP mm Hg E 15 ± 2 10 ± 2 10 ± 2 11 ± 3 11 ± 2 12 ± 3 13 ± 3 13 ± 3 11 ± 1 
  ED 16 ± 5 14 ± 4 § 14 ± 4 § 14 ± 5  15 ± 6  15 ± 5  15 ± 4  15 ± 5 15 ± 1 * 
     L/min E 15.01 ± 2.15 19.13 ± 1.44 17.53 ± 2.22 16.04 ± 1.26 14.05 ± 1.86 12.83 ± 2.41 12.56 ± 2.90 12.11 ± 2.54 15.45 ± 1.27 
  ED 15.39 ± 2.10 25.13 ± 4.95 § 22.89 ± 4.32 § 23.21 ± 6.09 § 21.76 ± 4.32 § 21.18 ± 4.20 § 20.30 ± 5.38 § 19.96 ± 5.34 § 22.12 ± 1.27 * 
SV mL E 378 ± 48 425 ± 51 406 ± 73 395 ± 50 363 ± 56 340 ± 63 340 ± 78 334 ± 69 379 ± 20 
  ED 396 ± 70 494 ± 50 § 466 ± 33  458 ± 46  432 ± 42 § 444 ± 63 § 407 ± 82  403 ± 100 § 445 ± 20 * 
SVR dyne.sec/cm
5
 E 261 ± 63 232 ± 66 257 ± 85 282 ± 77 352 ± 90 394 ± 114 400 ± 143 395 ± 143 318 ± 29 
    ED 225 ± 29  206 ± 37 231 ± 37 262 ± 79 296 ± 71 318 ± 98 356 ± 170 355 ± 180 274 ± 29 * 
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   No differences in arterial oxygen tension (PaO2) (Table 2) and haemoglobin saturation with 
oxygen (SaO2) could be detected between treatments, but an interaction effect between 
treatment and time was observed. During treatment E, PaO2 and SaO2 decreased at T10, 
returned to baseline values at T20 and gradually decreased again after T80. After a similar 
decrease at T10, a steady increase was observed throughout the remaining anaesthetic period 
during treatment ED. Also, venous haemoglobin oxygen saturation (SvO2) was higher during 
treatment ED (P=0.0084). This difference was significant from T60 onwards. At T80, a 
significant difference in venous oxygen tension (PvO2) was detected, most likely due to 
abnormally high values recorded in 2 ponies (15.8 and 17.7 kPa respectively). When these 
ponies were excluded from analysis, this difference was no longer significant.    
   Packed cell volume (PCV) was higher during treatment ED (P = 0.0018) with an interaction 
effect between treatment and time (P = 0.0348): PCV increased with treatment ED but 
remained constant with treatment E (Table 2). 
Respiratory system, oxygen delivery and oxygen consumption  
Overall RR was not different between treatments (E 11.3 ± 1.6 vs ED 12.5 ± 2.1 
breaths/min). While no differences in overall venous admixture (       ) were detected 
between the 2 treatments, overall alveolar dead space-to-tidal volume ratio (VD/VT) was 
lower during treatment ED (ED 35.3 ± 1.9 vs E 42.6 ± 1.9 %; P=0.0132) (Fig. 3). This 
difference was significant at T20 and from T80 onwards. For the alveolar-to-arterial oxygen 
tension difference (P(A-a)O2), an interaction effect between treatment and time was 
observed: it remained stable during treatment E, but gradually decreased over time during 
treatment ED (P=0.0067) (Fig. 4). 
   Overall and at each selected timepoint, higher values were found during treatment ED for 
the arterial oxygen content (CaO2) (P=0.0003), central venous oxygen content (CvO2) 
(P=0.0002) and end-capillary pulmonary oxygen content (CćO2) (P=0.0008) (Table 3). A 
significant interaction effect between treatment and time was also detected for all 3 variables: 
while these values remained stable throughout anaesthesia after treatment E, a gradual 
increase was observed during treatment ED. 
 
Chapter 4.2: Results 
 
 147 
Table 2: Body temperature, blood gas results and packed cell volume (PCV) in 6 anaesthetized ponies receiving enoximone alone (E) or enoximone 
followed by a CRI of dobutamine (ED). 
 
Values at individual timepoints are represented as mean  ±  SD (SD calculated for each treatment group separately).  
Overall values are represented as mean ± SE (SE calculated assuming homogeneity of variances).  
  * significant difference between E and ED for the overall comparison (P<0.05)  
  § significant difference between E and ED at individual timepoints (P<0.00625) 
Variable Unit Trt   Time after treatment (minutes)   
    Baseline T10 T20 T40 T60 T80 T100 T120 Overall 
Body temperature °C E 36.3 ± 0.3 35.8 ± 0.6 35.7 ± 0.6 35.5 ± 0.7 35.3 ± 0.8 35.1 ± 0.8 35.0 ± 0.9 34.9 ± 0.9 35.4 ± 0.3 
   ED 36.0 ± 0.4 35.7 ± 0.4 35.5 ± 0.4 35.1 ± 0.5 34.7 ± 0.7 34.5 ± 0.7 34.3 ± 0.8  34.1 ± 0.9  34.9 ± 0.3 
Central venous blood            
 pH  E 7.41 ± 0.05 7.42 ± 0.05 7.43 ± 0.05 7.44 ± 0.05 7.44 ± 0.04 7.43 ± 0.05 7.43 ± 0.05 7.43 ± 0.06 7.43 ± 0.02 
   ED 7.44 ± 0.03 7.42 ± 0.02 7.43 ± 0.03 7.44 ± 0.03 7.45 ± 0.04 7.46 ± 0.03 7.47 ± 0.05 7.47 ± 0.06 7.45 ± 0.02 
 pCO2 kPa E 6.85 ± 0.89 6.51 ± 0.93 6.35 ± 0.97 6.29 ± 0.89 6.47 ± 0.52 6.58 ± 0.77 6.53 ± 0.73 6.60 ± 0.80 6.50 ± 0.24 
   ED 6.30 ± 0.56 6.42 ± 0.32 6.40 ± 0.42 6.04 ± 0.44 6.02 ± 0.54 5.91 ± 0.53 5.84 ± 0.70 5.80 ± 0.80 6.06 ± 0.24 
 pO2  kPa E 4.86 ± 0.72 6.69 ± 5.13 4.78 ± 0.80 4.42 ± 0.76 4.20 ± 0.65 3.93 ± 0.54 3.73 ± 0.70 4.91 ± 2.62 4.70 ± 0.78 
   ED 4.70 ± 1.79 5.51 ± 1.78 5.98 ± 1.92 5.95 ± 2.30 5.95 ± 2.28 8.82 ± 6.22 § 5.95 ± 1.83 5.84 ± 2.02 6.29 ± 0.78 
 SBC mmol/L E 29 ± 3 29 ± 2 29 ± 2 30 ± 2 30 ± 2 30 ± 2 30 ± 2 30 ± 2 30 ± 1 
   ED 29 ± 1 29 ± 1 29 ± 1 29 ± 1 30 ± 1 30 ± 1 30 ± 1 30 ± 2 29 ± 1 
 PCV L/L E 0.27 ± 0.04 0.26 ± 0.05 0.26 ± 0.04 0.28 ± 0.05 0.26 ± 0.03 0.24 ± 0.02 0.24 ± 0.04 0.24 ± 0.02 0.25 ± 0.01 
   ED 0.27 ± 0.03 0.30 ± 0.04 § 0.31 ± 0.03 § 0.33 ± 0.04  0.33 ± 0.05 § 0.33 ± 0.04 § 0.33 ± 0.04 § 0.33 ± 0.04 § 0.32 ± 0.01 * 
Arterial blood            
 pH  E 7.45 ± 0.05 7.46 ± 0.06 7.47 ± 0.05 7.48 ± 0.05 7.47 ± 0.04 7.47 ± 0.04 7.48 ± 0.05 7.47 ± 0.05 7.47 ± 0.02 
   ED 7.47 ± 0.04 7.44 ± 0.03 7.45 ± 0.03 7.46 ± 0.04 7.47 ± 0.05 7.48 ± 0.04 7.50 ± 0.06 7.51 ± 0.06 7.47 ± 0.02 
 pCO2 kPa E 5.93 ± 0.68 5.87 ± 0.73 5.71 ± 0.69 5.53 ± 0.72 5.80 ± 0.52 5.71 ± 0.44 5.64 ± 0.49 5.69 ± 0.54 5.70 ± 0.20 
   ED 5.53 ± 0.50 5.98 ± 0.37 5.73 ± 0.42 5.51 ± 0.53 4.71 ± 2.12  5.40 ± 0.51 5.22 ± 0.78 5.07 ± 0.75 5.37 ± 0.20 
 pO2 kPa E 25.51 ± 13.85 18.62 ± 14.54 24.00 ± 19.74 24.62 ± 18.21 26.71 ± 17.66 25.69 ± 14.67 20.64 ± 7.49 20.80 ± 12.10 23.00 ± 5.28 
   ED 26.09 ± 18.25 17.93 ± 8.34 25.62 ± 15.14 32.26 ± 15.95 35.26 ± 14.44 37.69 ± 11.87 39.08 ± 12.84  39.26 ± 12.70  32.44 ± 5.28 
 SBC mmol/L E 30 ± 2 30 ± 3 30 ± 3 30 ± 2 31 ± 2 30 ± 2 31 ± 2 31 ± 2 30 ± 1 
   ED 30 ± 2 30 ± 1 29 ± 1 29 ± 2 30 ± 1 30 ± 1 30 ± 1 30 ± 2 30 ± 1 
 PCV L/L E 0.27 ± 0.03 0.25 ± 0.05 0.26 ± 0.04 0.26 ± 0.03 0.24 ± 0.03 0.27 ± 0.04 0.25 ± 0.03 0.24 ± 0.02 0.25 ± 0.01 
      ED 0.27 ± 0.03 0.30 ± 0.03  0.31 ± 0.03 § 0.33 ± 0.04 § 0.33 ± 0.05 § 0.32 ± 0.04 § 0.33 ± 0.04 § 0.32 ± 0.04 § 0.32 ± 0.01 * 
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Fig. 3:  Alveolar dead space-to-tidal volume ratio (VD/VT) in 6 anaesthetized ponies receiving 
enoximone alone or enoximone followed by a CRI of dobutamine.  
Values are displayed as mean ± SD.  
* indicates a significant difference between the 2 treatments (P<0.00625) 
 
 
 
 
Fig. 4: Alveolar - arterial oxygen tension difference [P(A-a)O2] in 6 anaesthetized ponies 
receiving enoximone alone or enoximone followed by a CRI of dobutamine.  
Values are displayed as mean ± SD.  
 
 
   Compared to enoximone alone, overall DO2 was higher with treatment ED (P=0.0011) 
(Table 3). This difference was significant at each selected timepoint during the observational 
period. No difference in overall oxygen consumption (  O2) could be detected between the 2 
treatments (Table 3). 
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Table 3: Arterial (CaO2), central venous (CvO2) and end-capillary pulmonary oxygen content (CćO2), degree of venous admixture (       ), oxygen 
delivery (DO2) and oxygen consumption (  O2) in 6 anaesthetized ponies receiving enoximone alone (E) or enoximone followed by a CRI of 
dobutamine (ED). 
 
Values at individual timepoints are represented as mean  ±  SD (SD calculated for each treatment group separately).  
Overall values are represented as mean ± SE (SE calculated assuming homogeneity of variances).   
* significant difference between E and ED for the overall comparison (P<0.05)  
§ significant difference between E and ED at individual timepoints (P<0.00625) 
 
 
 
Variable Unit Trt   Time after treatment (min)   
   Baseline T10 T20 T40 T60 T80 T100 T120 Overall 
CaO2 mL/L E 128 ± 7 118 ± 12 122 ± 10 122 ± 9 118 ± 9 129 ± 19 121 ± 13 116 ± 5 121 ± 5 
  ED 130 ± 13 140 ± 9 § 150 ± 10 § 160 ± 15 § 165 ± 23 § 161 ± 16 § 162 ± 17 § 161 ± 18 § 157 ± 5 * 
CvO2 mL/L E 90 ± 11 90 ± 18 90 ± 10 93 ± 13 82 ± 6 72 ± 11 70 ± 16 76 ± 12 82 ± 5 
  ED 85 ± 15 112 ± 17 § 118 ± 12 § 126 ± 14 § 128 ± 17 § 134 ± 15 § 131 ± 16 § 128 ± 19 § 125 ± 5 * 
CćO2 mL/L E 145 ± 8 136 ± 14 140 ± 11 139 ± 10 134 ± 11 146 ± 20 139 ± 13 134 ± 5 138 ± 5 
  ED 147 ± 15 158 ± 9 § 166 ± 10 § 175 ± 16 § 180 ± 23 § 175 ± 17 § 176 ± 18 § 175 ± 19 § 172 ± 5 * 
Venous admixture % E 32 ± 7 47 ± 24 35 ± 8 43 ± 19 32 ± 5 24 ± 7 28 ± 8 35 ± 16 35 ± 3 
  ED 29 ± 9 44 ± 15 36 ± 10 34 ± 13 31 ± 11 41 ± 18  32 ± 9 33 ± 14 36 ± 3 
DO2  L/min E 1.93 ± 0.33 2.25 ± 0.31 2.16 ± 0.44 1.96 ± 0.26 1.66 ± 0.31 1.66 ± 0.41 1.53 ± 0.45 1.41 ± 0.33 1.80 ± 0.25 
  ED 2.00 ± 0.34 3.51 ± 0.80 § 3.43 ± 0.76 § 3.69 ± 0.95 § 3.60 ± 0.95 § 3.39 ± 0.69 § 3.29 ± 0.97 § 3.21 ± 1.01 § 3.45 ± 0.25 * 
2OV

 L/min E 0.57 ± 0.23 0.51 ± 0.30 0.57 ± 0.18 0.46 ± 0.26 0.51 ± 0.19 0.73 ± 0.31 0.61 ± 0.22 0.51 ± 0.25 0.56 ± 0.09 
    ED 0.68 ± 0.25 0.70 ± 0.36 0.72 ± 0.26 0.74 ± 0.26  0.79 ± 0.39  0.53 ± 0.33 0.61 ± 0.20 0.63 ± 0.28 0.68 ± 0.09 
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Recovery (Table 4) 
The recovery scores were comparable for both treatments, although two ponies showed some 
excitation during recovery after treatment E, which was not observed after treatment ED. 
Time to stand up was 23.7 ± 7.1 minutes after treatment E, compared to 21.3 ± 5.4 minutes 
after treatment ED. 
 
Table 4: Recovery scores of 6 ponies, receiving either a bolus of enoximone or enoximone 
followed by dobutamine during anaesthesia. 
 
Pony Enoximone 
Enoximone + 
Dobutamine 
1 2 3 
2 4 3 
3 2 2 
4 2 2 
5 4 2 
6 2 3 
 
 
Discussion 
Compared to enoximone alone, a combination of enoximone and dobutamine increased HR, 
   , SV, arterial blood pressure and DO2. When comparing these results to those found with 
enoximone in ponies (Chapter 4.1) and with dobutamine in horses (Swanson et al. 1985, 
Swanson & Muir 1986, Gasthuys et al. 1991, Lee et al. 1998, Young et al. 1998, Raisis et al. 
2000), the cardiovascular effects of enoximone and dobutamine appeared to be at least 
additive, but perhaps even synergistic. Additive effects of PDE III inhibitors and ß-adrenergic 
sympathomimetics have also been reported in man (Royster et al. 1993, Thuillez et al. 1993, 
Gilbert et al. 1995, Cracowski et al. 1999, Via et al. 2003). Furthermore, the results of the 
present study indicate that a combination of enoximone and dobutamine may have beneficial 
effects on respiratory gas exchange, as a reduction in VD/VT was observed.  
   By increasing the intracellular concentration of cAMP through different pathways, 
enoximone and dobutamine can have additive or even synergistic effects. In horses, 
dobutamine was shown to increase     at dosages of 1.25 µg/kg/min or higher (Swanson et al. 
1985, Swanson & Muir 1986, Gasthuys et al. 1991, Lee et al. 1998, Young et al. 1998). 
However, infusion rates up to 1 µg/kg/min did not induce significant changes in     in several 
studies (Swanson & Muir 1986, Lee et al. 1998, Raisis et al. 2000). In the present study, a 
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dobutamine CRI of only 0.5 µg/kg/min
 
significantly increased CI from 54.08 ± 7.19 to 82.40 
± 7.19 mL/kg/min. In literature, such an increase was only reported with higher doses of 
dobutamine (Swanson et al. 1985, Gasthuys et al. 1991). It can be concluded that enoximone 
and dobutamine may have synergistic effects on     in isoflurane anaesthetized ponies. 
Furthermore, the difference between treatments E and ED was fairly constant throughout the 
observational period, indicating that a single bolus of enoximone potentiated the effects of 
dobutamine during at least 2 hours. This is in agreement with the results of chapter 4.1, where 
enoximone significantly increased     during 100 minutes.  
   The increase in     found in our ponies was due to increases in both SV and HR. 
Dobutamine was reported to increase SV at doses of 1 µg/kg/min or higher (Gasthuys et al. 
1991, Lee et al. 1998) but not at a low dose of 0.5 µg/kg/min (Raisis et al. 2000). Again this 
indicates that enoximone increases the effects of dobutamine in isoflurane anaesthetized 
ponies, as was reported in man for combinations of PDE III inhibitors and ß-adrenergic 
sympathomimetics (Royster et al. 1993, Gilbert et al. 1995). An increase in SV can result 
from an increase in preload, a decrease in afterload and/or an increase in contractility. 
Although RAP, which reflects preload, increased during administration of dobutamine, this 
difference was only significant during the first 20 minutes. Systemic vascular resistance, 
which reflects afterload, was significantly lower during treatment ED when overall data were 
analyzed. However, this difference was small and could not be confirmed statistically when 
analyzing the data at specific time points. These findings indicate that in the present study, 
dobutamine increased SV mainly by increasing contractility.  
    Heart rate, a second determinant of    , was also increased during treatment ED. The 
difference between the 2 treatments became larger over time, but was only significant from 
T60 onwards. In chapter 4.1 it was shown that a bolus of 0.5 mg/kg enoximone increased HR 
during 40 minutes in isoflurane anaesthetized ponies. During this time period, dobutamine 
did not induce further increases in HR in the present study, although human patients with 
class IV heart failure receiving enoximone and dobutamine had a higher increase in HR than 
patients receiving either of the drugs alone (Gilbert et al. 1995). The reason for this different 
response is not clear: the effects of dobutamine on HR reported in horses vary largely in 
literature, while no clear correlation seems to exist with the administered dose of dobutamine. 
Indeed, the influence of dobutamine on HR in anaesthetized horses varied between no effects 
with doses between 0.5 and 10 µg/kg/min (Swanson et al. 1985, Gasthuys et al. 1991, Lee et 
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al. 1998, Raisis et al. 2000), decreases with doses between 1.5 and 5 µg/kg/min (Swanson et 
al. 1985, Donaldson 1988) and increases with doses between 2.5 and 10 µg/kg/min (Gasthuys 
et al. 1991, Lee et al. 1998). In the present study, a low dose of dobutamine only increased 
HR after the effects of enoximone on HR had weaned off. As the time between sedation and 
administration of enoximone was 105 minutes, it is unlikely that romifidine influenced HR 
during the observational period. After a similar time period and compared to baseline, no 
differences in HR were reported after romifidine administration (Freeman et al. 2002). 
Alternatively, the increase in blood pressure during dobutamine administration may have 
elicited a vagal response, preventing a further increase in HR (Alexander & De Cuir 1963). 
Also, the influence of the infusion of dobutamine might have been delayed, similar to the 
findings of Young et al. (1998), where an increase in HR was not observed until 60 minutes 
after initiating an infusion of dobutamine at 4 µg/kg/min. Despite the increase in HR and 
similar to the human studies in patients with class IV heart failure (Gilbert et al. 1995), no 
arrhythmias occurred during the combined use of enoximone and dobutamine in the ponies of 
the present study. 
   Although enoximone did not induce any changes in blood pressure in healthy, isoflurane 
anaesthetized ponies (Chapter 4.1), it has been reported that the use of PDE inhibitors can be 
accompanied by a sudden decrease of the arterial blood pressure (Kulka & Tryba 1993). In 
those cases, excessive vasodilation had to be counteracted by catecholamine α-stimulation 
(Via et al. 2003). Results of the present study indicate that an infusion of dobutamine may be 
useful in such cases, as arterial blood pressure was always higher during treatment ED. 
Indeed, dobutamine is well known to increase arterial pressure in anaesthetized horses 
(Swanson et al. 1985, Gasthuys et al. 1991, Hellyer et al. 1998, Raisis et al. 2000). However, 
further studies are necessary in hypovolaemic horses, as the effects of dobutamine may be 
limited in those cases. 
   Dobutamine has been reported to reduce total peripheral and pulmonary resistances, 
suggesting vasodilation of the peripheral and pulmonary vascular beds (Gasthuys et al. 1991, 
Thuillez et al. 1993). Furthermore, combining dobutamine and enoximone potentiates the 
systemic and brachial vasodilator effects of each drug in man (Thuillez et al. 1993, Gilbert et 
al. 1995, Cracowski et al. 1999). Yet, in the present study, the overall difference in SVR, 
although statistically significant, was quite small (317.6 ± 29.3 vs 274.0 ± 29.3 
dynes.sec/cm
5
). Also, after Bonferroni correction, the differences were not significant at any 
of the selected timepoints. Apparently, both drugs appeared to reduce SVR to a lesser extent 
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in horses than in man: enoximone did not reduce SVR in isoflurane anaesthetized ponies 
(Chapter 4.1) and reported effects of racemic dobutamine on SVR in horses are only small 
and often not significant (Swanson et al. 1985, Raisis et al. 2000). This can be explained by 
the physiologic and pharmacologic antagonisms of the individual stereoisomers of the 
racemic mixture (Ruffolo et al. 1981). Also, the observed decrease in SVR in the present 
study may have been attenuated by an increase in PCV, which increases viscosity and thus 
SVR.  
   Right atrial pressure was larger during treatment ED compared to enoximone alone. 
Increases in RAP have indeed been reported with the use of dobutamine in horses (Swanson 
et al. 1985, Raisis et al. 2000). In the present study, this difference was significant during the 
first 20 minutes after the administration of enoximone. Dobutamine appeared to attenuate the 
venous vasodilating effect of enoximone, which has been shown to reduce RAP in isoflurane 
anaesthetized ponies (Chapter 4.1). This finding is in agreement with reports about the 
combination of enoximone and dobutamine in man (Gilbert et al. 1995). 
   During the observational period, general anaesthesia induced a gradual decrease in body 
temperature over time. An interaction effect between the factors treatment and time was also 
detected, with a more rapid decrease in body temperature during treatment ED, despite a 
similar room temperature. The reason for this difference is unclear. To the authors‟ 
knowledge, neither enoximone nor dobutamine have been reported to cause a decrease in 
body temperature. Perhaps a more pronounced vasodilation of the peripheral vasculature 
occurred during treatment ED. As hypothermia has been shown to reduce the MAC of 
isoflurane (Vitez et al. 1974, Antognini 1993), it is likely that anaesthetic depth gradually 
increased in the present study. However, the difference in body temperature between the two 
treatments was small and not significant and should therefore not have interfered with the 
comparison of both treatments.  
   Using a CRI of dobutamine at rates of 1, 3 and 5 µg/kg/min, Swanson and Muir (1986) did 
not detect any differences in the degree of venous admixture, VD/VT or P(A-a)O2. Similarly, 
no difference in the degree of venous admixture was detected between the two treatments in 
the present study. However, we did observe a decrease in VD/VT, which suggests increased 
blood flow to adequately ventilated lung regions, possibly due to vasodilation of the 
pulmonary circulation in these areas. In man, a combination of enoximone and dobutamine 
reduced pulmonary vascular resistance compared to enoximone treatment alone (Gilbert et al. 
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1995). While this reduction in dead space ventilation, which was most pronounced after T80, 
did not result in differences in P(A-a)O2 or PaO2, an interaction effect between treatment and 
time was observed for both of these variables: during treatment ED, P(A-a)O2 gradually 
became smaller and PaO2 larger than after enoximone treatment alone.  
   Partly due to this gradual increase in PaO2, but mainly due to the increase in PCV, CaO2 
was higher during treatment ED. Increases in PCV have indeed been described during or after 
dobutamine administration (Gasthuys et al. 1991, Hellyer et al. 1998, Raisis et al. 2000). The 
combination of increased     and augmented CaO2 resulted in a higher oxygen delivery with 
treatment ED. It should be noted however that increases in microcirculatory PCV may result 
in increased viscosity, which might reduce the flow in small vessels and limit oxygen 
delivery to the tissues (Raisis et al. 2000). Also, central indices of left ventricular function, 
(   , MAP and SVR) do not always predict the effects of agents on regional perfusion (Raisis 
et al. 2000). Therefore, further studies are needed to investigate the effects of enoximone and 
dobutamine on intramuscular blood flow. 
   In conclusion, the results of the present study indicate that a combination of a bolus of 
enoximone and a CRI of dobutamine produces greater cardiovascular stimulation than 
enoximone alone, whereby enoximone potentiated the effects of dobutamine on     and SV in 
isoflurane anaesthetized ponies. Although SVR was reduced, blood pressure was always 
higher during the infusion of dobutamine. Also, a reduction in VD/VT was detected, indicating 
that the combination of enoximone and dobutamine had beneficial effects on pulmonary 
perfusion. As the present study was conducted in ponies, further studies are necessary to 
examine the effects of a combination of enoximone and dobutamine in horses, especially in 
cases of dehydration and/or hypovolaemia.   
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SUMMARY 
The aim of this study was to examine the influence of calcium chloride (CaCl2) on the 
cardiorespiratory effects of enoximone in isoflurane anaesthetized ponies in a 
prospective, randomized, experimental trial. Six healthy ponies, weighing 287 ± 55 kg, 
were sedated with romifidine, 80 µg/kg intravenously (IV). Anaesthesia was induced 
with midazolam (0.06 mg/kg) and ketamine (2.2 mg/kg) and maintained with isoflurane 
in oxygen. The ponies' lungs were ventilated to maintain normocapnia. After 90 minutes, 
enoximone alone (0.5 mg/kg) (treatment E) or enoximone followed by a CaCl2 infusion 
(0.5 mg/kg/min over 10 minutes) (treatment EC) was administered. Each pony received 
both treatments on separate occasions, with a minimal interval of 2 weeks between 
treatments. Sodium, potassium, ionized and total calcium concentrations, cardiovascular 
variables and blood gases were measured during 120 minutes after treatment.  
   Ionized and total calcium concentrations were higher during treatment EC, but the 
cardiorespiratory effects of enoximone were comparable for both treatments. A small 
but significant difference in packed cell volume was detected. It can be concluded that 
calcium chloride does not influence the effects of enoximone in normocalcaemic 
anaesthetized ponies. 
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Introduction 
Calcium ions are essential for cardiac membrane depolarization, excitation-contraction 
coupling and actin-myosin interaction during muscle contraction (Abernethy et al. 1995). 
Volatile anaesthetics depress myocardial function by altering myocardial cell calcium 
homeostasis (Pagel et al. 1993) and by decreasing intracellular calcium transients (Bosnjak 
and Kampine 1986). Calcium influx through slow channels is reduced, resulting in a 
depression of the rate of upstroke of the slow calcium-mediated action potential (Rusy & 
Komai 1987). Inhalational agents also depress the maximal uptake of calcium by the 
sarcoplasmic reticulum (Casella et al. 1987) and may even cause a net loss of calcium from 
the sarcoplasmic reticulum (Wheeler et al. 1988). Finally, volatile anaesthetics decrease the 
myofibrillar responsiveness to calcium and/or the calcium sensitivity of the contractile 
proteins (Housmans & Murat 1988) and induce small but significant decreases in serum 
ionized and total calcium concentrations in horses (Gasthuys et al. 1985, Grubb et al. 1999). 
   Enoximone, a phosphodiesterase (PDE) III inhibitor, exerts powerful inotropic and 
lusitropic effects by increasing the cyclic adenosine monophosphate (cAMP) concentration in 
cardiac muscle. A cAMP dependent protein kinase is activated, which phosphorylates the L-
type calcium channels, facilitating calcium flux across myocardial cell membranes. 
Intracellular calcium concentrations increase, stimulating a further release of calcium from the 
sarcoplasmatic reticulum and resulting in an increase of the contractile forces (Vernon et al. 
1991). In ponies, enoximone induced significant increases in cardiac output (

Q

   ), stroke 
volume (SV) and heart rate (HR) (Chapter 4.1). 
   The inotropic state of the myocardium can also be ameliorated by increasing circulatory 
calcium concentrations. Calcium attenuated or completely reversed the negative lusitropic 
actions of halothane and isoflurane (Pagel et al. 1993) and produced positive inotropic effects 
in cats (Bosnjak and Kampine 1986), dogs (Pagel et al. 1993) and calves (Stanley et al. 1976). 
Increases in     and/or SV were demonstrated in conscious (Grubb et al. 1996) and 
anaesthetized horses (Grubb et al. 1999), anaesthetized ponies (Gasthuys et al. 1991), 
hypocalcaemic dogs (Drop and Scheidegger 1980) and humans with cardiac disease (Eriksen 
et al. 1983).  
   Because the effects of PDE III inhibitors result from an increased calcium influx in the 
myocardium, the effects of these drugs may be enhanced when administered simultaneously 
with calcium. On the other hand, calcium stimulates PDE activity, thereby increasing cAMP 
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degradation and possibly attenuating the effects of PDE inhibitors (Teo & Wang 1973). Also, 
calcium overload can induce side effects such as marked shortening of the QT interval, 
bradyarrhythmias (Drop 1985), impaired diastolic function (Schiffman et al. 2001) and even 
cardiac arrest (Bergman & Sellers 1953). To the authors‟ knowledge, no studies have reported 
the influence of calcium on the effects of enoximone in any species. The aim of the present 
study was to investigate if a calcium chloride infusion could increase the cardiovascular 
effects of enoximone in anaesthetized ponies.  
 
Materials & Methods 
The general experimental protocol has been described in chapter 4.1. Additionally, blood 
samples for measurement of serum total calcium (Spotchem SP-4420
®
, A. Menarini 
Diagnostics, Zaventem, Belgium) and plasma ionized calcium, sodium and potassium (AVL 
9180 Electrolyte Analyzer
®
, AVL scientific corporation, Roswell, Georgia, USA 30076) 
concentrations were collected before sedation (= standing values), at T-10 (= baseline), T30, 
T60, T90, T120 and T150 (= during recovery, 30 minutes after the end of anaesthesia) during 
treatments E and EC.  
   For statistical analysis, a paired samples t-test was performed to analyze the differences 
between pre-anaesthetic values and baseline values during anaesthesia for plasma sodium, 
potassium and ionized calcium and serum total calcium levels (α = 0.05). The same test was 
used to compare the pre-anaesthetic levels of these ions to the respective levels during 
recovery. For all variables, differences between treatments E and EC were compared using a 
mixed model with treatment, time and their interaction as fixed categorical effects and pony 
as random effect, comparing the treatments both globally over the entire period after treatment 
(at α = 0.05) and also at specific timepoints: baseline, T30, T60, T90, T120 and T150 for the 
different ions (at Bonferroni adjusted α = 0.0083) and baseline, T10, T20, T40, T60, T80, 
T100 and T120 for all other variables (at Bonferroni-adjusted α = 0.00625).   
 
Results 
Sodium, potassium and ionized and total calcium concentrations  
At baseline, ion concentrations were not significantly different between the 2 treatments 
(Table 1), but baseline Na
+
 (P = 0.008), ionized  (P < 0.001) and total Ca
2+ 
concentrations (P < 
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Table 1: Sodium, potassium and ionized and total calcium concentrations in 6 anaesthetized ponies receiving enoximone (0.5 mg/kg) alone (E), or 
enoximone (0.5 mg/kg) followed by a calcium chloride infusion (0.5 mg/kg/min during 10 minutes) (EC).  
 
 
 
 
Data are represented as mean  ±  SD (SD calculated assuming homogeneity of variances).  
* significant difference between E and EC for the overall comparison (P<0.05)  
§ significant difference between E and EC at individual timepoints (P<0.0083) 
£ baseline value and/or value during recovery significantly different from standing value (α = 0.05).  
          Time after enoximone treatment (minutes), CaCl2 infused from T5 to T15 during treatment EC   
Ion Unit Standing Trt Baseline T30 T60 T90 T120 Recovery Overall 
Sodium mmol/L
 
137 ± 1 E 133 ± 1 £ 132 ± 1 133 ± 1 131 ± 1 132 ± 1 132 ± 1 132 ± 1 
   EC 130 ± 1 £ 130 ± 1 135 ± 1 132 ± 1 132 ± 1 133 ± 1 132 ± 1 
Potassium mmol/L
 
3.8 ± 0.1 E 3.8 ± 0.2 3.9 ± 0.2 3.8 ± 0.2 4.2 ± 0.2 4.1 ± 0.2 4.2 ± 0.2 4.0 ± 0.2 
   EC 4.2 ± 0.2 4.0 ± 0.2 4.2 ± 0.2 4.2 ± 0.2 4.1 ± 0.2 4.3 ± 0.2 4.2 ± 0.2 
Ionized calcium mmol/L
 
1.49 ± 0.03 E 1.37 ± 0.01 £ 1.29 ± 0.01 1.29 ± 0.01 1.26 ± 0.01 1.26 ± 0.01 1.26 ± 0.01 £ 1.27 ± 0.01 
   EC 1.41 ± 0.01 £ 1.49 ± 0.01 § 1.43 ± 0.01 § 1.42 ± 0.01 § 1.40 ± 0.01 § 1.40 ± 0.01 £ 1.43 ± 0.01 * 
Total calcium mmol/L
 
3.00 ± 0.03 E 2.71 ± 0.03 £ 2.63 ± 0.03 2.59 ± 0.03 2.58 ± 0.03 2.58 ± 0.03 2.56 ± 0.03 £ 2.59 ± 0.03 
      EC 2.56 ± 0.03 £ 2.72 ± 0.03 2.69 ± 0.03 2.71 ± 0.03 2.69 ± 0.03 2.78 ± 0.03 £ 2.70 ± 0.03 * 
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0.001) were lower than their respective standing values, with a significantly higher 
ionized/total Ca
2+ 
ratio (P = 0.037). Ionized Ca
2+ 
concentration decreased over time in both 
groups (P = 0.003), but was significantly higher throughout the anaesthesia after treatment EC 
compared to treatment E. Overall, total Ca
2+ 
concentration was also significantly higher 
during treatment EC than during treatment E (P = 0.042), but this difference was quite small 
and not significant at the different time points separately. As a result, the ratio ionized/total 
Ca
2+ 
was higher during treatment EC (P<0.001). No differences in Na
+
 and K
+ 
concentrations 
were found between treatments. 
   During recovery, Na
+
 and K
+
 concentrations were not different from standing values and 
comparable for both treatments. Ionized and total Ca
2+ 
concentrations were still lower than 
before anaesthesia (P < 0.001), but not different between the 2 treatments. 
 
Cardiovascular system  
The cardiovascular effects of treatment EC were not significantly different from those 
previously reported for treatment E at any of the selected timepoints for any of the measured 
variables (Table 2). Diastolic (DAP) and mean (MAP) arterial pressure gradually increased 
over time (P < 0.0001). Systemic vascular resistance (SVR) and right atrial pressure (RAP) 
initially decreased after enoximone treatment, but increased significantly over time (P < 
0.0001) during the remaining anaesthetic period.  
 
Body temperature, respiratory gas exchange, packed cell volume  
Body temperature gradually decreased over time (P<0.0001), but was not different between 
the two treatments. Arterial and central venous blood gas results (Table 3) and parameters 
derived from these values (Table 4) were comparable for both treatments. Arterial pH 
gradually increased over time (P = 0.0048), while central venous oxygen content (CvO2) 
(P<0.0001) and haemoglobin saturation (SvO2) (P=0.0002) slowly, but significantly decreased 
over time. Overall, packed cell volume (PCV) was higher during treatment EC than during 
treatment E, both in arterial (P = 0.0345) and central venous (P = 0.0184) blood. 
 
Recovery  
The recovery scores after both treatments are represented in table 5. Time to stand up was 
23.7 ± 7.1 minutes after treatment E, compared to 30.3 ± 7.1 minutes after treatment EC. 
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Table 2: Systolic (SAP), diastolic (DAP), mean arterial (MAP) and right atrial (RAP) pressures, heart rate (HR), cardiac index (CI), stroke volume 
index (SI) and systemic vascular resistance (SVR) in 6 anaesthetized ponies receiving enoximone (0.5 mg/kg) alone (E), or enoximone (0.5 
mg/kg) followed by a calcium chloride infusion (0.5 mg/kg/min during 10 minutes) (EC).  
 
Variable Unit Trt   
Time after enoximone treatment (min), CaCl2 infused from T5 to T15 during 
treatment EC   
   
Baseline T10 T20 T40 T60 T80 T100 T120 Overall 
SAP 
§
 mm Hg E 83 ± 7 86 ± 14 84 ± 12 84 ± 11 88 ± 11 89 ± 10 87 ± 10 85 ± 10 86 ± 3 
  
EC 80 ± 5 84 ± 5 84 ± 5 82 ± 7 82 ± 7 83 ± 7 85 ± 7 86 ± 8 84 ± 3 
DAP 
§,#
 mm Hg E 51 ± 6 54 ± 14 54 ± 14 56 ± 15 60 ± 14 62 ± 12 61 ± 9 60 ± 10 57 ± 4 
  
EC 48 ± 4 49 ± 8 51 ± 6 52 ± 9 54 ± 8 55 ± 10 57 ± 8 59 ± 8 53 ± 4 
MAP 
§,#
 mm Hg E 63 ± 6 65 ± 14 65 ± 14 67 ± 14 72 ± 13 73 ± 11 71 ± 9 69 ± 9 68 ± 4 
  
EC 60 ± 4 61 ± 7 62 ± 6 62 ± 8 63 ± 8 65 ± 9 67 ± 9 69 ± 9 64 ± 4 
RAP 
#
 mm Hg E 15 ± 2 10 ± 2 10 ± 2 11 ± 3 11 ± 2 12 ± 3 13 ± 3 13 ± 3 11 ± 2 
  
EC 18 ± 5 14 ± 6 15 ± 6 16 ± 6 17 ± 6 17 ± 7 17 ± 6 18 ± 5 16 ± 2 
HR 
§,#
 beats/min E 40 ± 4 46 ± 6 44 ± 6 41 ± 5 39 ± 5 38 ± 4 37 ± 4 36 ± 3 41 ± 2 
  
EC 39 ± 2 46 ± 4 44 ± 3 42 ± 4 40 ± 3 41 ± 4 40 ± 3 40 ± 4 42 ± 2 
CI 
§,#
 mL/kg/min E 53.0 ± 12.2 67.5 ± 14.3 61.4 ± 11.2 56.5 ± 11.4 49.1 ± 9.8 44.7 ± 10.3 43.4 ± 10.1 42.0 ± 9.2 54.1 ± 5.8 
  
EC 53.3 ± 17.3 66.0 ± 19.9 58.8 ± 21.5 56.0 ± 20.3 52.6 ± 18.9 50.0 ± 16.7 49.1 ± 15.9 45.8 ± 16.3 56.9 ± 5.8 
SI 
§,#
 mL/kg E 1.3 ± 0.2 1.5 ± 0.2 1.4 ± 0.2 1.4 ± 0.2 1.3 ± 0.1 1.2 ± 0.1 1.2 ± 0.2 1.1 ± 0.2 1.3 ± 0.1 
  
EC 1.4 ± 0.4 1.4 ± 0.4 1.3 ± 0.4 1.3 ± 0.4 1.3 ± 0.5 1.2 ± 0.4 1.2 ± 0.4 1.2 ± 0.4 1.3 ± 0.1 
SVR 
#
 dyne.sec/cm
5
 E 261 ± 63 232 ± 66 257 ± 85 282 ± 77 352 ± 90 394 ± 114 400 ± 143 395 ± 143 318 ± 25 
    EC 228 ± 36 208 ± 36 240 ± 70 248 ± 80 268 ± 73 288 ± 67 295 ± 60 328 ± 64 255 ± 25 
  
 
 
Values at individual timepoints are represented as mean  ±  SD (SD calculated for each treatment group separately).  
Overall values are represented as mean ± SE (SE calculated assuming homogeneity of variances). 
 
§ significantly lower at baseline compared to the respective standing values (α = 0.05).  
 
#
 significant change over time during anaesthesia (α = 0.05).  
No significant differences between the 2 treatments were detected for any of the measured variables (α = 0.05).  
 
Chapter 4.3: Results 
 
165 
 
Table 3: Blood gas results, packed cell volume (PCV) and body temperature in 6 anaesthetized ponies receiving enoximone (0.5 mg/kg) alone (E), or 
enoximone (0.5 mg/kg) followed by a calcium chloride infusion (0.5 mg/kg/min during 10 minutes) (EC).  
 
Variable Unit Trt   Time after enoximone treatment (minutes), CaCl2 infused from T5 to T15 during treatment EC   
    Baseline T10 T20 T40 T60 T80 T100 T120 Overall 
Body temperature 
# 
°C E 36.3 ± 0.3 35.8 ± 0.6 35.7 ± 0.6 35.5 ± 0.7 35.3 ± 0.8 35.1 ± 0.8 35.0 ± 0.9 34.9 ± 0.9 35.4 ± 0.2 
   EC 36.0 ± 0.3 35.6 ± 0.2 35.5 ± 0.2 35.4 ± 0.2 35.2 ± 0.2 35.2 ± 0.2 35.0 ± 0.3 35.0 ± 0.4 35.5 ± 0.2 
Central venous blood            
 pH  E 7.41 ± 0.05 7.42 ± 0.05 7.43 ± 0.05 7.44 ± 0.05 7.44 ± 0.04 7.43 ± 0.05 7.43 ± 0.05 7.43 ± 0.06 7.43 ± 0.02 
   EC 7.42 ± 0.03 7.43 ± 0.05 7.43 ± 0.05 7.45 ± 0.04 7.44 ± 0.05 7.46 ± 0.04 7.45 ± 0.05 7.45 ± 0.06 7.44 ± 0.02 
 pCO2 kPa E 6.85 ± 0.89 6.51 ± 0.93 6.35 ± 0.97 6.29 ± 0.89 6.47 ± 0.52 6.58 ± 0.77 6.53 ± 0.73 6.60 ± 0.80 6.50 ± 0.19 
   EC 6.84 ± 0.48 6.73 ± 0.95 6.67 ± 0.88 6.35 ± 0.96 6.64 ± 1.14 6.27 ± 1.07 6.49 ± 1.01 6.40 ± 1.18 6.51 ± 0.19 
 pO2  kPa E 4.86 ± 0.72 6.69 ± 5.13 4.78 ± 0.80 4.42 ± 0.76 4.20 ± 0.65 3.93 ± 0.54 3.73 ± 0.70 4.91 ± 2.62 4.70 ± 0.43 
   EC 4.44 ± 0.80 4.73 ± 1.30 4.69 ± 1.09 4.38 ± 1.40 4.20 ± 1.35 4.11 ± 1.53 3.96 ± 1.47 3.82 ± 1.47 4.27 ± 0.43 
 SBC mmol/L
 
E 29± 3 29 ± 2 29 ± 2 30 ± 2 30 ± 2 30 ± 2 30 ± 2 30 ± 2 30 ± 1 
   EC 30 ± 2 30 ± 2 30 ± 2 30 ± 2 30 ± 2 31 ± 2 31 ± 2 31 ± 2 30 ± 1 
 PCV L/L
 
E 0.27 ± 0.04 0.26 ± 0.05 0.26 ± 0.04 0.28 ± 0.05 0.26 ± 0.03 0.24 ± 0.02 0.24 ± 0.04 0.24 ± 0.02 0.25 ± 0.01 
   EC 0.28 ± 0.02 0.27 ± 0.03 0.27 ± 0.03 0.27 ± 0.04 0.27 ± 0.04 0.27 ± 0.04 0.27 ± 0.05 0.27 ± 0.04 0.27 ± 0.01 * 
Arterial blood            
 pH 
# 
 E 7.45 ± 0.05 7.46 ± 0.06 7.47 ± 0.05 7.48 ± 0.05 7.47 ± 0.04 7.47 ± 0.04 7.48 ± 0.05 7.47 ± 0.05 7.47 ± 0.02 
   EC 7.46 ± 0.03 7.45 ± 0.05 7.46 ± 0.05 7.49 ± 0.04 7.49 ± 0.04 7.50 ± 0.04 7.50 ± 0.06 7.50 ± 0.06 7.48 ± 0.02 
 pCO2 kPa E 5.93 ± 0.68 5.87 ± 0.73 5.71 ± 0.69 5.53 ± 0.72 5.80 ± 0.52 5.71 ± 0.44 5.64 ± 0.49 5.69 ± 0.54 5.70 ± 0.34 
   EC 6.15 ± 0.46 6.15 ± 0.79 5.95 ± 0.80 5.60 ± 0.67 5.60 ± 0.57 5.49 ± 0.66 5.47 ± 0.73 5.44 ± 0.83 5.60 ± 0.34 
 pO2 kPa E 25.51 ± 13.85 18.62 ± 14.54 24.00 ± 19.74 24.62 ± 18.21 26.71 ± 17.66 25.69 ± 14.67 20.64 ± 7.49 20.80 ± 12.10 23.00 ± 5.47 
   EC 15.09 ± 13.55 13.38 ± 12.97 13.55 ± 8.44 13.69 ± 12.34 14.58 ± 15.11 13.95 ± 15.23 15.64 ± 16.46 16.73 ± 17.20 14.50 ± 5.47 
 SBC mmol/L
 
E 30 ± 2 30 ± 3 30 ± 3 30 ± 2 31 ± 2 30 ± 2 31 ± 2 31 ± 2 30 ± 1 
   EC 31 ± 2 31 ± 2 31 ± 2 31 ± 2 31 ± 2 32 ± 2 31 ± 2 31 ± 2 31 ± 1 
 PCV L/L
 
E 0.27 ± 0.03 0.25 ± 0.05 0.26 ± 0.04 0.26 ± 0.03 0.24 ± 0.03 0.27 ± 0.04 0.25 ± 0.03 0.24 ± 0.02 0.25 ± 0.01 
      EC 0.27 ± 0.02 0.27 ± 0.03 0.26 ± 0.04 0.27 ± 0.03 0.27 ± 0.04 0.27 ± 0.04 0.28 ± 0.04 0.27 ± 0.05 0.27 ± 0.01 * 
 
Values at individual timepoints are represented as mean  ±  SD (SD calculated for each treatment group separately).  
Overall values are represented as mean ± SE (SE calculated assuming homogeneity of variances). 
* significant difference between E and EC at the 5% global significance level  
 #
 significant change over time during anaesthesia (α = 0.05).  
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Table 4: Arterial (CaO2), central venous (CvO2) and end-capillary pulmonary oxygen content (CćO2), degree of venous admixture, alveolar dead 
space-to-tidal volume ratio (VD/VT), alveolar-arterial O2 tension difference, oxygen delivery (DO2) and oxygen consumption (  O2) in 6 
anaesthetized ponies receiving enoximone (0.5 mg/kg) alone (E), or enoximone (0.5 mg/kg) followed by a calcium chloride infusion (0.5 
mg/kg/min during 10 minutes) (EC).  
 
 
Variable Unit Trt   Time after enoximone treatment (minutes), CaCl2 infused from T5 to T15 during treatment EC   
   Baseline T10 T20 T40 T60 T80 T100 T120 Overall 
CaO2 mL/L
 
E 128 ± 7 118 ± 12 122 ± 10 122 ± 9 118 ± 9 129 ± 19 121 ± 13 116 ± 5 121 ± 4 
  EC 124 ± 11 117 ± 18 120 ± 21 117 ± 11 115 ± 4 117 ± 15 124 ± 8 118 ± 12 118 ± 4 
CvO2 
# 
mL/L
 
E 90 ± 11 90 ± 18 90 ± 10 93 ± 13 82 ± 6 72 ± 11 70 ± 16 76 ± 12 82 ± 7 
  EC 88 ± 15 90 ± 20 91 ± 19 84 ± 23 76 ± 22 80 ± 31 76 ± 30 72 ± 23 81.3 ± 7 
CćO2 m/ L
 
E 145 ± 8 136 ± 14 140 ± 11 139 ± 10 134 ± 11 146 ± 20 139 ± 13 134 ± 5 138 ± 4 
  EC 143 ± 11 137 ± 18 140 ± 20 137 ± 10 135 ± 4 136 ± 15 143 ± 9 137 ± 12 138.0 ± 4 
Venous admixture % E 32 ± 7 47 ± 24 35 ± 8 43 ± 19 32 ± 5 24 ± 7 28 ± 8 35 ± 16 35 ± 3 
  EC 29 ± 9 44 ± 15 36 ± 1 34 ± 13 31 ± 11 41 ± 18 32 ± 9 33 ± 14 38 ± 3 
VD/VT % E 39 ± 8 43 ± 4 42 ± 4 41 ± 5 42 ± 5 43 ± 5 42 ± 4 45 ± 6 43 ± 2 
  EC 40 ± 7 41 ± 6 40 ± 7 41 ± 6 42 ± 7 41 ± 6 41 ± 7 41 ± 7 41 ± 2 
P(A-a)O2 kPa E 76.14 ± 12.79 81.98 ± 12.46 76.60 ± 17.94 76.39 ± 17.32 74.17 ± 17.05 75.50 ± 14.46 81.02 ± 7.98 80.62 ± 13.24 78.04 ± 4.75 
  EC 84.43 ± 11.76 86.86 ± 10.85 87.53 ± 6.19 87.64 ± 10.86 86.75 ± 14.01 87.51 ± 13.94 86.25 ± 14.74 85.38 ± 15.27 86.84 ± 4.75 
DO2 
# 
L/min
 
E 1.93 ± 0.33 2.25 ± 0.31 2.16 ± 0.44 1.96 ± 0.26 1.66 ± 0.31 1.66 ± 0.41 1.53 ± 0.45 1.41 ± 0.33 1.80 ± 0.18 
  EC 1.84 ± 0.39 2.20 ± 0.63 2.01 ± 0.75 1.87 ± 0.67 1.70 ± 0.45 1.68 ± 0.65 1.76 ± 0.59 1.54 ± 0.51 1.82 ± 0.18 
  O2 L /min E 0.57 ± 0.23 0.51 ± 0.30 0.57 ± 0.18 0.46 ± 0.26 0.51 ± 0.19 0.73 ± 0.31 0.61 ± 0.22 0.51 ± 0.25 0.56 ± 0.06 
    EC 0.51 ± 0.07 0.51 ± 0.19 0.48 ± 0.27 0.50 ± 0.12 0.50 ± 0.21 0.47 ± 0.24 0.62 ± 0.24 0.55 ± 0.18 0.52 ± 0.06 
 
Values at individual timepoints are represented as mean  ±  SD (SD calculated for each treatment group separately).  
Overall values are represented as mean ± SE (SE calculated assuming homogeneity of variances). 
#
 significantly changing over time during anaesthesia (α = 0.05).  
No significant differences between the 2 treatments were detected for any of the measured variables (α = 0.05).  
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Table 5: Recovery scores of 6 ponies, receiving either a bolus of enoximone or enoximone 
followed by a calcium chloride infusion during anaesthesia. 
 
Pony Enoximone 
Enoximone + 
calcium 
1 2 3 
2 4 1 
3 2 1 
4 2 1 
5 4 1 
6 2 1 
 
Discussion 
In the present study, Na
+
, ionized and total Ca
2+ 
concentrations were significantly lower at 
baseline compared to the respective preanaesthetic values. Although this may reflect fluid 
shifts, with some plasma dilution as a result, the changes in ionized and total calcium 
concentrations were greater than the difference in Na
+
 concentration. Most likely, isoflurane 
additionally reduced calcium concentrations, since volatile anaesthetics reduced blood 
calcium concentrations in ponies (Gasthuys et al. 1985) and horses (Grubb et al. 1999, Boscan 
et al. 2007), while no changes in Na
+
 concentrations were reported after induction of 
anaesthesia in horses (Tevik et al. 1968, Gasthuys et al. 1986, Boscan et al. 2007). As 
enoximone exerts its effects by increasing calcium entry into the myocardial cells (Vernon et 
al. 1991) and peak effects were observed 5 minutes after administration in ponies (Chapter 
4.1), CaCl2 was administered from 5 to 15 minutes after the injection of enoximone, to 
maximize possible combined effects. Nonetheless, cardiovascular function and respiratory gas 
exchange were comparable with both treatments, despite a significant increase in the ionized 
calcium concentration after CaCl2 administration. 
   The absence of any effects of calcium administration on cardiovascular performance is in 
contrast with other studies in ponies (Gasthuys et al. 1991) and horses (Grubb et al. 1996, 
Grubb et al. 1999), where significant cardiovascular effects were reported after administration 
of calcium in doses comparable to or lower than the dose used in the present study. However, 
in dogs and humans, calcium administration has not always been found to increase     
(Marone et al. 1981, Butterworth et al. 1992, Royster et al. 1992). Furthermore, the effects of 
CaCl2 may in fact be limited when administered in combination with enoximone, since CaCl2 
also had no influence on the haemodynamic responses to other inotropic drugs, such as 
amrinone (Butterworth et al. 1992) and adrenaline (Royster et al. 1992). Apparently, when 
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intracellular calcium concentrations increase above a certain value, a negative feedback 
mechanism becomes active in the myocardium. In some cases, the inotropic effects of PDE III 
inhibitors were actually reduced when calcium was administered (Goyal & McNeill 1986), 
which would be due to a reduced activity of adenylyl cyclase (Drummond & Duncan 1970, 
Abernethy et al. 1995) and an increased PDE activity (Teo & Wang 1973) when calcium 
concentrations increase in the myocardium. Finally, all ponies in the present study were 
normocalcaemic before anaesthesia. Drop and Scheidegger (1980) reported increases in     
and SV after calcium administration in hypocalcaemic, but not in normocalcaemic dogs.  
   In the present study, HR was not influenced by the infusion of CaCl2, although calcium 
administration decreased HR in halothane anaesthetized ponies (Gasthuys et al. 1991) and 
horses (Grubb et al. 1999). Possibly, bradycardia in response to calcium is more likely during 
halothane anaesthesia, since HR was also not influenced by calcium during isoflurane 
anaesthesia in horses (Grubb et al. 1999) or neuroleptanaesthesia in humans (Eriksen et al. 
1983). Furthermore, the effects of calcium on HR may have been attenuated by the positive 
chronotropic effects of enoximone in ponies (Chapter 4.1). 
   Arterial blood pressure was also not affected by CaCl2 in our ponies. Although calcium 
gluconate infusion did not influence arterial pressure in conscious horses (Grubb et al. 1996), 
significant increases were reported in anaesthetized ponies (Gasthuys et al. 1991), horses 
(Grubb et al. 1999), dogs (Drop & Scheidegger 1980) and humans (Marone et al. 1981, 
Eriksen et al. 1983), mainly due to an increase in SVR. Calcium induces vasoconstriction by 
binding to calmodulin and activating myosin light chain kinase, which then phosphorylates 
myosin, initiating smooth muscle contraction. Calcium would further enhance smooth muscle 
contraction by binding directly to myosin and by activating protein kinase C, which 
phosphorylates myosin at a different site than myosin light chain kinase (Adelstein & Sellers 
1987). 
   In the present study, after administration of enoximone, infusion of CaCl2 did not increase 
SVR. The fact that enoximone promotes vasodilation through an increase in the cAMP level 
in vascular smooth muscle cells (Vernon et al. 1991) may interfere with the contractile 
response of smooth muscle cells to calcium in several ways. Firstly, cAMP decreases 
myoplasmic calcium concentrations (Itoh et al. 1993) by inhibiting calcium influx in vascular 
smooth muscle cells (Ishikawa et al. 1993) and by enhancing calcium pump activity by 
phosphorylation of phospholamban (Kimura et al. 1991). Secondly, when intracellular cAMP 
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levels rise, a cAMP-dependent protein kinase catalyzes the phosphorylation of myosin kinase. 
This decreases the activity of myosin kinase by interfering with the binding of calcium-
calmodulin (Adelstein et al. 1982). Finally, enoximone might also cause vasorelaxation 
through a decrease in calcium sensitivity of contractile elements (Itoh et al. 1993). In 
conclusion, enoximone may blunt the effects of calcium on the peripheral vasculature by 
decreasing intracellular calcium concentrations, lowering the activity of myosin light chain 
kinase and diminishing the calcium sensitivity of contractile elements. 
   Packed cell volume was not influenced by calcium administration in ponies (Gasthuys et al. 
1991) and horses (Grubb et al. 1996). However, in the present study, PCV was higher during 
treatment EC. This is in agreement with the results of Marone et al. (1981) in humans, who 
found a significant increase in PCV after administration of calcium gluconate. As in several 
similar studies (Gasthuys et al. 1991, Grubb et al. 1996), blood gases were not influenced by 
calcium administration in the present study.  
   Future studies are justified to determine whether the results of the present study in ponies 
also apply in horses and whether CaCl2 can increase the effects of enoximone in cases of 
hypocalcaemia and/or endotoxaemia. It might also be hypothesized that CaCl2 would produce 
clearer effects when administered during a constant rate infusion of enoximone. However, a 
bolus of enoximone produced long lasting effects in anaesthetized ponies, with increases in 
HR for 40 minutes and     and SV for 100 minutes (Chapter 4.1). Since CaCl2, infused shortly 
after administration of enoximone, did not induce any significant changes in the present study, 
it is unlikely that clearer effects would be observed during a constant rate infusion of 
enoximone. Furthermore, pharmacokinetic data on enoximone in ponies or horses, required to 
determine a suitable constant rate, are not available up to now. Finally, in the authors‟ 
opinion, it is unlikely that different results would be obtained when using calcium gluconate 
instead of CaCl2, since it has been demonstrated that equal elemental calcium doses of 
calcium gluconate and CaCl2, injected over the same time period, were equivalent in their 
ability to raise calcium concentrations during normocalcaemic situations and produced 
equivalent cardiovascular effects in children and dogs (Cote et al. 1987). 
   In conclusion, the previously reported positive cardiovascular effects of a bolus of 0.5 
mg/kg enoximone were not affected by a CaCl2 infusion in the present study in ponies.  
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SUMMARY 
The aim of this study was to examine whether enoximone improves cardiovascular 
function and reduces dobutamine requirement in anaesthetized colic horses. Forty eight 
adult colic horses were enrolled in this prospective, randomized clinical trial. After 
sedation [xylazine 0.7 mg/kg intravenously (IV)] and induction [midazolam 0.06 mg/kg 
IV,  ketamine 2.2 mg/kg IV], anaesthesia was maintained with isoflurane in oxygen and 
a lidocaine constant rate infusion (1.5 mg/kg, 2 mg/kg/h). All horses were ventilated 
(PaCO2<8.00 kPa). When hypotension occurred, dobutamine and/or colloids were 
administered. Ten minutes after skin incision, horses randomly received an IV bolus of 
enoximone (0.5 mg/kg) or saline. Monitoring included respiratory and arterial blood 
gases, heart rate (HR), arterial pressure and cardiac index (CI). Systemic vascular 
resistance (SVR), stroke index (SI) and oxygen delivery index (DO2I) were calculated. 
For each variable, changes between baseline and T10 within each treatment group 
and/or colic type (small intestines (SMA), large intestines (LAR) or mixed (MIX)) were 
analyzed and compared between treatments in a fixed effects model. Differences 
between treatments until T30 were investigated using a mixed model (α=0.05). 
   Ten minutes after enoximone treatment, CI (P=0.0010), HR (P=0.0033) and DO2I 
(P=0.0007) were higher and SVR lower (P=0.0043) than at baseline. The changes in CI, 
HR and SVR were significantly different from those after saline treatment. During the 
first 30 minutes after enoximone treatment, DO2I (P=0.0224) and HR (P=0.0003) were 
higher than after saline administration. Because the difference in HR between 
treatments was much clearer in LAR colic cases, an interaction was detected between 
treatment and colic type in both analyses (P=0.0076; P=0.0038 respectively). It is 
concluded that enoximone produces significant, but short lasting, cardiovascular effects 
in colic horses. 
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Introduction 
Emergency abdominal surgery carries a very high risk in horses: during or within 7 days after 
surgery, 11.7 % of the patients died unexpectedly or were euthanized because of perioperative 
complications (unrelated to pre-existing disease) (Johnston et al. 2002). Variables which 
assess cardiovascular status, including heart rate (HR), packed cell volume (PCV), capillary 
refill time, mucous membrane colour and/or blood pressure, are good prognostic indicators 
(Parry et al. 1983; Pascoe et al. 1983; Puotunen-Reinert 1986; French et al. 2002; Proudman 
et al. 2006). Furthermore, most causes of perianaesthetic death, including post-operative 
problems such as myopathies, were linked with cardiovascular depression (Johnston et al. 
2002). Perioperative cardiovascular support is thus crucial to improve outcome of horses 
anaesthetized for colic surgery.  
   Despite high-volume fluid therapy, sympathomimetic drugs, such as dobutamine 
(Donaldson 1988, Dugdale et al. 2007), dopamine (Trim et al. 1991) and ephedrine (McGrath 
1984) often remain an essential part of the supportive therapy in these patients. Another class 
of inotropic drugs are the phosphodiesterase (PDE) III inhibitors, who inhibit enzymatic 
cAMP breakdown, producing positive inotropic and lusitropic effects, as well as systemic 
vasodilation (Vernon et al. 1991). In chapter 4.1 it was shown that the PDE III inhibitor 
enoximone induced significant increases in cardiac output (   ), HR, stroke volume (SV) and 
oxygen delivery (DO2), without affecting arterial pressure in anaesthetized ponies. When 
combining this drug with a constant rate infusion (CRI) of dobutamine, further increases in 
   , SV and DO2 were observed, together with increases in arterial pressure (chapter 4.2). The 
results even suggested that enoximone potentiates the effects of dobutamine in ponies. Since 
the effects of enoximone have not been studied in horses under clinical conditions and 
because cardiovascular function may be quite compromised in colic horses, the aim of this 
study was to evaluate the cardiorespiratory effects of enoximone in horses undergoing 
emergency laparotomy. It was hypothesized that enoximone would increase    , SV, HR and 
DO2 and reduce the dobutamine requirement.  
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Materials & Methods 
Patients and anaesthetic protocol  
This prospective, randomized, clinical study included 48 horses undergoing emergency colic 
surgery at the Faculty of Veterinary Medicine of Ghent University. Before surgery, all horses 
received broad spectrum antibiotics and flunixin meglumine 1.1 mg/kg intravenously (IV) 
(Finadyne
®
, Schering Plough Animal Health, Heist-Op-Den-Berg, Belgium) intravenously 
(IV). When indicated based on a physical examination and/or PCV, hypertonic saline (4 
mL/kg bwt) or a colloid (2–4 mL/kg bwt Geloplasma®, Fresenius Kabi, Schelle, Belgium) 
was infused before sedation.  
   Horses which had already been sedated during clinical examination received the same α2 
adrenoreceptor agonist as premedication; the other horses were sedated with xylazine (Xyl-
M
®
, VMD, Arendonk, Belgium). Doses varied depending on the condition of the individual 
horse and prior administration of sedatives, but in general, standard doses (IV) were 0.7 
mg/kg for xylazine, 10 µg/kg for detomidine (Domosedan
®
, Pfizer Animal Health S.A., 
Louvain-la-Neuve, Belgium) and 80 µg/kg for romifidine (Sedivet
®
, Boehringer Ingelheim, 
Brussels, Belgium). After sedation, a nasogastric tube was placed to evacuate stomach 
contents. Anaesthesia was induced using a combination of 0.06 mg/kg midazolam IV 
(Dormicum, Roche, Brussels, Belgium) and 2.2 mg/kg ketamine IV (Anesketin, Eurovet, 
Heusden-Zolder, Belgium). After orotracheal intubation (26-30 mm OD, soft rubber tracheal 
tube, Rüsch AG, Kernen, Germany), the horse was hoisted onto a padded surgery table, in 
dorsal recumbency. 
   General anaesthesia was maintained with isoflurane (Isoflo
®
, Abbott Laboratories Ltd., 
Queenborough, Kent, United Kingdom) in oxygen, using a large animal anaesthetic unit 
(Matrx
®
, Matrx medical inc., Orchard Park, New York, USA + Sulla 909V
®
, Dräger, Lübeck, 
Germany). A bolus of 1.5 mg/kg lidocaine (Laocaïne
®
, Schering-Plough Vétérinaire, 
Levallois Perret, France) was administered over 10 minutes, followed by a CRI at 2 
mg/kg/hour. This CRI was discontinued 30-45 minutes before the end of anaesthesia. 
Mechanical ventilation (Smith respirator LA 2100
®
, model 2002, Veterinary Technics/BDO-
Medipass, Hoogezand, the Netherlands)
 
was applied in all horses to maintain PaCO2 < 8 kPa, 
in an assisted, volume controlled, pressure limited mode, delivering a tidal volume (TV) of 10 
mL/kg, with a maximal peak inspiratory pressure (PIP) of 20-30 cm H2O. When respiration 
rate (RR) was lower than 4 breaths/minute during more than 3 minutes or if arterial blood gas 
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analysis (ABL5
®
, Radiometer, Copenhagen, Denmark) revealed a high PaCO2 (>8 kPa) or a 
low PaO2 (<13 kPa), respirations were both assisted and controlled (RR6-12 breaths/minute). 
Crystalloids were infused at 10 mL/kg/h. Fluid choice depended on the base excess (BE), 
using lactated Ringer‟s solution (Haemofiltration Formula E2®, Bieffe Medital, Grosotto, 
Italy) or saline (NaCl 0.9%, Baxter, Lessines, Belgium) if BE was below or above 5 mEq/L
 
respectively. If BE was below -5 mEq/L and PaCO2 did not exceed 8 kPa, bicarbonate 
(Bicarbonate de sodium 8.4 %
®
, B Braun, Melsungen, Belgium) was additionally infused. 
When mean arterial pressure was lower than 70 mm Hg, dobutamine (Dobutamine Mayne
®
, 
Mayne Pharma, Brussels, Belgium) was administered at a rate of 0.3-1.5 µg/kg/min. When 
arterial pressure was unresponsive to dobutamine or when PCV exceeded 0.45 L/L, 
Geloplasma
®
 (4 mL/kg) was infused and a second jugular catheter was placed for additional 
administration of crystalloids. At the end of anaesthesia, 0.2 mg/kg xylazine was administered 
IV. The horses recovered spontaneously in a padded recovery box. The recovery time and 
recovery score, based on a simple grading system, were recorded. 
 
Monitoring 
Anaesthetic gases were monitored using a calibrated multi-gas analyzer (HP M1025B
®
, 
Hewlett Packard Company, Houston, USA). Cardiovascular monitoring consisted of pulse 
oximetry, a base-apex electrocardiogram (ECG), invasive blood pressure measurement from 
the facial artery (HP M1165A
®
, model 56S, Hewlett-Packard, GmbH, Böblingen, Germany) 
and     measurements using the lithium dilution technique (LiDCO-plus Hemodynamic 
Monitor, LiDCO Ltd., London, UK). For     measurements, a lithium chloride bolus of 5 
µmol/kg was used. The pressure monitoring system was calibrated against a mercury 
manometer and zeroed at the level of the right atrium before anaesthesia in each horse. Blood 
samples withdrawn from the arterial catheter were immediately analyzed for pH, partial 
pressures of oxygen (PaO2) and carbon dioxide (PaCO2), saturation (SaO2), base excess (BE) 
and bicarbonate level (ABL5
®
, Radiometer, Copenhagen, Denmark). The PCV was obtained 
by centrifugation. 
 
Experimental design 
Ten minutes after skin incision, baseline measurements (T0) were obtained for inspiratory and 
expiratory CO2, O2 and isoflurane, pulse saturation (SpO2), HR, systolic (SAP), diastolic 
(DAP) and mean arterial pressure (MAP),     and arterial blood gases. Subsequently, a bolus 
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of 0.5 mg/kg enoximone 0.5% (Perfan
®
, Myogen GmbH, Bonn, Germany) (treatment E) or an 
equivalent volume of saline (treatment S) was administered at a rate of 20 mL/min. The 
random treatment assignment of E and S was stratified for colic type (small intestines (SMA), 
large intestines (LAR) or a combination of both (MIX)). Cardiac output measurements and 
arterial blood gas analysis were performed at T10 and T30; all other measurements were 
performed at T10, T20 and T30.  
   Stroke volume, systemic vascular resistance (SVR) and DO2 were calculated according to 
standard formulae (Muir 2007), with right atrial pressure (RAP) arbitrarily taken as 7 mm Hg. 
Cardiac index (CI), and oxygen delivery index (DO2I) were expressed in mL/kg/min, stroke 
index (SI) in mL/kg.  
 
Statistical analysis 
To investigate the short term effects of enoximone administration, it was tested whether there 
was a significant change between baseline and T10 within each treatment group and/or colic 
type for the different variables, using a mixed model with time as categorical fixed effect and 
horse as random effect. The difference between T10 and baseline was also used as the 
response variable in a fixed effects model with colic type, treatment and their interaction as 
fixed effects, to investigate whether the change between baseline and T10 was different 
between treatments and/or between colic types. Finally, the effects of enoximone during a 
period of 30 minutes after treatment were investigated using a mixed model with horse as 
random effect and colic type, treatment, time and interaction between colic type and treatment 
as categorical fixed effects.  
   The need for a colloid or a second jugular catheter for additional fluid administration and 
the ventilation mode used (assisted or assisted-controlled) were compared between treatments 
using Fisher‟s exact tests. 
   The recovery scores and recovery times for both treatments were compared using the 
Wilcoxon rank sum test.  
   For all analyses mentioned, a 5% significance level was used. 
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Results 
Patient data 
The study population included 23 mares, 11 stallions and 14 geldings. The horses were 
between 1 and 24 years old (mean age 8.3 ± 5.5 years), their body weight ranged between 252 
and 703 kg (mean weight 522.7 ± 97.3 kg). All horses were Dutch, French or Belgian 
warmbloods, except for 5 Thoroughbreds, 1 Standardbred, 1 Friesian horse, 2 Haflingers, 1 
Belgian Draught horse and 2 Quarter horses. Colic causes are listed in Table 1.  
Table 1: Causes of colic in 48 horses undergoing emergency laparotomy, receiving an 
intravenous bolus of enoximone (0.5 mg/kg bwt) or an equivalent volume of saline 10 
minutes after skin incision. Total numbers are written in bold. 
      Treatment 
   Enoximone Saline 
Small intestines  9 8 
 Strangulations  6 5 
  with resection 3 2 
  no resection necessary 0 2 
  euthanasia 3 1 
 Gastro-enteritis 1 1 
 Impaction ileum 2 2 
     
Large intestines  14 12 
 Displacement colon 4 2 
 Impaction 3 3 
  Large colon 2 3 
  Small colon 1 0 
 Torsions/strangulations  3 3 
  Strangulation colon 0 1 
  Torsion colon 1 2 
  Torsion caecum 2 0 
 Other  4 4 
  Type 2 caecal impaction 1 1 
  Nephrosplenic entrapment 2 1 
  Caecocolic intussusception 1 0 
  Intramural haematoma colon 0 1 
  Enterolith 0 1 
     
Mixed disorders  2 3 
 Generalized tympany 1 1 
 Colon displacement    
  with ileum obstipation 0 1 
  with ileum strangulation 0 1 
 Colon impaction   
  with strangulation small intestine 1 0 
     
Overall total 25 23 
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   Seven horses were euthanized intraoperatively (Table 2), including 4 horses with 
strangulation of the small intestines, 2 colonic torsions and 1 horse with impaction of the 
colon and necrosis of the colon wall. In 3 of these horses, values were only available until 
T20, all other horses were euthanized after completion of the study period (T30). Three horses 
within colic type LAR were premedicated with detomidine (2 of group E and 1 of group S) 
and 1 with romifidine (group E), all other horses were sedated with xylazine. 
 
Infusions, ventilation and recovery 
In groups S and E, a second catheter was placed to administer additional fluids in 7/23 (30%) 
and 7/25 (28%) horses respectively, while colloids were administered in 6/23 (26%) and 7/25 
(28%) horses respectively. Bicarbonate was infused intraoperatively in 2 horses in group E 
and in 1 horse in group S, while 2 horses in group E were hypocalcaemic and received an 
infusion with calcium gluconate (Calcii borogluconas
®
, Eurovet) during anaesthesia. 
Ventilation mode was assisted throughout the 30 minute period after treatment in 7/23 (30%) 
and 6/25 (24%) horses of groups S and E respectively. In all other horses, ventilation mode 
was assisted-controlled. Recovery scores and duration (Table 2) were not significantly 
different between groups. In one horse in group S, with a strangulation of the small intestines, 
recovery duration was 360 minutes. This value was not included in the calculation of mean 
recovery duration of group S. 
 
Table 2:  Recovery and euthanasia data in 48 colic horses, receiving an intravenous 
bolus of enoximone (0.5 mg kg
-1
) or an equivalent volume of saline during 
anaesthesia. Because 7 horses were euthanized during surgery and recovery 
lasted 6 hours in 1 horse of the saline group, calculation of the recovery 
duration is based on data of 40 horses. For the recovery scores, the values 
represent the number of horses receiving the respective scores. 
                  
 
Enoximone Saline
Duration of recovery (min)
52 ± 20 47 ± 14
Recovery Score 
1 1 3
2 10 7
3 7 9
4 3 0
5 0 1
Peroperative euthanasia 4 3
Treatment
mean ± SD      
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Table 3:  Systolic (SAP), diastolic (DAP) and mean arterial pressure (MAP), stroke index (SI) 
and oxygen delivery index (DO2I) in 48 anaesthetized colic horses, receiving an 
intravenous bolus of enoximone (0.5 mg/kg) or an equivalent volume of saline 10 
minutes after incision of the skin (=Baseline). 
 
 
 
SMA = small intestines, LAR = large intestines, MIX = mixed disorders 
Data are displayed as mean ± SD, α = 0.05 for all analyses 
* Value at T10 significantly different from baseline 
b
 Changes between baseline and T10 significantly different between colic types 
c
 Values from T10 to T30 significantly different between treatments within colic type 'all' 
d
 Overall values from T10 to T30 significantly different between colic types 
Time after treatment (min)
Variable Colic type Baseline T10 T20 T30
SAP d All S 105 ± 23 105 ± 16 95 ± 16 92 ± 13
(mm Hg) E 103 ± 26 101 ± 29 100 ± 26 95 ± 22
SMA S 106 ± 21 114 ± 15 102 ± 19 96 ± 15
E 107 ± 29 109 ± 26 114 ± 23 105 ± 15
LAR S 106 ± 26 99 ± 16 90 ± 14 90 ± 13
E 101 ± 27 96 ± 32 92 ± 26 91 ± 26
MIX S 100 ± 13 106 ± 9 96 ± 12 92 ± 3
E 95 ± 0 96 ± 1 98 ± 4 95 ± 5
DAP d All S 69 ± 18 71 ± 17 61 ± 16 57 ± 15
(mm Hg) E 66 ± 20 64 ± 19 66 ± 19 65 ± 14
SMA S 71 ± 16 78 ± 14 70 ± 19 62 ± 18
E 73 ± 20 74 ± 19 77 ± 21 71 ± 11
LAR S 69 ± 20 66 ± 20 55 ± 14 54 ± 16
E 62 ± 22 59 ± 19 59 ± 17 60 ± 16
MIX S 68 ± 19 75 ± 9 65 ± 10 62 ± 10
E 66 ± 3 62 ± 11 69 ± 8 69 ± 1
MAP b,d All S 82 ± 18 81 ± 16 73 ± 15 69 ± 14
(mm Hg) E 78 ± 20 77 ± 22 77 ± 21 76 ± 15
SMA S 83 ± 16 89 ± 14 80 ± 16 74 ± 15
E 84 ± 22 86 ± 22 89 ± 22 82 ± 12
LAR S 83 ± 21 75 ± 16 * 68 ± 14 67 ± 15
E 75 ± 21 71 ± 22 70 ± 19 72 ± 17
MIX S 79 ± 18 87 ± 6 77 ± 11 72 ± 10
E 77 ± 1 75 ± 4 80 ± 6 78 ± 2
SI All S 1.64 ± 0.56 1.69 ± 0.76 1.64 ± 0.50
(mL/kg) E 1.45 ± 0.51 1.59 ± 0.62 1.61 ± 0.65
SMA S 1.50 ± 0.59 1.59 ± 0.73 1.60 ± 0.42
E 1.52 ± 0.45 1.76 ± 0.64 1.57 ± 0.45
LAR S 1.76 ± 0.56 1.71 ± 0.83 1.68 ± 0.61
E 1.45 ± 0.58 1.49 ± 0.6 1.65 ± 0.76
MIX S 1.58 ± 0.54 1.89 ± 0.75 1.58 ± 0.25
E 1.18 ± 0.28 1.58 ± 0.92 1.32 ± 0.54
DO2I 
c All S 11.19 ± 3.49 11.92 ± 4.03 11.88 ± 4.22
(mL/kg/min) E 12.06 ± 3.28 13.83 ± 4.27 * 14.27 ± 4.94
SMA S 11.46 ± 3.66 12.87 ± 4.26 13.01 ± 4.61
E 12.76 ± 2.93 15.02 ± 5.23 * 13.77 ± 4.55
LAR S 11.77 ± 3.35 11.37 ± 4.18 11.91 ± 4.47
E 11.87 ± 3.66 13.32 ± 3.72 14.5 ± 5.38
MIX S 8.15 ± 3.01 11.90 ± 3.89 * 9.50 ± 1.67
E 10.29 ± 2.12 12.07 ± 4.09 12.38 ± 5.18
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Figure 1:  Cardiac index (CI) in 48 anaesthetized colic horses, receiving an intravenous bolus of 
enoximone (0.5 mg/kg) or an equivalent volume of saline 10 minutes after incision of 
the skin (=T0). 
Data are displayed as mean ± SD, * indicates a significant difference between baseline 
and T10, § indicates that the change between baseline and T10 was significantly 
different between treatments (P<0.05). No significant difference was found between 
treatments in overall CI over a 30 minute period after drug administration. 
 
 
 
Figure 2:  Systemic vascular resistance (SVR) in 48 anaesthetized colic horses, receiving an 
intravenous bolus of enoximone (0.5 mg/kg) or an equivalent volume of saline 10 
minutes after incision of the skin (=T0). 
Data are displayed as mean ± SD, * indicates a significant difference between baseline 
and T10, § indicates that the change between baseline and T10 was significantly 
different between treatments (P<0.05). No significant difference was found between 
treatments in overall SVR over a 30 minute period after drug administration. 
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Table 4: pH, arterial partial pressures of carbon dioxide (PaCO2) and oxygen (PaO2), packed 
cell volume (PCV) and arterial oxygen content (CaO2) in 48 anaesthetized colic horses, 
receiving an intravenous bolus of enoximone (0.5 mg/kg) or an equivalent volume of 
saline 10 minutes after incision of the skin (=Baseline). 
 
SMA = small intestines, LAR = large intestines, MIX = mixed disorders 
Data are displayed as mean ± SD, α = 0.05 for all analyses 
* Value at T10 significantly different from baseline 
a
 Change between baseline and T10 significantly different between treatments within colic type 
'all'  
c
 Values from T10 to T30 significantly different between treatments within colic type 'all' 
f
 Significant interaction between treatment and colic type in comparison of 30 minute period 
after treatment 
Time after treatment (min)
Variable Colic type Treatment Baseline T10 T30
pH All S 7.24 ± 0.10 7.25 ± 0.10 7.25 ± 0.09
E 7.24 ± 0.10 7.24 ± 0.09 7.27 ± 0.07
SMA S 7.26 ± 0.09 7.25 ± 0.09 7.23 ± 0.09
E 7.28 ± 0.07 7.28 ± 0.05 7.29 ± 0.07
LAR S 7.23 ± 0.11 7.24 ± 0.12 7.26 ± 0.10
E 7.21 ± 0.11 7.21 ± 0.11 7.25 ± 0.07
MIX S 7.23 ± 0.10 7.25 ± 0.09 7.28 ± 0.06
E 7.29 ± 0.02 7.30 ± 0.01 7.30 ± 0.01
PaCO2 
f All S 8.40 ± 2.27 8.40 ± 2.13 8.13 ± 1.33
(kPa) E 8.40 ± 1.47 8.27 ± 1.60 7.60 ± 0.93
SMA S 7.33 ± 0.93 7.73 ± 1.87 8.13 ± 1.20
E 7.87 ± 0.93 7.87 ± 0.67 7.33 ± 0.53
LAR S 8.53 ± 1.87 8.27 ± 2.00 8.13 ± 1.07
E 8.67 ± 1.73 8.40 ± 2.00 7.60 ± 1.07
MIX S 10.40 ± 4.40 10.00 ± 3.20 8.80 ± 2.53
E 9.20 ± 1.73 8.40 ± 1.07 8.27 ± 0.13
PaO2 
c All S 17.46 ± 9.07 20.66 ± 12.93 * 21.60 ± 13.33
(kPa) E 24.26 ± 14.00 27.60 ± 16.53 * 30.26 ± 17.20
SMA S 19.06 ± 10.53 24.13 ± 16.93 21.20 ± 13.33
E 26.80 ± 11.47 28.66 ± 13.87 31.20 ± 13.47
LAR S 17.60 ± 8.80 19.73 ± 11.2 23.06 ± 15.07
E 20.26 ± 14.67 23.46 ± 16.93 26.66 ± 17.86
MIX S 12.13 ± 6.00 16.53 ± 11.73 16.13 ± 4.53
E 40.93 ± 2.80 50.79 ± 2.27 * 51.73 ± 0.53
PCV a All S 37 ± 6 39 ± 6 * 39 ± 7
(%) E 40 ± 8 39 ± 8 38 ± 8
SMA S 37 ± 5 39 ± 4 40 ± 8
E 40 ± 8 39 ± 7 40 ± 7
LAR S 38 ± 8 40 ± 7 39 ± 7
E 40 ± 8 39 ± 10 37 ± 8
MIX S 35 ± 4 39 ± 2 39 ± 1
E 43 ± 1 43 ± 1 44 ± 1
CaO2 
a All S 168.5 ± 28.8 179.8 ± 29.0 * 182.6 ± 31.3
(mL/L) E 188.6 ± 37.1 185.1 ± 37.5 185.2 ± 35.1
SMA S 173.5 ± 28.0 183.9 ± 16.6 189.9 ± 32.0
E 193.2 ± 39.7 187.0 ± 30.4 192.3 ± 31.1
LAR S 168.7 ± 31.5 178.3 ± 37.1 179.0 ± 35.6
E 182.3 ± 37.8 179.7 ± 43.1 177.7 ± 36.4
MIX S 154.2 ± 22.9 176.3 ± 18.1 * 182.1 ± 4.5
E 212.4 ± 6.0 214.6 ± 7.2 217.2 ± 3.2
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Figure 3:  Heart rate (HR) in 48 anaesthetized colic horses, receiving an intravenous bolus of 
enoximone (0.5 mg/kg) (E) or an equivalent volume of saline (S) 10 minutes after 
incision of the skin (=T0). Because a significant interaction was found between 
treatment and colic type, separate curves are displayed per colic type (curves a, b and 
c represent colic types ‘small intestines’, ‘large intestines’ and ‘mixed’ respectively). 
Data are displayed as mean ± SD  
* indicates a significant difference between baseline and T10.  
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Comparison between baseline and T10 
Irrespective of treatment, significant changes occurred between baseline and T10 in all colic 
types, but especially in colic type LAR, where HR, DO2I, PaO2 and TV were higher and the 
end tidal carbon dioxide tension (PE´CO2), SAP and MAP lower at T10 than at baseline. 
When comparing the changes between baseline and T10 for the 2 treatments (Tables 3, 4 & 5, 
Fig. 1, 2 & 3), significant differences were detected for CI (P=0.0133), HR (P=0.0027), SVR 
(P=0.0080), TV (P=0.0446), PCV (P=0.0078) and CaO2 (P=0.0317). Indeed, CI (P=0.0010), 
HR (P=0.0033) and TV (P=0.0405) increased and SVR (P=0.0043) decreased after treatment 
E, while none of these variables changed after treatment S. Packed cell volume (P=0.0116) 
and CaO2 (P=0.0142) both increased after treatment S, but not after treatment E. There was a 
significant interaction between treatment and colic type (P=0.0076) for HR: a significant 
difference between E and S was only observed in colic type LAR, with an increase in HR 
after treatment E compared to treatment S (Fig. 3). A similar interaction effect was found for 
TV (P=0.0161). Finally, DO2I  increased (P=0.0007) after treatment E and not after treatment 
S, but the difference between treatments was not significant. 
 
Differences between treatments and colic types from T10 to T30 
Only PaO2 (P=0.0016), SaO2 (P=0.0092) and DO2I (P=0.0224) were higher during the first 30 
minutes after treatment E than after treatment S (Tables 3 & 4). Although HR was not 
significantly different between treatments, a significant interaction between treatment and 
colic type was again detected for HR (P=0.0038), which was always higher after treatment E 
than after treatment S, but with a much clearer difference in group LAR than in the other 
groups (Fig. 3). During the first 30 minutes after treatment, significant differences were also 
detected between the 3 colic types for several variables, which are represented in Tables 3, 4 
& 5.  
 
Discussion 
In the present study, DO2I, CI and HR increased and SVR decreased 10 minutes after 
administration of enoximone, but in the overall analysis comparing the first 30 minutes after 
treatment, only DO2I and HR were higher after treatment E, while a clinically relevant 
difference in HR was only found in colic type LAR. These results do not agree with reports in 
anaesthetized ponies under standardized experimental conditions, where long lasting 
cardiovascular effects were observed after a single bolus, with increases in     and SV during  
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Table 5: Rate of dobutamine infusion, end-tidal isoflurane concentration (FE´Iso) and end-tidal 
carbon dioxide partial pressure (PE´CO2), tidal volume and peak inspiratory pressure 
(PIP) in 48 anaesthetized colic horses, receiving a bolus of enoximone (0.5 mg/kg) or an 
equivalent volume of saline 10 minutes after skin incision (=Baseline). 
 
SMA = small intestines, LAR = large intestines, MIX = mixed disorders 
Data are displayed as mean ± SD, α=0.05 for all analyses 
* Value at T10 significantly different from baseline 
a
 Change from baseline at T10 significantly different between treatments within colic type 'all'  
d
 Overall values from T10 to T30 significantly different between colic types 
e
 Significant interaction between treatment and colic type in analysis of changes between 
baseline and T10 
Time after treatment (min)
Variable Colic type Treatment Baseline T10 T20 T30
Dobutamine d All S 0.41 ± 0.29 0.34 ± 0.30 * 0.35 ± 0.33 0.42 ± 0.33
(µg/kg/min) E 0.36 ± 0.23 0.38 ± 0.23 0.42 ± 0.37 0.46 ± 0.40
SMA S 0.31 ± 0.28 0.15 ± 0.30 * 0.15 ± 0.30 0.21 ± 0.31
E 0.28 ± 0.23 0.33 ± 0.20 0.27 ± 0.19 0.28 ± 0.19
LAR S 0.44 ± 0.29 0.45 ± 0.28 0.50 ± 0.31 0.57 ± 0.29
E 0.38 ± 0.25 0.39 ± 0.27 0.51 ± 0.45 0.55 ± 0.47
MIX S 0.55 ± 0.33 0.40 ± 0.24 0.30 ± 0.27 0.30 ± 0.27
E 0.51 ± 0.11 0.51 ± 0.11 0.44 ± 0.21 0.44 ± 0.21
FE´ Iso d All S 0.93 ± 0.17 0.95 ± 0.19 1.01 ± 0.20 1.11 ± 0.17
(%) E 1.00 ± 0.18 0.98 ± 0.19 1.01 ± 0.21 1.06 ± 0.26
SMA S 1.01 ± 0.20 0.92 ± 0.26 1.02 ± 0.28 1.19 ± 0.24
E 0.89 ± 0.17 0.92 ± 0.20 0.94 ± 0.22 1.00 ± 0.25
LAR S 0.95 ± 0.16 1.00 ± 0.12 1.04 ± 0.14 1.08 ± 0.12
E 1.07 ± 0.18 1.03 ± 0.18 1.06 ± 0.20 1.10 ± 0.26
MIX S 0.93 ± 0.21 0.87 ± 0.14 0.88 ± 0.08 1.07 ± 0.16
E 0.95 ± 0.14 0.93 ± 0.18 0.90 ± 0.14 0.90 ± 0.14
PE'CO2 All S 5.79 ± 1.11 5.47 ± 0.63 * 5.43 ± 0.71 5.49 ± 0.77
(kPa) E 5.99 ± 0.81 5.83 ± 0.80 5.57 ± 0.85 5.48 ± 1.06
SMA S 5.49 ± 0.94 5.43 ± 0.87 5.47 ± 0.80 5.65 ± 0.75
E 6.01 ± 0.80 6.01 ± 0.73 5.88 ± 0.60 5.77 ± 0.63
LAR S 5.85 ± 0.78 5.47 ± 0.37 5.36 ± 0.54 5.29 ± 0.77
E 6.08 ± 0.85 5.77 ± 0.90 5.42 ± 0.99 5.35 ± 1.28
MIX S 6.34 ± 2.50 5.55 ± 0.99 5.64 ± 1.30 5.93 ± 0.82
E 5.28 ± 0.07 5.37 ± 0.07 5.42 ± 0.27 5.56 ± 0.07
Tidal volume a,e All S 7.9 ± 1.8 7.9 ± 1.7 8.3 ± 1.9 9.0 ± 1.5
(mL/kg) E 8.0 ± 3.3 8.8 ± 2.4 * 9.2 ± 1.9 9.0 ± 2.1
SMA S 8.4 ± 1.7 8.4 ± 1.7 8.2 ± 1.5 8.4 ± 1.4
E 9.3 ± 2.6 9.3 ± 2.6 10.1 ± 1.8 9.5 ± 2.6
LAR S 8.1 ± 1.7 7.9 ± 1.6 8.6 ± 1.9 9.0 ± 1.5
E 7.1 ± 3.6 8.8 ± 2.4 * 9.1 ± 1.8 8.9 ± 1.7
MIX S 5.3 ± 0.2 5.9 ± 0.9 7.8 ± 3.0 10.1 ± 1.2
E 7.8 ± 3.6 6.9 ± 2.4 6.9 ± 2.4 6.1 ± 1.2
PIP All S 21 ± 3 21 ± 3 21 ± 3 21 ± 3
(cm H2O) E 21 ± 4 22 ± 4 22 ± 4 21 ± 3
SMA S 20 ± 0 20 ± 0 20 ± 0 20 ± 0
E 20 ± 4 21 ± 3 22 ± 2 22 ± 2
LAR S 20 ± 3 21 ± 3 21 ± 3 21 ± 3
E 23 ± 4 23 ± 4 22 ± 5 21 ± 3
MIX S 24 ± 6 24 ± 7 24 ± 7 24 ± 7
E 19 ± 1 19 ± 1 19 ± 1 19 ± 1
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100 minutes and increases in HR during 40 minutes (Chapter 4.1). It may therefore be 
concluded that the effects of enoximone are either less pronounced and of shorter duration in 
horses with compromised cardiovascular function, or that the effects were masked by the 
administration of other drugs and by haemodynamic differences between or changes within 
patients.   
   Although a stratified treatment assignment was used to attain a more equal distribution in 
colic types between both treatment groups, a large variability in the cardiovascular status of 
individual horses in each group was still possible, depending on many factors such as the 
actual aetiology (Table 1), duration of symptoms, treatments initiated or drugs administered 
prior to admission/surgery. To minimize the influence of differences between individual 
horses when analyzing the short term effects of enoximone, the changes between baseline and 
T10 were calculated and compared between treatments, rather than comparing the absolute 
values at T10. By using this approach, it became clear that in all colic types, clear and 
significant changes occurred during this phase of surgery, irrespective of the treatment 
administered, which may be related to waning of the effects of induction/sedative drugs,  
increasing effects from fluids/inotropes, and surgical factors such as decompression of the 
abdomen. 
   The most pronounced and significant changes occurred in the LAR group, where HR, TV 
and PaO2 were higher at T10 than at baseline, while the opposite was observed for PE´CO2, 
SAP and MAP. These changes were most likely related to fast surgical decompression of the 
abdomen by removal of gas from tympanic large intestines and/or by partial exteriorization of 
intestines. By using a volume controlled, pressure limited mode of ventilation, the set TV was 
often not delivered in the initial phase of the anaesthesia in tympanic horses, because PIP 
exceeded the preset pressure limit of the ventilator. In these cases, TV would indeed be 
expected to increase when pressure on the diaphragm is reduced by surgical decompression of 
the abdomen. The decrease in PE´CO2 and improvement in arterial oxygenation confirm this 
hypothesis. Although PaCO2 was also lower at T10 than at baseline, this difference was not 
significant. This disagreement between PE´CO2 and PaCO2 may be statistical coincidence, or 
may result from an increase in alveolar dead space ventilation due to reduced pulmonary 
perfusion. Indeed, a second possible effect of reducing intra-abdominal pressure is 
hypotension, due to decompression of the mesenteric vascular bed and larger abdominal 
vessels, leading to reductions in venous return (Vos et al. 1995), central venous pressure 
(Mohapatra 2004) and SVR (Shelly et al. 1987, Mohapatra 2004). In the present study, SAP 
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and MAP were indeed lower and HR higher at T10 than at baseline in colic type LAR, while 
no changes in these variables were observed in the other 2 colic types. 
   Ten minutes after enoximone administration, CI and HR were higher and SVR lower than at 
baseline. These changes were significantly different from those after saline treatment, where 
these variables remained constant. Stroke index also tended to increase after enoximone 
administration, but this difference was not significant (P=0.0519). Finally, DO2I increased 
significantly in the enoximone group and not in the saline group, but the change was not 
significantly different between treatments. The cardiovascular effects of enoximone in this 
study are in agreement with the inotropic, vasodilating and mild chronotropic effects of 
enoximone described in humans (Vernon et al. 1991, Lehtonen et al. 2004), dogs (Dage et al. 
1982) and ponies (Chapter 4.1). Due to its vasodilating properties, enoximone can induce a 
decrease in SVR (arterial vasodilation) (Dage et al. 1982, Boldt et al. 1993) and a certain 
degree of venous pooling (venous vasodilation) (Boldt et al. 1993, Lehtonen et al. 2004). 
Indeed, RAP was lower after enoximone administration in isoflurane anaesthetized ponies 
(Chapter 4.1). Because of these combined arterial and venous vasodilating effects, it may be 
expected that enoximone would induce pronounced arterial hypotension and be 
contraindicated in patients with low SVR, such as hypovolemic and/or endotoxaemic colic 
horses during isoflurane anaesthesia. Nevertheless, it was hypothesized that enoximone may 
still be valuable in colic horses, since this drug was shown to have beneficial effects in 
humans with endotoxin shock (Ringe et al. 2003) or sepsis (Schmidt et al. 2001) and induced 
increases in CI without influencing arterial pressure in isoflurane anaesthetized ponies 
(Chapter 4.1). Similarly, in the present study in colic horses, the effect of enoximone on 
arterial pressure was not different from the effect of saline. These results and those in ponies 
indicate that the increase in CI outweighs possible vasodilatory effects of enoximone and/or 
that enoximone induces less pronounced reductions in SVR in equids compared to humans. It 
must also be remembered that central venous/right atrial pressure was not measured, but 
arbitrarily taken as 7 mm Hg, since placement of a central venous catheter was not feasible in 
these client-owned horses during emergency surgery. This may have biased our calculation of 
absolute values of SVR, as well as the relative comparison between both treatments. Saline 
treatment is not expected to affect RAP, but since enoximone has been shown to reduce RAP 
in ponies (Chapter 4.1), we may have slightly overestimated the reduction in SVR in response 
to enoximone.  
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   When analyzing the changes between baseline and T10, a significant interaction effect was 
observed for HR and TV, indicating that the response to treatment depended on the type of 
colic. Indeed, compared to the other colic types, the increases in HR and TV 10 minutes after 
enoximone administration were much more pronounced in the LAR group. As mentioned 
earlier, TV could only increase when airway resistance decreased and/or compliance 
increased , since pressure-limited ventilation was used in this study and because the pressure 
limit was not different between baseline and T10. A higher compliance would most likely 
result from a decrease in intra-abdominal pressure, which agrees with the observed increase in 
HR, as described earlier. Since enoximone should not affect intra-abdominal pressure and 
because TV was already lower at baseline in group E than in group S, it seems likely that, as a 
coincidence, the initial intra-abdominal pressure of horses in group E was higher and 
therefore decreased more after surgical decompression of the abdomen. The increase in tidal 
volume could also have resulted from increased inspiratory effort by the patient during 
assisted respiration. However, this seems unlikely since no significant changes in PaCO2, 
PaO2, end tidal isoflurane concentration or RRwere noted between baseline and T10 and 
because enoximone would not be expected to influence respiratory drive. Finally, it has been 
shown that combined PDE IV/III inhibitors relax airway smooth muscles and may even be 
effective for the long-term therapy of asthma (Nicholson et al. 1995). Enoximone, a selective 
PDE III inhibitor, would also have bronchodilating properties, since this drug reduced lung 
resistance and increased dynamic lung compliance in spontaneously breathing and artificially 
ventilated patients with decompensated chronic obstructive pulmonary disease (Leeman et al. 
1987). Although bronchodilation would additionally reduce airway resistance, this effect 
appears less important in the present study since no change in TV was observed after 
enoximone treatment in the other colic types. 
   The immediate cardiovascular effects of enoximone in this study (including increases in 
HR, CI, SI and DO2I and a decrease in SVR) were in agreement with those observed in ponies 
(Chapter 4.1), but most of these effects were less pronounced and not significant in the overall 
analysis of the first 30 minutes after treatment. Several factors may have contributed to this 
finding. First, the cardiovascular status of individual colic horses can vary widely, leading to 
high standard deviations of the different variables, which may decrease the sensitivity of 
statistical tests. Secondly, dobutamine and fluid therapy were used in both groups, which may 
have further reduced cardiovascular differences between treatments. Although it has been 
shown that enoximone and dobutamine had additive or perhaps even synergistic effects on 
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cardiovascular function in ponies (Chapter 4.2), administration of enoximone did not reduce 
dobutamine requirement in the present study. Administration of colloids and placement of a 
second jugular catheter were also needed in comparable numbers of horses in both groups. 
Finally, cardiovascular function is often compromised in colic horses (Parry et al. 1983, 
Puotunen-Reinert 1986, French et al. 2002) and may be expected to be less responsive to 
inotropes, especially in case of hypovolaemia (due to decreased venous return and thus a low 
preload) and/or endotoxaemia (Takeuchi et al. 1999, Tavernier et al. 2001). In experimental 
models, endotoxaemia rapidly impaired myocardial intracellular calcium handling and 
contractile protein sensitivity to calcium, a state which was resistant to beta-agonist inotropic 
stimulation (Takeuchi et al. 1999). Vesnarinone, a PDE inhibitor like enoximone, was able to 
normalize lipopolysaccharide-induced myocardial dysfunction and partially restore abnormal 
calcium cycling, but these effects were more likely a result of the drug‟s immunomodulatory 
effects than of myocardial PDE inhibition (Takeuchi et al. 2000). Nevertheless, even in 
patients with severe prolonged catecholamine and volume refractory endotoxin shock, 
enoximone could restore myocardial contractility in man (Ringe et al. 2003) and prevented 
mucosal hypoperfusion despite inducing hypotension during an early stage of sepsis (Schmidt 
et al. 2001). Therefore, enoximone might be valuable in endotoxaemic horses, but further 
studies are needed since only a limited number of horses in the present study were suspected 
to be endotoxaemic. 
   A potential limitation of this study is that the anaesthetist was not blinded to treatment. 
However, these horses were operated under emergency circumstances and cardiovascular 
function was often compromized. To optimize patient safety, it was preferred that the 
anaesthetist was aware of which drugs were being administered, such that appropriate action 
could be taken when needed. Additionally, enoximone is commercialised as a bright yellow 
solution, which makes it less practical to use in a blinded study performed under emergency 
circumstances, with limited staff available. By not performing this study blinded, the 
anaesthetist could have influenced cardiovascular function by changing the anaesthetic 
protocol or the depth of anaesthesia, by altering the fluid administration rate and the type of 
fluid used and by administering vasoactive/inotropic drugs. However, a similar anaesthetic 
protocol was used in all cases, the end tidal isoflurane concentration (correlated to depth of 
anaesthesia) was not significantly different between treatments, and was quite constant over 
the study period (maximal change within each group always less than 0,2%). Decisions about 
fluids and/or dobutamine administration rate were based on arterial blood pressure values (an 
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objective criterion), with the aim to keep MAP above a fixed, predetermined value, which 
was the same in both treatment groups (70 mm Hg).  
   In conclusion, a bolus of enoximone induced increases in DO2, CI and HR and a decrease in 
SVR in colic horses, but most of these differences were only transient and not significant over 
a 30 minute period after treatment. Further studies may be useful to investigate the effects of 
enoximone at different doses or as a CRI, in specific classes of colic or other disease. 
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The anaesthetic risk in horses is markedly higher than in most other commonly anaesthetized 
species. The results of different studies, including the confidential enquiry into perioperative 
equine fatalities (CEPEF) (Johnston et al. 2002), suggested that one of the important targets 
when attempting to reduce anaesthesia related mortality in horses, is the optimization of tissue 
oxygen supply.  
   In the introductory chapter to this PhD thesis, existing methods to diagnose and prevent or 
treat inadequate tissue oxygen supply in horses and other species were reviewed. Several 
conclusions were drawn from this literature review. One general finding was that no easily 
applicable, safe, noninvasive, continuous and accurate method for measuring     is available 
although optimizing cardiac output (   ) during anaesthesia is important to augment oxygen 
delivery (DO2) in horses. However, pulse contour analysis appeared to be an attractive 
alternative. Other conclusions drawn from our literature review were that, in order to optimize 
   , inotropes are needed more often in horses compared to other species, and that extensive 
research therefore has been performed regarding β-sympathomimetic drugs. Of these, 
dobutamine appears to be the most effective and safe drug to maintain cardiac output in 
anaesthetized horses. Some other classes of inotropic drugs had received little to no attention 
in equine anaesthesia, although in humans, phosphodiesterase (PDE) III inhibitors  had shown 
characteristics that, if similar in horses, could be of interest.    
   Based on the first conclusion from the literature review, i.e. the lack of an ideal     
measurement technique in horses, the reliability of a novel method of estimating    , namely 
analysis of the arterial pressure waveform, or Pulse Contour analysis (PulseCO
®
), was 
investigated in equids. The experimental part of this PhD research, which investigated the 
cardiovascular effects of different inotropic and/or vasoactive drugs in ponies, enabled us to 
simultaneously evaluate the accuracy and precision of the PulseCO
®
 software by comparing 
this technique with the validated lithium dilution method (LiDCO
®
). In the past, agreement 
between two measurement techniques has often been evaluated inappropriately by the use of 
correlation coefficients. In 1986, Bland & Altman proposed a different statistical approach, 
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the so-called Bland-Altman plot, which has been used extensively to display and describe data 
from studies comparing two different techniques for measuring the same variable. This 
statistical method is based on the bias and limits of agreement. Bias refers to the average 
difference between the new and reference techniques and therefore allows an estimation of the 
accuracy of the new technique as compared to the reference technique, which is considered to 
be the gold standard (Cecconi et al. 2009). The limits of agreement, i.e. the limits within 
which 95% of the observations fall (corresponding to ± 1.96 times the standard deviation 
around the bias), give an estimation of the precision or random error around the bias (Cecconi 
et al. 2009). Ideally, a measurement device is both accurate and precise. If a technique has a 
high bias and narrow limits of agreement, this indicates low accuracy but high precision, so 
repeated measurements will be close together although their mean will not be close to the 
actual value. This often results from a systematic error, which in many cases can be corrected 
for by calibrating the measurement device, or taking the systematic error into account if it is 
known. On the other hand, a technique with wide limits of agreement has low precision, 
which is much more difficult to correct for. One solution is to perform each measurement 
more than once and calculate the mean of these values as a better estimate of the true value, a 
strategy that is often performed with the intermittent thermodilution technique (Colgan & 
Stewart 1977).  
   In chapter 3, Bland-Altman plots were obtained and bias and limits of agreement were 
calculated to evaluate the accuracy and precision of the PulseCO
®
 technique in ponies under 
experimental conditions. In most treatment groups, bias appeared to be acceptable, but limits 
of agreement were very wide. Critchley and Critchley (1999) advised that the limits of 
agreement of a new technique compared to the thermodilution technique should not be wider 
than -30 and +30%. These maximal values were calculated by assuming that the reference 
technique (thermodilution) had a precision of around 20%, while a similar precision was 
desired for the new technique. Cecconi et al. (2009) recently accentuated that the precision of 
the reference technique should be known before limits of agreement can be evaluated, 
because this precision influences the maximally acceptable values for the limits of agreement. 
To the authors‟ knowledge, no data are available regarding the precision of LiDCO® 
measurements in ponies or horses. Nevertheless, because LiDCO
®
 and thermodilution 
measurements showed good agreement in anaesthetized horses (Linton et al. 2000), 
maximally acceptable limits of agreement of -30 and +30%, as suggested by Critchley and 
Critchley (1999), seem reasonable. In fact, in the study of Linton et al. (2000), it was even 
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shown that single LiDCO
®
 measurements agreed well with the mean of triplicate 
thermodilution measurements, so the error of LiDCO
®
 measurements may actually be lower 
than 20%. Assuming this is true, the acceptable limits of agreement between LiDCO
®
 and 
PulseCO
®
 would be even lower than ±30%. In the saline treated ponies of the present PhD 
study, where cardiovascular performance was stable, limits of agreement were  -19.7 and + 
29.5%. When the ponies were treated with enoximone, alone or combined with other drugs, 
the limits of agreement were even higher, i.e. clearly above the ±30% limits. This 
demonstrates an unacceptably low precision for PulseCO
®
 measurements under changing 
haemodynamic conditions.  
   It must be noted that the Bland-Altman method was developed to compare two independent 
measurement techniques and is in fact not suitable for repeated measures data, although many 
authors have (mis)used the technique for such analyses (Myles & Cui 2007). In our 
experimental study, the two techniques for cardiac output measurement were not independent, 
since the PulseCO
®
 algorithm was calibrated using the reference technique (LiDCO
®
). This 
equalized both measurements at the start of the study, so the initial bias was actually set at 
zero. It is therefore not surprising that mean bias was quite acceptable in most groups. 
However, limits of agreement in the placebo group were wide despite zero bias in each 
individual pony at the start of the study and the short study duration, and became even larger 
when inotropic and vasoactive drugs were administered. This indicates that the reliability of 
the PulseCO
®
 values in the individual patient will be low, and both over- and underestimation 
of the actual value can occur. Furthermore, the precision of an intermittent, absolute technique 
for     measurement can be augmented by averaging repeated measurements, but this is not an 
option in the individual patient when using a continuous, relative method such as pulse 
contour analysis, which does not measure     but attempts to estimate the change in     from 
the change in the arterial waveform compared to the time of initial calibration. Because of the 
rather low bias, it might be hypothesized that, if a sufficient number of animals are used in an 
experimental study of similar duration, the average value for     would be quite acceptable. 
Yet, because of the low precision, standard deviations would most likely be „artificially‟ high, 
i.e. not caused by differences in the response to treatment between animals, but due to 
measurement errors.  
   Another limitation of the Bland-Altman method is that it does not analyze whether the 
differences found between the two techniques are significant. Therefore, the data were also 
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evaluated using a paired t-test and a mixed model approach. The paired t-test compared 
overall values for     and systemic vascular resistance (SVR) during the placebo treatment 
with saline. As mentioned for the Bland-Altman analysis, PulseCO
®
 and LiDCO
®
 were equal 
at the start of the study. Because the difference between both techniques would therefore be 
expected to be low during the initial phase of the experiment, an overall comparison carried 
the risk of masking significant differences occurring mainly at the end of the study period. 
Nevertheless, a significant difference between both measurement techniques was found 
during the placebo treatment. This difference significantly increased over time and was even 
larger during treatment with enoximone, alone or combined with dobutamine.  
   Based on the results from both statistical approaches, it was concluded that the reliability of 
the PulseCO
®
 software was insufficient in ponies under stable haemodynamic conditions and 
became worse during induced haemodynamic changes, especially when arterial pressure 
changed. Unfortunately, a     monitor would of course mainly be useful when changes in     
or SVR occur. Although the study was performed in ponies, in the authors‟ opinion it seems 
unlikely that better results would be obtained in horses. For this reason, the PulseCO
®
 
software was not used for     measurements during the clinical study in colic horses. 
   The second conclusion that could be drawn from our literature review was that, in order to 
maintain oxygen supply to the tissues (especially the muscles), inotropic drugs are probably 
needed/used more often in anaesthetized horses than in humans or small animals without 
cardiac disease, for several reasons. It has been documented that horses are prone to develop 
inadequate respiratory function and cardiovascular depression during anaesthesia, while 
intracompartmental pressures in the limbs are high because of their high body weight. In 
anaesthetized, recumbent horses, the occurring ventilation-perfusion mismatching often 
results in arterial hypoxaemia (Hall et al. 1968, Nyman & Hedenstierna 1989, Nyman et al. 
1990). Although the sigmoid shape of the oxyhaemoglobin dissociation curve serves as a 
safety factor (Bohr et al. 1904), pronounced hypoxaemia with a reduction in arterial oxygen 
content (CaO2) may still decrease delivery of oxygen (DO2) to the tissues. Many strategies to 
prevent or treat arterial hypoxaemia were reported to be rather ineffective (Young et al. 1999, 
Kalchofner et al. 2009), caused further deterioration of PaO2 (Dodam et al. 1993) or decreased 
    (Hall & Trim 1975, Wilson & Soma 1990, Mizuno et al. 1994, Edner et al. 2005), which 
can negate any beneficial effect of increases in CaO2 on DO2. An alternative possibility to 
restore DO2 when CaO2 is low, is to increase    . One might even hypothesize that, under 
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some circumstances, higher than normal     values may be beneficial. Not only could this 
normalize DO2 despite a limited degree of arterial hypoxaemia, but it may also prove to be 
useful to optimize muscle oxygen delivery in a species where intracompartmental pressure in 
the muscles reaches high values during recumbency. In this respect, to increase vascular 
transmural pressure in dependent muscles of horses, blood pressure needs to be increased to 
levels higher than those usually needed in other species to maintain perfusion of vital tissues 
such as the brain and kidneys. Although this increase in blood pressure may be achieved by 
increasing SVR using vasopressors, perfusion of certain tissues, such as the splanchnic 
organs, muscles and/or skin may be reduced. Vasopressors are therefore best reserved for 
situations where hypotension is mainly attributable to vasodilation. More desirable would be 
an increase in     and although this can be achieved using chronotropic drugs (such as 
antimuscarinics), this strategy is not advisable, for many reasons which were mentioned in 
Chapter 1. It would be a better option to reduce anaesthetic depth using balanced anaesthetic 
techniques, with the aim to minimize cardiovascular depression, but this is less 
straightforward in horses than in many other species. Opioids, which are often used for 
perioperative analgesia in humans and small animals, appear to have less clear analgesic 
effects in horses and produced little to no decrease or in some cases even an increase in the 
minimal alveolar concentration (MAC) of inhalant anaesthetics (Pascoe et al. 1993, Steffey et 
al. 2003, Bennett et al. 2004, Thomasy et al. 2006, Knych et al. 2009). Furthermore, 
locoregional anaesthetic techniques are not always without risk in horses, e.g. epidural 
anaesthesia using local anaesthetic drugs causes paralysis or muscle weakness and ataxia 
(LeBlanc et al. 1988, Olbrich & Mosing 2003), while regional anaesthesia of the limbs at the 
level of or proximal to the fetlock may interfere with normal proprioception (Dreverno et al. 
1999). Both techniques may therefore increase the risk of injury during recovery in horses.  
   Fluid therapy is also important to maintain or improve    . However, because of the high 
body weight of horses, administration of large volumes of intravenous fluids on a „per kg‟ 
basis is difficult to achieve under clinical conditions. In dogs with symptoms of shock due to 
absolute hypovolaemia, the use of „shock doses‟ of crystalloids with rates up to 90 mL/kg in 
10 to 15 minutes has been advised (Day 2000). In a typical 500 kg horse, this infusion would 
be equivalent to a rate of 180-270 L/hour, which is hard to achieve even when using more 
than one catheter and/or pressurized infusion systems. Hypertonic saline offers an attractive 
alternative but only a limited amount can be administered, mainly because cellular 
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dehydration has to be avoided. Colloids are another possibility, but these solutions are quite 
expensive and not completely free of side effects.  
   Since balanced anaesthetic techniques and fluid administration are not always effective, 
inotropes can be regarded as indispensable to optimize     during anaesthesia in horses. These 
drugs often need to be administered even before adequate fluid resuscitation is achieved. This 
situation differs from the one in other species including humans, where inotropes are mostly 
reserved for patients with compromised cardiac contractility, e.g. due to cardiac disease or 
sepsis. Probably, this is partly related to the fact that     during anaesthesia can usually be 
maintained at an acceptable level using balanced anaesthetic techniques and fluid therapy. On 
the other hand, there is less need for a „supra-normal‟     compared to the situation in horses, 
because arterial hypoxaemia occurs less frequently in humans without respiratory disease and 
lower levels of blood pressure are acceptable to maintain tissue perfusion. Additionally, 
inotropic drugs usually increase myocardial work and oxygen consumption (Notterman 
1991), which is preferably avoided in the human population, with a high incidence of 
cardiovascular disease, including arteriosclerosis, chronic hypertension and coronary artery 
disease (Franklin 2006).  
   Because of the clear need for inotropic drugs in horses, the relevant literature was reviewed 
in order to summarize which agents were presently used, what their positive and negative 
effects were, and which drugs may be promising for use in horses. Some inotropic drugs, 
including calcium salts, calcium sensitizers and digitalis glycosides, appeared to be less 
suitable for use during anaesthesia for different reasons, as mentioned in Chapter 1. Extensive 
research has been performed on the effects of β-sympathomimetic drugs in anaesthetized 
horses. These drugs can indeed be quite effective at increasing    , while most of them are 
suitable for use as a constant rate infusion (CRI). Their rapid onset and short duration of 
action enable quick alterations of the obtained effects. Still, negative side effects, which are 
dose-dependent and differ between the individual drugs, may occur and include tachycardia, 
excessive vasoconstriction or vasodilation, increased myocardial oxygen consumption and 
arrhythmias (Notterman 1991). Dobutamine appeared to be the most effective and a relatively 
safe β-sympathomimetic for use in horses. In humans, dobutamine mainly produces positive 
inotropic effects, together with some vasodilation (Morrill 2000). Phosphodiesterase (PDE) 
III inhibitors have similar effects in humans and are associated with few side effects during 
short-term perioperative use (Barnard & Linter 1993). It was therefore hypothesized that these 
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drugs may be useful in anaesthetized horses. Furthermore, their combined use with a β-
sympathomimetic appeared attractive, because this may theoretically result in additive or even 
synergistic effects. Finally, because PDE III inhibitors cause inotropic effects through 
increased intracellular calcium concentrations in the myocardium, it was hypothesized that 
calcium salts may accentuate their inotropic effects. Up to now, milrinone and enoximone are 
probably the most often used PDE III inhibitors in human medicine. The effects of milrinone 
have already been described in horses (Muir 1995), but no reports were available on the use 
of enoximone. Because the drug has a rather long half-life (Morita et al. 1995), it was 
preferred to evaluate the effects of a single bolus in anaesthetized ponies, alone or followed 
by infusions of dobutamine or calcium chloride. 
   As illustrated in Chapter 4.1, an intravenous bolus of 0.5 mg/kg enoximone administered 
over 1-2 minutes, induced significant increases in     and stroke volume (SV) during 100 
minutes and an increase in heart rate (HR) during 40 minutes, while right atrial pressure 
(RAP) decreased during at least 2 hours. These findings were similar to the ones reported in 
human medicine, except that SVR was somewhat lower, but not significantly different from 
saline treatment in our ponies. This situation appears similar to the one described for 
dobutamine, which mainly has inotropic, but also some vasodilating activity in humans 
(Morrill 2000), while most authors reported clear inotropic, but limited or no effects on SVR 
in anaesthetized ponies (Gasthuys et al. 1991) and horses (Swanson et al. 1985, Raisis et al. 
2000). It is unclear why this difference between species actually occurs. In most anaesthetic 
protocols for horses, α2 agonists, including romifidine, are administered for sedation before 
the induction of general anaesthesia. By inducing vasoconstriction, these agents may 
counteract the vasodilatory effects of other drugs. Nonetheless, it seems unlikely that 
romifidine had a clear effect on the response to enoximone in our experimental study, since a 
period of 105 minutes elapsed between the administration of romifidine (for sedation) and 
enoximone (during anaesthesia). Another difference between humans and horses is the dose 
of dobutamine that is usually administered. The vasodilatory effects of dobutamine in humans 
are mostly observed when higher doses are infused (Morrill 2000), while the doses routinely 
used during clinical anaesthesia in horses are quite low. It is possible that the effects of 
enoximone are also dose-dependent. Furthermore, slow injection of PDE III inhibitors largely 
prevents hypotension compared to rapid bolus administration in humans (Barnard & Linter 
1993). In our study, enoximone was administered over 1-2 minutes, which may have 
attenuated the drug‟s vasodilatory effects. As mentioned in the literature review, not only low 
General discussion 
 
202 
 
   , but also hypotension with decreased transmural pressures in the vessels of the muscles 
may be detrimental in horses. In this respect, it is beneficial that enoximone did not induce 
excessive vasodilation. It must also be noted that SVR is a general reflection of changes in 
(mainly) arteriolar tone throughout the body, but changes may differ between individual 
tissues. In humans, enoximone preferentially reduced limb vascular resistance and augmented 
blood flow to the peripheral musculoskeletal system (Leier et al. 1987). It would therefore be 
interesting to evaluate the effects of enoximone on local tissue perfusion, especially of the 
muscles, in horses. 
   Unlike SVR, RAP significantly decreased during at least 2 hours after administration of 
enoximone in the experimental part of this PhD. This may have been related to venous 
vasodilation (Grossman et al. 1998), causing a reduction in mean systemic filling pressure 
(Pmsf) and therefore venous pooling of blood. This could reduce venous return and    , 
especially in hypovolaemic horses where Pmsf is already low. However, since enoximone did 
not seem to affect SVR, which mainly reflects arteriolar tone, pronounced venous 
vasodilation seems rather unlikely. On the other hand, positive inotropic drugs shift the     
curve upwards and to the left, such that the equilibrium point (the intersection of the cardiac 
output and venous return curves) is equally shifted upwards and to the left. The upward shift 
of the equilibrium point indicates increased venous return and    , while the left shift indicates 
a reduction in RAP (Power & Kam 2001). Therefore, the decrease in RAP was probably 
mainly attributable to the inotropic effects of enoximone. 
   Enoximone significantly increased HR, which is not always desirable with respect to 
myocardial oxygen balance and/or efficiency of the heart (work done per unit of energy used), 
especially when pre-existing HR is already high, e.g. due to hypotension induced by 
hypovolaemia, endotoxaemia, etc. When cardiac oxygen supply becomes inadequate, 
myocardial contractility will be lower (Jose & Stitt 1969, Nayler et al. 1971) and arrhythmias 
may occur (Senges et al. 1979, Hjalmarson 1980). However, the maximal increase in HR 
occurred 5 minutes after enoximone administration, with a mean difference to saline of 7 ± 1 
beats/min, which gradually decreased and became nonsignificant 40 minutes after 
administration, while the effects on SV and     lasted for 100 minutes. Consequently, the 
increase in HR appears to be primarily associated with bolus administration and might be less 
pronounced during a CRI of enoximone. Furthermore, no excessive tachycardia was noted 
during the study, and arrhythmias were not observed. 
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   When enoximone was combined with low-dose dobutamine, additional increases in SV, HR 
and     were observed in isoflurane anaesthetized ponies. When comparing to the reports on 
dobutamine administration in horses, it became clear that dobutamine‟s effects on SV and     
were more pronounced than would be expected at the dose given. This observation suggests 
that enoximone and dobutamine may have synergistic effects on SV and     in ponies. 
Fortunately, such synergism was not observed for the effects on HR. During the first 40 
minutes after enoximone administration, when HR was significantly higher than after saline 
administration, dobutamine did not significantly induce further increases in HR. It was only 
after this time, when HR started to decrease again in the enoximone group but remained 
constant in the group receiving enoximone and dobutamine, that the difference in HR between 
both groups became significant. This suggests that an infusion of dobutamine after a bolus of 
enoximone maintains the increase in HR seen after administration of enoximone alone, but 
does not significantly affect its magnitude. At the same time, no arrhythmias were observed. 
   Other beneficial effects of the combination of enoximone and dobutamine, compared to 
enoximone alone, were increases in blood pressure, RAP, packed cell volume (PCV) and 
DO2. As outlined earlier, not only    , but also blood pressure is important in maintaining 
peripheral tissue perfusion, especially in horses with a high bodyweight. The increase in 
blood pressure was caused by an increase in    , since SVR was even slightly lower compared 
to enoximone treatment. Again, it would be interesting to see the effects of a combination of 
enoximone and dobutamine on muscle blood flow in anaesthetized horses. Right atrial 
pressure and PCV were higher during dobutamine administration, which may both be related 
to splenic contraction (Fuchs et al. 1980). Additionally, increased RAP may also have been 
the result of venoconstriction in response to dobutamine administration, due to the α1 effects 
of dobutamine (Fuchs et al. 1980). The increase in PCV caused a significant increase in CaO2. 
This, together with the increase in    , explains the improvement in DO2, which is of course 
highly desirable during cardiovascular support in horses.  
   The results of combining enoximone with calcium chloride were somewhat disappointing, 
but not unexpected given the data mentioned in literature. As explained in Chapter 1, 
inconsistent results have been reported regarding the cardiovascular effects of calcium salts in 
different species, which may be explained by differences in cardiovascular status, pre-existing 
serum calcium levels, etc. Furthermore, calcium salts did not produce any effects when 
combined with other inotropes, such as amrinone (Butterworth et al. 1992) and adrenaline 
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(Royster et al. 1992), and even reduced the effects of dobutamine (Butterworth et al. 1992) 
and milrinone (Goyal & McNeill 1986). 
   Based on the experimental part of this PhD thesis, it was concluded that a single bolus of 
enoximone induced beneficial effects on cardiovascular performance in isoflurane 
anaesthetized healthy ponies, with rather long lasting increases in SV and    , without 
reducing blood pressure, overly increasing HR or producing other undesirable effects. These 
effects were not altered by additional administration of calcium chloride, but could be 
accentuated by infusing low doses of dobutamine after administration of enoximone, with at 
least additive but possibly even synergistic effects on SV and    , while increasing blood 
pressure, CaO2 and DO2. Because of these encouraging results in experimental ponies, it was 
decided to investigate the cardiovascular effects of enoximone in a clinical study. Horses 
undergoing colic surgery were selected as study population, because many of these patients 
require pharmacological cardiovascular support.  
   The results of the clinical study in colic horses indicated that enoximone initially produced 
similar effects to those in experimental ponies, with increases in    , SV, HR and DO2 and a 
decrease in SVR 10 minutes after enoximone administration. However, most of these changes 
were less pronounced and of shorter duration compared to the ones observed under 
experimental (standardized) conditions in anaesthetized ponies. This may be related to several 
factors, including variability of the cardiovascular status of individual patients and other 
factors concurrently affecting cardiovascular performance, including surgical manipulations 
and administration of dobutamine and fluids, which possibly masked some of enoximone‟s 
effects. On the other hand, the effects of enoximone may have been limited by the presence of 
hypovolaemia, endotoxaemia or other factors which reduce the response to inotropes in colic 
horses. In humans, PDE III inhibitors are in fact avoided in patients with inadequate filling 
pressures, pre-existing severe vasodilation (Barnard & Linter 1993) or hypotension (Hall 
1993). Simultaneous administration of vasopressors may even be needed to avoid hypotension 
(Barnard & Linter 1993). 
   Hypovolaemia in colic horses results from reduced intake and intestinal absorption of fluids, 
combined with (sometimes excessive) sweating and increased losses to the interstitium, 
intestinal lumen or intraperitoneal space (transudate or exsudate). In hypovolaemic patients, 
inotropes are expected to be less effective because Pmsf, and therefore preload, is low. 
Consequently, in humans and small animals, fluid resuscitation is usually performed before 
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inotropes are administered. In anaesthetized horses, as indicated earlier, inotropes are often 
already administered during fluid resuscitation. Clinical experience suggests that dobutamine 
remains quite effective at improving cardiovascular function in these cases, despite 
incomplete restoration of the circulating volume. Possibly, enoximone is less effective in 
hypovolaemic animals.  
   Endotoxaemia also occurs frequently in colic horses, usually because the normal gut barrier 
function is lost in strangulated intestines. In those cases, circulating endotoxins induce 
hypotension by causing vasodilation, depressing myocardial contractility and reducing the 
response to ß-agonistic inotropic drugs (Takeuchi et al. 1999). It might therefore be 
hypothesized that the effects of enoximone in the clinical study were reduced because 
endotoxaemia occurred in several horses. However, strangulation of some part of the 
intestines was only found in 19 of 48 horses in our clinical study, and certainly not all of these 
horses were endotoxaemic at the time of surgery. Furthermore, enoximone was able to restore 
myocardial contractility in human patients with severe and prolonged endotoxaemic shock, 
unresponsive to catecholamine and fluid administration (Ringe et al. 2003). The drug also 
prevented mucosal hypoperfusion despite the induction of hypotension during an early stage 
of sepsis (Schmidt et al. 2001). Based on these results, enoximone might even prove to be 
valuable in endotoxaemic horses with a low response to sympathomimetic drugs, although 
further studies are needed to confirm this hypothesis. 
   Based on the results of this PhD thesis, it can be concluded that enoximone is an effective 
inotrope in healthy equids, with few undesirable effects. These results are encouraging for 
future research. Since HR increased only initially after bolus administration of enoximone, it 
may be interesting to investigate whether this increase in HR can be avoided by administering 
the drug as a CRI. To establish suitable loading doses and infusion rates for such a CRI, 
pharmacokinetic and pharmacodynamic studies in anaesthetized horses are required. Also, 
enoximone‟s effects on tissue perfusion in horses remain unknown. Studies looking at the 
effects of enoximone on intramuscular blood flow, splanchnic perfusion, etc. in horses are 
therefore needed. When administered after enoximone, several of dobutamine‟s 
cardiovascular effects appeared to be more pronounced compared to previous reports, but a 
specifically designed study would be needed before synergism between both drugs can be 
confirmed with certainty. In view of the positive effects of enoximone in humans with 
endotoxaemia and/or sepsis, further studies under similar clinical conditions are also justified 
in horses. Other possible uses of enoximone would be to counteract the negative inotropic 
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effects of other drugs administered in the perioperative period, mainly anaesthetics, and in the 
treatment of cardiac failure in horses or ponies. 
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In anaesthetized horses, the combined effects of recumbency, a high body weight, respiratory 
disturbances and cardiovascular depression often cause decreases in arterial oxygen content, 
blood pressure and cardiac output (   ). As a result, tissue oxygenation often becomes 
inadequate, which is one of the major factors contributing to the high death rate associated 
with anaesthesia in horses. Pulmonary ventilation-perfusion mismatching, which results in 
arterial hypoxaemia, is difficult to treat and most strategies using artificial ventilation have the 
propensity to compromise cardiovascular function. However, oxygen delivery to the tissues 
(DO2) can also be improved by optimizing tissue perfusion. Routine monitoring of the 
cardiovascular system during equine anaesthesia includes subjective clinical assessment, 
electrocardiography and measurement of heart rate (HR) and blood pressure. Although these 
techniques provide the anaesthetist with valuable information, measuring     would allow an 
even better estimation of DO2. Most previously described techniques for     measurements in 
horses only provide intermittent values, are difficult to use routinely and/or were found to 
have low accuracy. However, pulse contour analysis (PulseCO
®
) appeared promising for use 
in horses, since it is a continuous, noninvasive and easily applicable method that was found to 
be quite accurate over prolonged periods of time in humans. The first aim of this PhD thesis 
was therefore to evaluate the reliability of the pulse contour analysis algorithm implemented 
in the LiDCO-Plus
®
 monitor.  
   Once cardiovascular depression has been diagnosed, an appropriate treatment should be 
initiated. Reduction of anaesthetic depth and fluid therapy are often insufficient in 
anaesthetized horses and the use of cardiovascular stimulant drugs, such as antimuscarinics, 
inotropic drugs and vasopressors, is often needed. Antimuscarinic drugs increase HR and, for 
many reasons, are not suitable to augment     unless under specific circumstances. 
Vasopressors, such as vasopressin analogues, calcium salts and α-sympathomimetics, are only 
useful when hypotension is caused by vasodilation, e.g. induced by drugs or endotoxins, while 
myocardial contractility and     are normal or even increased and vascular transmural pressure 
needs to be restored to maintain normal tissue perfusion. Inotropic drugs include digitalis 
glycosides, β-sympathomimetics, calcium salts, calcium sensitizers and phosphodiesterase 
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(PDE) III inhibitors. Most of these drugs increase the availability of calcium to the contractile 
apparatus of the cardiac muscle. Extensive research has been performed on the effects of β-
sympathomimetics in horses. Many of these agents are suitable to be used as a constant rate 
infusion (CRI) during anaesthesia and effectively increase cardiac contractility, but some 
negative side effects can occur, including tachycardia, arrhythmias and in some cases 
undesirable vasoconstriction or vasodilation. Digitalis glycosides seem to be less useful for 
routine perioperative cardiovascular support in anaesthetized horses, because of unfavourable 
pharmacokinetic properties, toxicity and possibly lower efficacy in equine patients without 
cardiac disease. The effectiveness of calcium salts for cardiovascular support in horses varied 
between different studies and probably depends on different factors such as pre-existing 
serum calcium levels and degree of cardiovascular depression. Calcium sensitizers are quite 
expensive and long acting and are probably better used only in patients with cardiac disease. 
While PDE III inhibitors, i.e. inodilators, are potent inotropes with few important side effects 
during short-term use in humans, very little information is available on the use of these drugs 
in horses. In human medicine, milrinone and enoximone are nowadays the most widely used 
inodilatory PDE III inhibitors. Because the effects of milrinone, but not those of enoximone, 
had previously been described in horses, the second major aim of this PhD thesis was to 
evaluate the cardiovascular effects and possible side effects of enoximone in ponies under 
experimental conditions, alone or combined with dobutamine or calcium chloride. If 
beneficial, the drug‟s effectiveness during colic surgery in horses would be additionally 
evaluated. 
   In an experimental randomized cross-over study, 6 ponies were anaesthetized 4 times with a 
minimal interval of 3 weeks between treatments. Their age ranged between 4 and 6.5 years 
and body weight between 212 and 368 kg (mean bodyweight 286 ± 53 kg). The ponies were 
sedated with romifidine [80 µg/kg intravenously (IV)] and anaesthesia was induced with 
midazolam (0.06 mg/kg IV) and ketamine (2.2 mg/kg IV) and maintained with isoflurane in 
oxygen (FE´Iso 1.7%). Normocapnia (PaCO2 4.66-6.00 kPa) was maintained using artificial 
ventilation. Ninety minutes after induction (=T0), the ponies received 1 of 4 treatments: slow 
IV administration of enoximone 0.5 mg/kg (E), an equivalent volume of saline (S), 
enoximone 0.5 mg/kg IV followed by a dobutamine CRI at 0.5 µg/kg/min during the 
remaining period of anaesthesia (ED) or an infusion of calcium chloride 0.5 mg/kg/min from 
T5 until T15 (EC). On all occasions, cardiopulmonary function was monitored during 120 
minutes after the end of enoximone administration. Heart rate, blood pressure and right atrial 
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pressure (RAP) were measured before treatment, every 5 minutes between T0 (treatment) and 
T30 and then every 10 minutes until T120. Before T0, the pulse contour analysis monitor was 
calibrated three times using the lithium dilution technique. Thereafter, no further 
recalibrations were performed. Cardiac output measurements (lithium dilution (   LiDCO) and 
pulse contour analysis (   PulseCO) techniques) and blood gas analysis (arterial and central 
venous samples) were performed before treatment and at T5, T10, T20, T40, T60, T80, T100 
and T120. Stroke volume (SV), systemic vascular resistance (SVRLiDCO and SVRPulseCO), 
venous admixture (       ) and DO2 were calculated. Additionally, for each pair of     
measurements after T0, the absolute and relative differences between both techniques were 
calculated. 
   For all statistical analyses, a 5 % significance level was used. The differences between 
   LiDCO and    PulseCO in the saline group were analyzed using a paired t-test. Mixed models 
were used to evaluate whether these differences changed over time and whether they were 
influenced by the different treatments or by changes in HR, blood pressure, RAP, packed cell 
volume (PCV) and SVRLiDCO. Additionally, bias and precision were documented using Bland-
Altman plots and mean bias and limits of agreement between both techniques were calculated 
for each treatment group. The cardiopulmonary effects of enoximone were compared to those 
of the other treatments using a mixed model with treatment, time and their interaction as fixed 
categorical effects and pony as random effect, comparing the treatments both globally and at 
specific timepoints after treatment. 
   During treatment S, the limits of agreement between both     measurement techniques were 
wide and    PulseCO was 4.9 ± 12.3 % lower than     LiDCO (P<0.001), while SVRPulseCO was 6.9 
± 14.4 % higher than SVRLiDCO (P<0.01). These differences increased over time and were 
significantly larger during treatments E and ED. At the same time, the limits of agreement 
were wider during treatments E, ED and EC compared to treatment S. Furthermore, the 
differences between both techniques were significantly affected by changes in blood pressure. 
It was concluded from these results that the reliability of the pulse contour analysis algorithm 
was low in anaesthetized ponies, despite recent calibration and even under stable 
haemodynamic conditions, and became worse when haemodynamics changed. 
   Compared to saline treatment, enoximone induced significant increases in     and SV during 
100 minutes and an increase in HR during 40 minutes. Right atrial pressure decreased during 
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at least 2 hours. Despite increases in        , DO2 to the tissues was improved. Additional 
administration of dobutamine as a constant rate infusion caused further increases in     and 
SV, which were larger than previously reported with dobutamine infusions in horses and 
ponies, suggesting that enoximone might augment the inotropic potency of dobutamine. At 
the same time, the increase in HR seen after enoximone administration was maintained during 
the entire dobutamine infusion period, although the magnitude of this increase was not 
altered. Other effects of dobutamine administration were an increase in blood pressure, RAP, 
PCV and DO2. In contrast to the findings with a dobutamine infusion, administration of 
calcium chloride did not have any detectable influence on the cardiovascular effects of 
enoximone in anaesthetized ponies. No clinically important adverse effects were noted during 
any of the treatments in this experimental study. Based on these results, it was concluded that 
a single bolus of enoximone is able to improve cardiac performance during almost 2 hours in 
isoflurane anaesthetized ponies, appears to be quite safe and can be combined with low doses 
of dobutamine when blood pressure needs to be increased or when more pronounced increases 
in     are desired. 
   Based on these beneficial results under experimental conditions, a prospective, randomized 
clinical trial was set up to investigate the cardiovascular effects of enoximone in anaesthetized 
colic horses undergoing emergency laparotomy. After sedation (xylazine 0.7 mg/kg) and 
induction (midazolam 0.06 mg/kg, ketamine 2.2 mg/kg), anaesthesia was maintained with 
isoflurane in oxygen and a lidocaine constant rate infusion (1.5 mg/kg, 2 mg/kg/h). All 48 
horses were ventilated to maintain PaCO2 below 8.00 kPa. Dobutamine and/or colloids were 
administered when hypotension occurred. Ten minutes after skin incision, an intravenous 
bolus of enoximone (0.5 mg/kg) or an equivalent volume of saline was administered (= T0). 
Respiratory and arterial blood gases, HR, blood pressure and cardiac index (CI) were 
monitored. Systemic vascular resistance (SVR), stroke index (SI) and oxygen delivery index 
(DO2I) were calculated. For each variable, changes between baseline and T10 within each 
treatment group and/or colic type (small intestines, large intestines or mixed) were analyzed 
and compared between treatments in a fixed effects model. Differences between treatments 
and colic types until T30 were investigated using a mixed model. For all analyses, the 
significance level was set at 5 %.  
   Ten minutes after enoximone administration, CI (P=0.0010), HR (P=0.0033) and DO2I 
(P=0.0007) were higher and SVR lower (P=0.0043) than at baseline. However, during the 
  Summary 
 
 
 215 
first 30 minutes after enoximone treatment, only DO2I (P=0.0224) and HR (P=0.0003) were 
higher than after saline administration. Furthermore, all differences were less pronounced and 
of shorter duration than in the experimental study in ponies. This may have been caused by 
variability of the cardiovascular status of individual colic horses, other factors affecting 
cardiovascular function (thus masking the effects of enoximone) or the presence of factors 
which possibly reduced the efficacy of enoximone, such as hypovolaemia or endotoxaemia.   
   One of the general conclusions that can be drawn from these studies is that the pulse contour 
analysis algorithm is of limited usefulness to estimate cardiac output in anaesthetized ponies. 
Secondly, enoximone is able to improve cardiac performance and appeared to be quite safe in 
anaesthetized ponies and colic horses. The drug can also be safely combined with low doses 
of a dobutamine infusion. This combination causes a more pronounced increase in cardiac 
function and results in a higher arterial pressure compared to enoximone administration alone. 
However, the cardiovascular effects of enoximone were less pronounced and of shorter 
duration in colic horses. Further studies evaluating the cardiovascular effects and influence on 
muscle perfusion of different doses of enoximone, administered as a bolus or as a constant 
rate infusion, the drug‟s pharmacokinetics and its efficacy under different clinical conditions, 
are warranted. 
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Tijdens de anesthesie van paarden veroorzaken de gecombineerde effecten van decubitus, een 
hoog lichaamsgewicht, ademhalingsproblemen en cardiovasculaire depressie vaak een 
duidelijke daling in het arterieel zuurstofgehalte, de bloeddruk en het hartdebiet (   ). Dit kan 
leiden tot onvoldoende zuurstofvoorziening van de weefsels, wat één van de belangrijkste 
factoren is die bijdragen tot de hoge sterftepercentages tijdens of kort na de anesthesie van 
paarden. Een slecht evenwicht tussen ventilatie en perfusie van de longen is moeilijk te 
corrigeren en de meeste beademingstechnieken die men hiervoor gebruikt onderdrukken in 
meer of mindere mate de functie van het cardiovasculair systeem. De zuurstofvoorziening van 
de weefsels kan echter ook verbeterd worden door de weefseldoorbloeding te optimaliseren. 
Voor routine monitoring van het cardiovasculair systeem tijdens de anesthesie wordt bij 
paarden doorgaans gebruik gemaakt van subjectieve klinische beoordeling, 
electrocardiografie en het meten van de hartfrequentie (HR) en de bloeddruk. Alhoewel deze 
technieken waardevolle informatie opleveren, zou het meten van het hartdebiet een nog betere 
inschatting van de zuurstofvoorziening van de weefsels mogelijk maken. De meeste 
technieken die beschreven zijn om     te bepalen bij paarden laten alleen intermitterende 
metingen toe, zijn moeilijk routinematig te gebruiken en/of zijn weinig betrouwbaar. Het 
nieuwe algorithme voor het analyseren van de arteriële bloeddrukgolven van de LiDCO-Plus
®
 
monitor leek echter veelbelovend voor gebruik bij paarden, aangezien het een continue, non-
invasieve en eenvoudig te gebruiken methode is, die vrij accuraat bleek te zijn over lange 
periodes in de humane geneeskunde. De eerste doelstelling van deze doctoraatsthesis was dan 
ook de betrouwbaarheid na te gaan van het algorithme waarmee de LiDCO-Plus
®
 monitor 
veranderingen in     schat op basis van de arteriële bloeddrukgolf.  
   Eens cardiovasculaire depressie vastgesteld is, moet een gepaste behandeling ingesteld 
worden. Het verminderen van de diepte van de anesthesie en toedienen van vloeistoffen 
volstaan vaak niet bij paarden, zodat farmaca met een stimulerend effect op het 
cardiovasculair systeem, zoals antimuscarinica, inotropica en vasopressoren vaak nodig zijn. 
Antimuscarinica verhogen de hartfrequentie en zijn om vele redenen niet geschikt om het 
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hartdebiet te verhogen, tenzij onder zeer specifieke omstandigheden. Vasopressoren, zoals 
vasopressine analogen, calciumzouten en α-sympathicomimetica, zijn enkel nuttig wanneer 
hypotensie veroorzaakt wordt door vasodilatatie, bv. uitgelokt door farmaca of endotoxines, 
terwijl de myocardiale contractiliteit en     normaal of zelfs verhoogd zijn en de transmurale 
druk in de bloedvaten verhoogd moet worden om de perfusie van de weefsels in stand te 
houden. Bij de inotropica horen de digitalis glycosides, β-sympathomimetica, calciumzouten, 
calcium „sensitizers‟ en phosphodiesterase (PDE) III inhibitors. De meeste van deze 
producten veroorzaken een inotroop effect door de beschikbaarheid van calcium voor het 
contractiele apparaat van de hartspier te verhogen. Uitgebreid onderzoek werd reeds 
uitgevoerd aangaande de effecten van β-sympathomimetica bij paarden. Vele leden van deze 
groep zijn geschikt voor gebruik als continu infuus tijdens de anesthesie en zijn vrij effectief 
om de contractiliteit van het hart te verhogen, maar kunnen ook neveneffecten veroorzaken, 
zoals tachycardie, aritmieën en in sommige gevallen overmatige vasoconstrictie of 
vasodilatatie. Digitalis glycosides lijken minder nuttig voor routine cardiovasculaire 
ondersteuning van paarden tijdens de anesthesie, omwille van ongunstige farmacokinetische 
eigenschappen, toxiciteit en een mogelijks lagere efficaciteit bij paarden zonder 
hartproblemen. Het effect van calciumzouten voor cardiovasculaire ondersteuning bij paarden 
varieerde tussen verschillende studies en hangt wellicht af van verschillende factoren zoals de 
calciumconcentratie in het serum en de graad van cardiovasculaire depressie. Calcium 
sensitizers zijn vrij duur, werken lang en worden waarschijnlijk beter gereserveerd voor 
patiënten met hartfalen. Phosphodiesterase III inhibitors of zogenoemde inodilatoren zijn 
potente inotropica met relatief weinig belangrijke neveneffecten wanneer ze gebruikt worden 
voor korte periodes bij mensen. Toch is er zeer weinig informatie voorhanden over het 
gebruik van deze farmaca bij het paard. In de humane geneeskunde zijn milrinone en 
enoximone momenteel de meest gebruikte inodilatorische PDE III inhibitors. Omdat de 
effecten van milrinone, maar niet deze van enoximone, reeds beschreven waren bij paarden, 
was de tweede algemene doelstelling van dit doctoraatswerk de cardiovasculaire effecten en 
eventuele neveneffecten van enoximone te onderzoeken bij pony‟s, onder experimentele 
omstandigheden, alleen of gecombineerd met dobutamine of calcium chloride. Indien de 
resultaten gunstig waren zou de efficaciteit van enoximone voor het verhogen van het 
hartdebiet tijdens koliekchirurgie bij paarden bestudeerd worden. 
   In een experimentele, gerandomiseerde cross-over studie, werden 6 pony‟s 4 keer onder 
anesthesie gebracht, met een interval van minimum 3 weken tussen elke behandeling. De 
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dieren waren tussen 4 en 6,5 jaar oud en hun lichaamsgewicht varieerde tussen 212 en 368 kg 
(gemiddeld 286 ± 53 kg). Na sedatie met romifidine [80 µg/kg intraveneus (IV)] en inductie 
met midazolam (0.06 mg/kg
 
IV) en ketamine (2.2 mg/kg
 
IV), werd de anesthesie onderhouden 
met isofluraan in zuurstof (FE´Iso 1.7%). Aan de hand van kunstmatige beademing werd er 
gezorgd voor normocapnie (PaCO2 4.66-6.00 kPa). Negentig minuten na de inductie (= T0) 
werd 1 van de 4 behandelingen toegediend: trage IV toediening van enoximone 0.5 mg/kg 
(E), een equivalent volume fysiologische zoutoplossing (S), enoximone 0.5 mg/kg IV gevolgd 
door een dobutamine infuus aan 0.5 µg/kg/min gedurende het verder verloop van de 
anesthesie (ED) of een infuus met calcium chloride aan 0.5 mg/kg/min van T5 tot T15 (EC). 
De cardiopulmonaire functie werd telkens opgevolgd gedurende 120 minuten na het einde van 
de toediening van enoximone. De HR, bloeddruk en rechter atriale druk (RAP) werden 
gemeten voor de behandeling, om de 5 minuten tussen T0 (behandeling) en T30 en daarna om 
de 10 minuten tot T120. Vóór T0 werd de „Pulse contour analysis‟ (PulseCO) software drie 
maal gecalibreerd met behulp van de lithium-dilutietechniek (LiDCO). Daarna werden geen 
verdere calibraties meer uitgevoerd over het verloop van de studie. De metingen van het 
hartdebiet (lithium dilutie (   LiDCO) en pulse contour analysis (   PulseCO) technieken) en 
bloedgas-analyses (arteriële en centraal veneuze stalen) werden uitgevoerd vóór de 
behandeling en op T5, T10, T20, T40, T60, T80, T100 and T120. Het slagvolume (SV), de 
systemisch vasculaire weerstand (SVRLiDCO en SVRPulseCO), het percentage veneuze 
bijmenging (       ) en de zuurstofvoorziening (DO2) werden berekend. Bijkomend werden 
voor elk paar     metingen na T0 de absolute en relatieve verschillen tussen beide technieken 
bepaald. 
   Voor alle statistische analyses werd een significantieniveau van 5 % aangehouden. De 
verschillen tussen    LiDCO en    PulseCO tijdens de placebo behandeling werden geanalyseerd 
met een gepaarde t-test. Mixed model variantie-analyse werd gebruikt om te evalueren of 
deze verschillen veranderden over de tijd en of ze beïnvloed werden door de verschillende 
behandelingen of door de HR, bloeddruk, RAP, hematocriet (PCV) of SVRLiDCO. Bijkomend 
werden de accuraatheid en precisie gedocumenteerd op basis van Bland-Altman plots en 
berekeningen van de gemiddelde bias en zogenaamde „grenzen van overeenkomst‟ (limits of 
agreement) tussen de beide technieken tijdens de verschillende behandelingen. De 
cardiopulmonaire effecten van enoximone werden vergeleken met deze van de andere 
behandelingsprotocols op basis van een mixed model met behandeling, tijd en hun interactie 
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als vaste categorische effecten en pony als random effect, waarbij de verschillen zowel 
globaal als op specifieke tijdspunten geanalyseerd werden. 
   Tijdens behandeling S werden wijde limits of agreement gevonden tussen de    LiDCO en 
   PulseCO waardes. Bovendien was    PulseCO 4.9 ± 12.3 % lager dan     LiDCO (P<0.001), terwijl 
SVRPulseCO 6.9 ± 14.4 % hoger was dan SVRLiDCO (P<0.01). Deze verschillen werden 
geleidelijk groter tijdens het verloop van de studie en waren significant hoger tijdens 
behandelingen E en ED. Daarnaast waren de limits of agreement wijder tijdens behandelingen 
E, ED en EC dan tijdens behandeling S. Er werd eveneens vastgesteld dat veranderingen in de 
bloeddruk de verschillen tussen de twee meettechnieken beïnvloedden. Uit deze resultaten 
werd afgeleid dat het PulseCO algorithme bij pony‟s weinig betrouwbaar is, ondanks recente 
calibratie en zelfs onder haemodynamisch stabiele omstandigheden. Wanneer er medicatie 
toegediend werd met een invloed op het cardiovasculair systeem verminderde de 
betrouwbaarheid verder.  
   Vergeleken met de placebo behandeling veroorzaakte enoximone een significante stijging 
van     en SV gedurende 100 minuten en een stijging van HR gedurende 40 minuten. De RAP 
daalde gedurende minstens 2 uur. Ondanks een stijging van de         was de DO2 hoger. 
Bijkomende toediening van dobutamine als continu infuus zorgde voor een verdere stijging 
van     en SV, waarbij deze stijging meer uitgesproken was dan voorheen gerapporteerd met 
het gebruik van dobutamine aan vergelijkbare of zelfs hogere dosissen bij pony‟s en paarden. 
Het is daarom mogelijk dat enoximone de inotrope eigenschappen van dobutamine versterkt. 
Terzelfdertijd bleef de HR gedurende de volledige periode waarin dobutamine toegediend 
hoger dan tijdens behandeling S, alhoewel deze stijging kwantitatief niet groter was dan 
tijdens behandeling E. Andere effecten van het toedienen van dobutamine waren een stijging 
van de bloeddruk, RAP, PCV en DO2. Daarentegen had toediening van calcium chloride geen 
enkele invloed op de effecten van enoximone bij pony‟s. Er werden trouwens geen klinisch 
belangrijke neveneffecten vastgesteld na toediening van enoximone in de experimentele 
studie. Uit deze resultaten werd afgeleid dat een enkele bolus enoximone in staat is het 
slagvolume en hartdebiet gedurende bijna 2 uur te verhogen bij pony‟s tijdens algemene 
anesthesie met isofluraan, vrij veilig lijkt te zijn en ook gecombineerd kan worden met een 
lage dosis dobutamine wanneer de arteriële bloeddruk moet verhoogd worden of wanneer een 
meer uitgesproken stijging van het hartdebiet nodig is.  
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   Op basis van de gunstige resultaten onder experimentele omstandigheden werd een 
prospectieve, gerandomiseerde klinische studie uitgevoerd om de cardiovasculaire effecten 
van enoximone te bestuderen tijdens koliekchirurgie bij paarden. Na sedatie (xylazine 0.7 
mg/kg) en inductie (midazolam 0.06 mg/kg, ketamine 2.2 mg/kg) werd de anesthesie 
onderhouden met isofluraan in zuurstof en een continu lidocaïne-infuus (1.5 mg/kg, 2 
mg/kg/h). Alle 48 paarden werden kunstmatig beademd om de PaCO2 lager dan 8.00 kPa te 
houden. Dobutamine en/of colloïden werden toegediend in geval van hypotensie. Tien 
minuten na incisie van de huid werd een intraveneuze bolus enoximone (0.5 mg/kg) of 
eenzelfde volume fysiologische zoutoplossing toegediend (= T0). Respiratoire en arteriële 
bloed-gassen, HR, bloeddruk en het hartdebiet per kg lichaamsgewicht (cardiac index, CI) 
werden opgevolgd. Verder werden ook de systemisch vasculaire weerstand (SVR), 
slagvolume index (SI) en zuurstofvoorzieningsindex (DO2I) berekend. Voor elke variabele 
werd het verschil bekeken tussen de waarden op T10 en deze net voor de toediening van 
enoximone, om vervolgens deze verschillen te vergelijken tussen de 2 behandelingen en 
tussen de verschillende koliektypes (dunne darm, dikke darm of gemengd), aan de hand van 
variantie-analyse („vast effect‟ model). De waardes tot T30 van de beide behandelingen en de 
drie koliektypes werden eveneens met elkaar vergeleken aan de hand van variantie-analyse 
(gemengd model). Voor alle analyses werd een significantieniveau van 5 % aangehouden.  
   Tien minuten na de toediening van enoximone waren de CI (P=0.0010), HR (P=0.0033) en 
DO2I (P=0.0007) hoger en SVR lager (P=0.0043) dan op T0. Daarentegen waren alleen DO2I 
(P=0.0224) en HR (P=0.0003) tijdens de eerste 30 minuten na behandeling met enoximone 
hoger dan na de placebobehandeling. Bovendien waren alle verschillen minder uitgesproken 
en van kortere duur dan in de experimentele studie bij pony‟s. Dit kan te wijten zijn aan de 
variabiliteit van de cardiovasculaire status van individuele koliekpaarden, andere factoren die 
een effect hadden op het cardiovasculair systeem (en zo de effecten van enoximone 
maskeerden) of factoren die mogelijks de efficaciteit van enoximone verminderden, zoals 
hypovolemie of endotoxemie. 
   Eén van de algemene conclusies van deze studies is dat het PulseCO algorithme van de 
LiDCO-Plus
®
 monitor weinig betrouwbaar is om veranderingen in het hartdebiet te schatten 
bij pony‟s tijdens de anesthesie. Daarnaast werd vastgesteld dat enoximone de hartfunctie 
stimuleert en vrij veilig lijkt te zijn bij pony‟s en koliekpaarden, ook wanneer gecombineerd 
met lage doses van een dobutamine-infuus. Deze combinatie leidt tot een sterkere stijging van 
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het slagvolume en het hartdebiet en een hogere arteriële bloeddruk vergeleken met toediening 
van enoximone alleen. Anderzijds waren de cardiovasculaire effecten van enoximone minder 
uitgesproken en van kortere duur bij koliekpaarden. Verdere studies die de cardiovasculaire 
effecten en de invloed op de spierperfusie van verschillende doses enoximone nagaan, 
toegediend als een bolus of als continu infuus, evenals studies die de farmacokinetiek van 
enoximone bij paarden en de efficaciteit van deze molecule onder verschillende 
omstandigheden onderzoeken, zijn aangewezen. 
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Bij het einde van deze doctoraatsthesis zou ik nog een aantal mensen willen bedanken voor 
hun rechtstreekse of onrechtstreekse bijdrage aan dit werk. Allereerst hoort hier uiteraard een 
woord van dank voor mijn hoofdpromotor, Prof. Dr. Frank Gasthuys. Ik herinner mij nog 
goed dat Prof. Steenhaut ooit aan de studenten in de operatiezaal zei: “Anesthesie is niet 
alleen een wetenschap, het is een kunst waarvoor je een zekere feeling moet krijgen.” Dankzij 
Prof. Gasthuys heb ik mij in deze „kunst‟ kunnen bekwamen en er een voorliefde voor 
ontwikkeld, en merkte ik dat anesthesie dé tak van de diergeneeskunde was waarin ik me 
wilde specialiseren. Hij bood mij alle kansen hiertoe en gaf mij voldoende vrijheid in het 
kiezen van een onderwerp en het opstellen van de proeven voor mijn doctoraat, maar stond 
tegelijk altijd klaar met een nimmer aflatende steun, hulpvolle commentaren en goede raad en 
daad. Ook mijn medepromotor, Prof. Dr. Ingeborgh Polis, mag niet ontbreken in dit 
dankwoord. Ingeborgh, dankjewel voor de nuttige suggesties en commentaren die je als 
promotor en lid van de begeleidingscommissie hebt gegeven. Prof. Duchateau zou ik willen 
bedanken voor alles wat hij gedaan heeft voor dit doctoraat, zoals het uitvoeren van de 
statistische analyses, zijn hulp als lid van de begeleidingscommissie, zijn raad bij het 
interpreteren en beschrijven van de resultaten van de studies, etc. Ook aan de leden van de 
lees- en examencommissie een ferme dankjewel voor de tijd en de moeite die ze aan dit 
doctoraat hebben besteed en de nuttige suggesties die ze hebben gegeven. Een speciale dank 
hierbij aan Jackie Brearley en Yves Moens, die uit het buitenland zijn gekomen om de 
openbare verdediging van dit doctoraat bij te wonen. Het was een hele eer om als leden van 
de examencommissie zowel de president van de Association of Veterinary Anaesthetists als 
de president van de European College of Veterinary Anaesthesia and Analgesia te mogen 
verwelkomen. 
   Een aparte alinea van dit dankwoord zou ik willen richten aan Dr. Stefaan Bouchez van het 
Universitair Ziekenhuis in Gent. Ik heb ontzettend veel geleerd tijdens de anesthesieën die we 
samen hebben uitgevoerd, vooral in verband met cardiovasculaire fysiologie en farmacologie. 
Hij vertelde mij over phosphodiësterase III remmers, waaruit het idee rees de effecten van 
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enoximone bij paarden na te gaan en het product eventueel te combineren met dobutamine of 
calcium chloride. Dus Stefaan, bedankt voor je zo substantiële bijdrage aan dit werk. 
   Daarnaast verdienen de leden van de vakgroep een woord van dank. In de eerste plaats wil 
ik de anesthesisten bedanken die over het verloop van de jaren op de heelkunde gewerkt 
hebben: Linda en Véronique (mijn collega-residents destijds), Annelies, Els, Lindsey, 
Hannah, Miguel, Caroline, Stefanie en Barbara. Stuk voor stuk heb ik graag met jullie 
gewerkt en elk van jullie heeft zijn/haar steentje bijgedragen door de kliniek draaiende te 
houden wanneer ik tijd nodig had om aan mijn doctoraat te werken, mee te helpen met de 
studies en ook buiten het werk zo‟n aangenaam gezelschap te zijn. Woorden schieten tekort 
om jullie te bedanken. De chirurgen en de mensen uit de sterilisatieruimte wil ik danken voor 
de aangename werksfeer in de operatiezalen, de hulp bij het uitvoeren van de experimenten 
en/of het begrip wanneer ik tijdens de koliekstudie weer eens het colon niet kon helpen 
spoelen of geen materiaal kon aangeven omdat ik nog een „metingske‟ aan het doen was. Prof. 
Steenhaut, dankjewel voor alles wat ik van u geleerd heb, het was steeds een plezier om voor 
u een paard of herkauwer onder anesthesie te brengen, u blijft voor mij de standaard waarnaar 
iedere chirurg moet streven, en dan zeker niet alleen ivm de snelheid (waar iedereen nog 
steeds over spreekt), maar vooral ook ivm de kwaliteit van het afgeleverde werk en de 
nuchterheid in het nemen van beslissingen en het afwegen van wat wel of niet belangrijk is. 
Ann, Lieven, Stefaan, Geert, Jeroen, Tamara, Frederik, Mireia en Caroline, dankjewel om het 
cliché over de altijd slechte verstandhouding tussen anesthesisten en chirurgen teniet te doen. 
Guido, Caroline, Valerie, Cindy en Nadine, ook aan jullie bedankt voor de hulp bij het 
uitvoeren van de experimenten en het verzamelen en proper maken van alle katheters, 
guidewires, sleeves, dilatoren, introducers en al het andere materiaal dat ik nodig had voor de 
proeven, evenals voor het aangenamer maken van de vele uren die ik bij de slapende pony‟s 
doorbracht. Wie ik niet mag vergeten is Fernand, van het labo op de vakgroep inwendige 
ziekten, die voor mij heel wat bloedstalen analyseerde en zelfs zo vriendelijk was ongevraagd 
de stalen persoonlijk te komen halen en de resultaten terug te brengen. Prof. Desmet verdient 
eveneens een plaats in dit epistel, door mij indertijd te begeleiden bij het schrijven van mijn 
scriptie heeft hij me geleerd hoe een grondige literatuurstudie uit te voeren en op een correcte 
manier weer te geven. Ook alle andere leden van onze vakgroep en van de inwendige ziekten 
en de verloskunde wil ik bedanken voor hun bijdrage aan dit doctoraat en/of omdat ze het 
aangenaam maken om elke dag opnieuw op het werk te verschijnen. Aan de secretaresses, de 
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interns, de „mankmeesters‟, de mensen van de hospitalisatie, de hoefsmeden, de stalknechten, 
Cindy, Remi en Annemie: dankjewel. 
   Niet alleen mijn collega‟s, maar ook de mensen uit mijn persoonlijke omgeving zou ik 
willen bedanken bij het beëindigen van dit doctoraat. Een speciale dankjewel gaat uit naar 
mijn ouders, die me altijd door dik en dun gesteund hebben in alles wat ik ondernam, me in 
mezelf deden geloven en steeds een voorbeeld waren (en nog altijd zijn) van hoe ik zelf wilde 
worden als persoon. Ook mijn zussen Tamara en Jette en mijn schoonfamilie wil ik bedanken 
om altijd voor me klaar te staan en steeds in mij te geloven. Tot slot wil ik de twee personen 
die alles voor mij betekenen nog eens speciaal bedanken: Elke en Seth, ik weet dat het niet 
altijd eenvoudig was als ik ‟s avonds of in het weekend weer eens moest studeren voor mijn 
examen of tijd moest besteden aan mijn doctoraat en daardoor geen tijd had voor jullie. 
Bedankt om begrip te tonen en mij al deze kansen te geven. Maar eigenlijk nog veel meer: 
gewoon bedankt dat jullie er zijn en het leven pas echt de moeite waard maken…  
    
     
 
 
 
 
 
